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“It is not titles that honor men, but men that honor titles.”  
 
 
Niccolò Machiavelli 
 
 
 
 
 
 
 
 
 
“I have been impressed with the urgency of doing. Knowing is not enough; we must apply. 
Being willing is not enough; we must do.”  
 
 
Leonardo da Vinci 
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  Concept 
 
 
The term “privileged structure” is used in medicinal chemistry to define a single molecular 
framework able to provide ligands for diverse receptors. Among the different classes of 
compounds that have been proposed as privileged scaffolds for the drug discovery 
process we can find morpholines. These six membered heterocycles are widely used in 
medicinal chemistry, not only as simple secondary amines during the diversification of 
combinatorial libraries, but also as proper platforms on which a diversification process 
itself is developed. Many bioactive compounds are based on carbon-substituted 
morpholines and out of these several are already marketed drugs such as Reboxetine, 
Aprepitant and many others (a complete overview is given in Chapter 1). The strong 
attention of the medicinal chemist community for the morpholine core prompted us to 
investigate new and more efficient routes for the preparation of this heterocycle. An 
interesting subclass of carbon-substituted morpholines that attracted our attention are 
those presenting a carboxylic moiety in position three of the ring (morpholine-3-caroxylic 
acids). 
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This set of morpholines is an interesting case of study since it represents a group of cyclic, 
non natural α-amino acids that can be applied in the field of peptidomimetics and, again, 
as nucleus of various bioactive compounds (a detailed discussion of such structures is 
given in Chapter 2, Section 1). This PhD work was aimed to develop new synthetic 
strategies towards the production of diversely functionalized morpholine-3-carboxylic acids 
and towards the application of these structures in the field of peptidomimetics. The idea 
for the preparation of our target structures was that of using enantiomerically pure β-
hydroxy-α-amino acids as building blocks for the creation of the morpholine ring. Initially, it 
was decided to develop a new methodology for the synthesis of morpholines using natural 
occurring β-hydroxy-α-amino acids, namely serine and threonine. Once this new 
methodology was succesfully developed, it appeared clear that the major drawback was 
represented by the limited avaibility of enantiomerically pure β-hydroxy-α-amino acids. In 
order to overcome this problem and increase the diversity of morphloines that can be 
obtained with our methodology we required a new and reliable source of β-hydroxy-α-
amino acids. Although some methods for the preparation of enantiomerically pure β-
hydroxy-α-amino acids are reported (Chapter 5), we found it challenging to develop our 
own strategy. Moreover β-hydroxy-α-amino acids themselves are attracting targets and 
their asymmetric preparation is a current hot topic in organic synthesis because these 
compounds are constituents of many natural products such as vancomicyn and other 
natural antibiotics. An innovative synthetic strategy towards this class of compounds, 
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 6 
needed the development of a catalytic asymmetric synthesis, instead of using  
approaches which are based on chiral auxiliaries. 
Therefore we decided to develop a new methodology for the asymmetric preparation of β-
hydroxy-α-amino acids and do scientific collaboration with the group of professor Darren 
J. Dixon (Manchester University), which is specialized in the area of asymmetric catalysis 
and could provide the required “know how” to face our objective.  
This thesis discusses both concepts presented in this section and is divided into two parts. 
First part introduces a new strategy for the preparation of morpholines strating from β-
hydroxy-α-amino acids which is described together with an application of morpholine-3-
carboxylic acid as β-turn inducer. The second part discusses the development of a new 
catalytic system for the preparation of optically active β-hydroxy-α-amino acids. 
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Abstract 
 
 
This thesis is divided into two parts. The first part describes the development and the 
application of a new methodology for the synthesis of morpholines starting from β-amino 
alcohols. In particular the focus is on the construction of diversified morpholine-3-carbixylic 
acids (F and H), which can be obtained using β-hydroxy-α-amino acids as precursors. 
This methodology is based on an acid catalysed transactelysation of a linear precursor (A) 
and a subsequent elimination of MeOH, in order to obtain dihydroxazine scaffolds B that 
can be further functionalyzed leading to diversified, biologiacally relevant morpholines. 
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In Chapter 2 the dihydroxazine scaffolds are reduced by means of a catalytic 
hydogenation, providing an easy access to Fmoc-protected morpholine-3-carboxylic acids 
F, unnatural cyclic amino acids used in poptidomimetics and drug design. The synthesis 
proved particularly efficient, providing access to the target products in less steps and 
better yields than previously reported approaches. 
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In Chapter 3, it is fully described how the previously synthesised Fmoc-morpholine-3-
carboxylic acid F has been inserted into model tetrapeptide sequences, in order to study 
the attitude of acting as a proline surrogate. The peptides conformation has been studied 
by means of NMR, IR and molecular modeling techniques and the tendency to nucleate 
into folded structures such as β-turns has also been investigated.  
Chapter 4 describes the diastereoselective cyclopropanation of dihydroxazines with diazo-
acetates to access geometrically diversified and orthogonally protected scaffolds to be 
used in peptidomimetics and combinatorial chemistry (H). The stereochemical diversity is 
obtained starting from β-hydroxy-α-amino acids with different configuration and also by 
means of a transition metal-catalyzed cyclopropanation step, where the stereochemical 
outcome is governed by PyBOX chiral ligands. 
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The second part of the thesis is focused on the development of a new synthetic strategy to 
access enantiopure β-hydroxy-α-amino acids, the starting materials used for the 
preparation of dihydroxazine scaffolds. A reliable source of these compounds guarantees 
the possibility of further increase the diversity of the morpholine platforms introduced in 
the first part. In order to develop a new methodology for the preparation of β-hydroxy-α-
amino acids, it was decided to exploit a catalytic, enantioselective version of the aldol 
reaction of α-isocyanoacetates. The products of this reaction are oxazolines L, which are 
a protected form of β-hydroxy-α-amino acids. Chapter 6 describes the design and the 
synthesis of a small library of amino-phosphines based on cinchona alkaloid-derived 
scaffolds. The synthesised ligands are then screened for the enantio- and 
diastereoselective addtion of α-isocyanoaacetates to aldehydes, in the presence of 
different transition metals. It is found that ligand K is particularly effective in the control of 
enantio- and diastereo-selectivity, providing the desired products with ee up to 97%.  
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The new catalytic system is also efficient in the presence of α-substituted isocyanides J, 
thus allowing the simultaneous creation of a quaternary and a tertiary stereogenic center 
next to each other. Finally, an efficient hydrolysis procedure for the conversion of 
oxazolines to the corresponding β-hydroxy-α-amino acids is disclosed.  
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Abbreviations 
 
 
°C   degrees Celsius 
Å   ångström 
Ac   acetyl 
Ar   aromatic group, not phenyl 
Atm.   standard atmosphere 
Bn   benzyl 
Boc   Di-tert-butyl dicarbonate 
Bs   broad signal 
Bu   butyl 
C   cyclo / concentration 
Cat   catalyst 
Cbz   Carboxybenzyl 
Conv   conversion 
COSY   correlation spectroscopy 
D   doublet 
Dd   doublet of doublets 
De   diastereomeric excess 
DFT   density functional theory 
DIAD   diisopropyl azodicarboxylate 
DKR   dynamic kinetic resolution 
DMAP   4-dimethylaminopyridine 
DMF   dimethylformamide 
DMSO   dimethylsulfoxide 
DPPA   diphenylphosphoryl azide 
Dr   diastereomeric ratio 
EDG   electron donating group 
Ee   enantiomeric excess 
eq.   equivalents 
ESI   electrospray ionisation 
Et   ethyl 
EWG   electron withdrawing group 
Fmoc   9H-(f)luoren-9-yl(m)eth(o)xy(c)arbonyl 
H   hour(s) 
HPLC   high performance liquid chromatography 
HRMS   high-resolution mass spectrometry 
Hz   hertz 
I   iso 
IPA   isopropylalcohol 
IR   infrared 
M   molar 
m   meta 
m   multiplet 
m/z   mass-to-charge ratio 
Me   methyl 
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Mg   milligram 
MHz   megahertz 
Min   minute 
mL   millilitre 
µL   microlitre 
mmol   millimole 
Mol   mole 
MP   melting point 
MS   molecular sieves / mass spectrometry 
n   normal, straight chain 
nm   nanometre 
NMR   nuclear magnetic resonance 
NOE   nuclear Overhauser effect 
Nu   nucleophile 
o   ortho 
p   para 
Ph   phenyl 
Pr   propyl 
ppm   parts per million 
q   quartet 
quat   quaternary 
R   any alkyl group 
Ref   reference 
rt   room temperature 
s   singlet 
t   retention time (HPLC) / triplet (NMR) / tertiary 
TBME   tert-butyl methyl ether 
TBS   tertiary butyldimethylsilyl 
Temp   temperature 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
TMS   trimethylsilyl 
Ts   p-toluenesulfonyl 
p-TsOH  toluene sulfonic acid 
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Introduction to part I: carbon-substituted 
morpholines 
 
 
 
1.1 Biological Relevance of Morpholines 
 
Carbon-functionalized morpholines find a wide application as constituent of many 
pharmacological relevant compounds and are also a relatively common moiety among 
natural products. Many morpholine-based structures are under development or are 
currently marketed for treatment of various diseases.  
Reboxetine 1 is an antidepressant drug used in the treatment of clinical depression, panic 
disorder and attention-deficit hyperactivity disorder, acting as a a norepinephrine reuptake 
inhibitor.1 Its mesylate salt is sold under different tradenames including Edronax, Norebox, 
Prolift, Solvex, Davedax or Vestra. 
 
 
 
 
 
 
 
 
Figure 1.1 
 
Racemic bupropion 3 has been used in the treatment of depression and has been 
approved as an aid in smoking cessation treatment. It is believed that its biological activity 
is related to an oxidized form (morpholine 4) which is formed when bupropion is 
metabolized.  
Scheme 1.1 Bupropion mechanism of action 
 
 
 
 
 
 
 
On the basis of this work, many analogues of morpholine 4 have been synthesized and 
compound 2 was identified as novel antidepressant and selective inhibitor of 
                                               
1 Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.; Wong, E. H. F., CNS Drug Reviews, 2004, 
10, 23-44 and references therein. 
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noerepinephrine uptake.2 Morpholines are also found as many weight loss pescriptions. 
One example is the widely prescribed phendimetrazine 6 which is metabolized as 
phenmetrazine 7.3  
 
 
 
 
 
 
Figure 1.2 
 
2-Benzyl-morpholine 7 is another appetite suppressant. Tests on animals proved that the 
active enatiomer is the one having positive optical rotation, which was then assigned as 
the R-enantiomer by D’Arrigo and co-workers.4  
From structure activity research, the orally active compound 8 was found to have potent 
antibacterial activity against Pseudomonas aeruginosa, and Helicobacter pylori,5 the 
primary cause of chronic gastritis and highly associated with peptic ulcer.6 The S-
enantiomer proved to be thirty times more active then the corresponding R-enantiomer. 
Further studies on the same scaffold led to the development of Levofloxacin 9, a third-
generation fluoroquinolone antibiotic, marketed by Ortho-McNeil under the trade name 
Levaquin in the United States. In Europe, it is marketed by Sanofi-Aventis under the trade 
name Tavanic. Levofloxacin is one of the so-called respiratory quinolones, which are 
effective against a number of Gram-positive and Gram-negative bacteria and, specifically, 
against the organisms that cause atypical pneumonia. Because of its broad spectrum of 
action, levofloxacin is frequently prescribed empirically for a wide range of infections (such 
as pneumonia and urinary tract infection) before the causal organism is known.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 
 
                                               
2 Kelley, J.L.; Musso, D.L.; Boswell, G.E.; Soroko, F.S.; Cooper, B.R., J. Med. Chem. 1996, 39, 347-349. 
3 Rothman, R.B.; Katsnelson, M.; Vu, N.; Partilla, J.S.; Dersch, C.M.; Blough, B.E.; Baumann, M.H. Eur. J. 
Pharmacol. 2002,  51. 
4 D’Arrigo, P.; Lattanzio, M.; Fantoni, G.P.; Servi, S.; Tetrahedron: Asymmetry 1998, 9, 4021-4026. 
5Araki, k.; Kuroda, t.; Uemori, S.; Moriguchi, A.; Ikeda, Y.; Hirayama, F.; Yokoyama, Y.; Iwao, E.; Yakushiji, T. 
J. Med. Chem. 1993, 36, 1356-1363. 
6Sakurai, N.; Sano, M.; Hirayama, F.; Kuroda, T.; Uemori, S.; Moriguchi, A.; Yamamoto, K.; Ikeda, Y.; 
Kawakita, T. Bioorg. Med. Chem. Lett. 1998, 8, 2185-2190. 
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Centrally acting α1-agonist may be of therapeutic value in dementia and other CNS 
disorders characterized by symptoms of noradrenergic insufficiency. Compound 10 was 
found to be a potent selective α1-agonist in a study conducted by Sandoz Ltd.7 
In a study targeted to discover new neurokinin-1 receptor antagonist, Merck laboratories 
identified the series of morpholine-based structures 11.8 Compound 11a was found to be   
a orally active, water-soluble neurokinin-1 receptor antagonist and is currently marketed 
under the trade name of Aprepitant. 
Kim and co-workers synthesized many analogs of Camptothecin 12, a natural compound 
isolated from the Chinese tree Camptotheca Acuminata, which was reported to have 
antitumor activity. The morpholine analogue 13 showed promising in vitro antitumor 
activity.9 
 
 
 
 
 
 
Figure 1.4 Camptothecin and its synthetic analogue 13 
 
Many morpholine-derivatives were found to have antioxidant activity. The Morpholine-
derivatives of lipoic acid illustrated in figure 1.5 were found to have enhanced antioxidant 
activity when compared to lipoic acid itself.10 Moreover some of these new compounds 
were able to cross the blood-brain barrier, an important feature for antioxidant candidates, 
since the brain is the most susceptible organ to oxidative stress.  
 
 
 
 
 
 
 
 
Figure 1.5 
 
The morpholine-acetal 15, prepared by Chrysellis and co-workers, displayed antioxidant 
activity and also was able of releasing NO, thing which was considered advantageous for 
the inhibition of atherogenic mechanisms.11  
. 
 
                                               
7Nozulak, J.; Vigouret, J.M.; Jaton, A.L.; Hofmann, A.; Dravid, A.R.; Weber, H.P.; Kalkman, H.; Walkinshaw, 
M.D. J. Med. Chem. 1992,35,480-489. 
8Timothy Harrison, T.; Owens, A.P.; Williams, B.J.;  Swain, C.J.; Williams, A.;  Carlson, E.J.; Rycroft, W.; 
Tattersall, F.D.; Cascieri, M.A.; Chicchi, G.G.; Sadowski, S.; Rupniak, N.M.J.; Hargreaves, R.J. J. Med. Chem. 
2001, 44, 4296-4299. 
9 Kim, D.K.; Ryu, D.H.; Lee, J.Y.; Lee, N.; Kim, Y.W.; Kim, J.S.; Chang, K.; Im, G.J.; Kim, T.K.; Choi, W.S. J. 
Med. Chem. 2001, 44, 1594-1602.  
10Claude Guillonneau, C.; Charton, Y.; Ginot, Y.M.; Fouquier-d’Herouel, M.V.; Bertrand, M.; Lockhart, B.; 
Lestage, P.; Goldstein, S. Eur. J. Med. Chem. 2003, 38, 1-11. 
11Chrysellis, M.C.; Rekka, E.A.; Kourounakis, P.N.; J. Med. Chem. 2000, 43, 609-612. 
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1.2 Synthesis of Morpholines 
 
Many approaches have been reported so far. In this section the most significant strategies 
for the synthesis of the morpholine-ring will be reviewed and illustrated through the 
presentation of some selected significant examples. The focus will be on the key reactions 
used to create the morpholine ring and not on further chemical modifications made once 
the morpholine ring itself has been formed. 
Due to the presence of the two heteroatoms, the morpholine ring suggests obvious 
disconnections between the α-carbons and the heteroatoms. The most of these 
disconnections are based on the nucleophilic character of nitrogen and oxygen, which can 
easily cyclize on electrophilic carbons and form the heterocyclic ring. So the most evident 
disconnection is that shown in scheme 1.2, where the morpholine ring is derived from an 
amino alcohol and a 1,2-dielectrophile. Many synthetic equivalents are available and have 
been applied as 1,2-dielectrophile. The most common of them are illustrated in scheme 
1.2.  
Scheme 1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Usually the ring formation consists of two steps and the two electrophilic centers are 
differentiated. Many times the 1,2-dielectrophile presents explicitly the two electrophilic 
centers when it is reacted with the amino alcohol and none of the two is in a “masked 
form”. This is the case, for example, of the use of chloroacetyl chloride. This is a very 
common strategy and is illustrated by the preparation of compound 10.12 
 
 
 
 
 
                                               
12 Nozulak, J.; Vigouret, J.M.; Jaton, A.L.; Hofmann, A.; Dravid, A.R.; Weber, H.P.; Kalkman, H.; Walkinshaw, 
M.D. J. Med. Chem. 1992,35,480-489. 
N
O
NH
OH
O
Y
X
O
X
X
OO
R1 H
X2
O
X
X = OAlk, Halide
R1 = Alk, Ar, OAlk
or
Y = Halide
X = Halide
X
PART I - Introduction                                                                                                 CHAPTER 1 
 
 
 16
Scheme 1.2 Use of chloroacteyl chloride for the synthesis of morpholines 
 
 
 
 
 
 
 
 
 
 
 
Other electrophiles that act in a similar way to chloroacetil chloride are the α-halo-esters, 
α-halo-ketons/aldehydes etc. 
In some other cases one of the two electrophilic centers is masked or requires a further 
activation in order to create to final ring. This is the case of the use of epoxides in the 
reaction with amino alcohol. Once the epoxide has reacted with the amine, the cyclization 
is usually induced by a further activation of one of the two alcoholic groups. The kind of 
activation, in this case, depends on the nature of the two hydroxyl groups. If one of them is 
in a particularly reactive position (for example is a benzylic alcohol such in Scheme 1.313) 
acid treatment and/or heating is enough to obtain the cyclization. If the hydroxyl group is 
not activated, common cyclization strategies are the use of Mitsunobu conditions14 or the 
use of mesyl/tosyl chloride to activate one of the alcohols followed by treatment with a 
base.15 
Scheme 1.3 
 
 
 
 
 
 
 
 
 
 
 
Also when allyl halides are used, the first electrophilic center is readily reacted with the 
amino alcohol and then the alkene requires a further activation, unless it is not a Michael 
acceptor16 as in scheme 1.4  
 
                                               
13 Somei, M.; Aoki, K.; Nagaham, Y.; Nakagawa, K.; Heterocycles, 1995, 41, 5-8. 
14 Nishi, T.; Ishibashi, K.; Takemoto, T.; Nakajima, K.; Fukazawa, T.; Iio, Y.; Itoh, K.; Mukayama, O.; 
Yamaguchi, T. Biorg. Med. Chem. Lett. 2000, 10, 1665. 
15 Lanman, B.A.; Myers, A.G. Org. Lett. 2004, 6, 1045-1047. 
16 Fustero, S.; Jimenez, D.; Moscardo’, J.; Catalàn, S.; Del Pozo, C. Org. Lett., 2007, 5283-5286. 
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Scheme 1.4 Oranocatalytic, enantioselective synthesis of morpholine ring through 
intramolecular aza-Michael reaction. The olefin is activated by imminium ion catalysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The second electrophilic activation of the alkene can be obtained with different methods. 
Common are the use of transition metal catalysts, reaction with bromine/iodine,17 
epoxidation18 (Scheme 1.5 ), oxidation of the alkene to aldehyde (scheme 1.6).19 
 
Scheme 1.5 Sharpless Asymmetric Epoxidation strategy for the morpholine ring closure. 
 
 
 
 
 
 
Scheme 1.6 Cyclization through alkene ozonolysis and N-acyl-iminium functionalization  
 
 
 
 
 
 
 
 
 
A second possible disconnection is breaking between atoms 1-2 and 3-4, as shown in 
scheme 1.7. This second possibility is less common compared to the previously reported 
but is a valuable alternative. The major drawback is the availability of synthetic 
                                               
17 D’hooghe, M.; Vanlangendonck, T.; Tornroos, K.W.;  De Kimpe, N. J. Org. Chem. 2006, 71, 4678-4681. 
18 Kozlowski M.C.; Bartkett, P.A. J. Org. Chem. 1996, 61, 7681-7696. 
19 Steven V. O’Neil, S.V.; Wang, Y.; Laufersweiler, M.C.; Oppong, K.A.; Soper, D.L.; Wos, J.A.; Ellis, C.D.; 
Baize, M.W.; Bosch, G.K.; Fancher, A.N.; Lu, W.; Suchanek, M.K.; Wang, R.L.; De, B.; and Demuth, Jr. J.P. 
Biorg. Med. Chem. Lett. 2005, 5434-5438. 
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equivalents.  The nitrogen containing synthons are usually represented by an aziridine20 or 
a cyclic sulfamidate which often needs to be prepared from an independent route.  
 
Scheme 1.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
A recent example of this disconnection is based on a regiospecific nucleophilic cleavage 
of enantiopure sulfamidates with 2-bromo-phenols (cleavage occurs on the carbon next to 
oxygen) and a subsequent Pd(0) mediated amination to provide the final morpholine ring. 
The strategy has been applied to the synthesis of the blockbuster antibiotic Levofloxacin 
and is illustrated in scheme 1.8.21  
 
Scheme 1.8 Application of sulfamidates to the synthesis of Levofloxacin 
 
 
 
 
 
 
 
 
 
 
 
 
 
A third possible disconnection is the cleavage between the nitrogen and the two α-
carbons. This cleavage has been used mainly to prepare morpholines from furanosides22 
and it has been proved particularly suitable for the preparation of morpholines bearing 
stereogenic centers next to the oxygen, as illustrated in scheme 1.10. 
 
 
                                               
20 Kogami Y., Okawa K., Bull. Chem. Soc. Jpn. 1987, 2963-2965. 
21 Bower, J.; Szeto, P.; Gallagher, T. Org. Lett. 2007, 3283-3286. 
22 Grotenbreg, G.M.; Christina, A.E.; Buizert, A.E.M.; Van der Marel, G.A.; Overkleeft, H.S.; Overhand, M. J. 
Org. Chem. 2004, 69, 8331-8339. 
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Scheme 1.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this case an cleavage of the cis diols with H5IO6 is used to obtain the dialdehyde 42, 
which is then converted into the morpholine 43 using a double reductive amination with a 
primary amine. 
Scheme 1.10 
 
 
 
 
 
 
Finally some non-conventional disconnections will be briefly reviewed. Many of these 
strategies are based on rearrangements or multicomponent reactions. Molinski reported 
an oxidative rearrangement of oxazoline to morpholine-2-ones, induced by SeO2. The 
proposed reaction mechanism is illustrated in scheme 1.11 and it is supposed to proceed 
through a first oxidation of the oxazoline α-carbon to the corresponding aldehyde that in 
presence of the Lewis acid gives rise to a “nitrilium to acylium” rearrangement  that 
originates the morphilone-2-one 48.23 
 
Scheme 1.11 Oxazoline to morpholine-2-one rearrangement in the presence of SeO2 
 
 
 
 
 
 
 
 
 
 
 
                                               
23 Shafer, C. M.; Molinski, T. F. J. Org. Chem. 1995, 61, 2044-2050.  
N
O
R
NH2
O
R
O
OO
O
O
CO2Me
O
O
CO2Me
O
HO O
O
HO OH
N3 CO2Me O
O O
N3 CO2Me
O
N3 CO2Me
OHO OH
H2OH5IO6
THF, 20'
94%
PhH2N
NaCNBH3
MeOH-CH(OMe)3
AcOH-MS 3Å
O
N3 CO2Me
N
Ph41 42 43
N
O
RH2C
R1
SeO2
Dioxane
 N
O
R1
O
R
LA+
:
LA
N R1
O
R
O
LA
Nitrilium-Acilium
Rearrangment
N R1
O
R
LA
O
N
O
R1R
O
R = H, Ph44 46
4847
45
PART I - Introduction                                                                                                 CHAPTER 1 
 
 
 20
A similar rearrangement has been reported by Agami24 and has been applied to the 
synthesis of aprepitant by Merck.25 Both papers report the condensation of phenylglyoxals 
with amino alcohol. The reaction proceeds through the formation of a hemiacetal that 
rearranges to morpholinone species, most presumably by the mechanism reported below, 
where a phenyl cation migrates from the acetal carbon to the adjacent iminium moiety. 
 
Scheme 1.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recently the group of Kim described an approach to morpholine-2-one derivatives based 
on a multicomponent Ugi reaction using glycoladehyde dimer, amino acids and an 
isocyanide.26 
 
Scheme 1.13 Ugi 5-centers-3-components reaction to access morpholine-2-one 
derivatives. 
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24 Agami, C.; Couty, F.; Prince, B.; Venier, O. Tetrahedron. Lett.1993, 34, 7061-7062.  
25 Zhao, M.M. McNamara, J.M.; Ho, G.J.; Emerson, K.M.; Song, Z.J.; Tschaen, D.M.; Brands, K.M.J.; Dolling, 
U.H.; Grabowsky, E.J.J.; Reider, P. J. Org. Chem. 2002, 67, 6743-6747. 
26 Kim, Y.B.; Choi, E.H.;  Keum, G.; Kang, S.B.; Lee, D.h.;  Koh, H.Y.; Kim, Y. Org. Lett. 2001, 3, 4149-4152. 
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1.3 Aims & Concept 
 
The first part of this thesis work will describe a new approach to the construction of the 
morpholine ring. This strategy is briefly summarized and introduced in this section and 
then it will be illustrated and discussed in detail in the next two chapters.  
The starting point for the development of a new strategy for the synthesis of enantiopure 
morpholines was the isolation of an elimination by-product (62), during some reactivity 
studies involving morpholine-acetals of the kind reported below (60).  
During these studies, an activation of the acetal with Lewis acids was attempted, in order 
to obtain a condensation product in the presence of the protected thymine 61. 
 
Scheme 1.14 
 
 
 
 
 
 
 
Unfortunately all attempts to convert acetal 60 to the desired product were unfruitful or 
very low yielding. Anyway, from the crude reaction mixture it was evident the presence of 
dihydroxazine 62. Compound was also isolated in low to moderate yields. The formation 
of the dihydroxazine occurred presumably through the mechanism reported in scheme 
1.15. In a first step the methyl-acetal is cohordinated by the lewis acid and the resultant 
cation does not react with the nucleophile but readily rearranges to the stable 
dihydroxazine 62. 
 
Scheme 1.15 Mechanism for the Lewis acid catalysed formation of dihydroxazine 62 
 
 
 
 
 
 
 
Dihydoxazines 62 are attractive scaffolds because of the presence of the electron-rich 
olefin which can be used as a reactive intermediate, in order to access a wide range of 
medicinally relevant structures and many cyclic unnatural amino acids. We decided to 
consider the formation of dihydroxazines as a starting point and we planned to optimise 
the reaction conditions in order to obtain the desired scaffolds in higher yield.  
A quick conditions screen took us to identify the use of a catalytic amount of p-TsOH as 
the ideal acid to obtain the elimination of MeOH. Heating in toluene was beneficial, in 
order to remove methanol from the reaction mixture and drive the equilibrium towards 
dihydroxazines 62. Finally, the use of 4Å molecular sieves to trap MeOH and a Dean 
Stark apparatus allowed reaching yields higher then 80%.  
In a second optimisation stage we considered that the acetal precursor 60 was also 
formed in an acid catalysed trans-acetalysation and we envisaged the possibility of 
carrying both steps (trans-acetalysation, MeOH elimination) together. This intuition proved 
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feasible and allowed the synthesis of dihydroxazines 62 from linear precursors 63 in a 
single step by simply refluxing in toluene in the presence of a catalytic amount of p-TsOH.  
 
Scheme 1.16 
 
 
 
 
 
In chapters 2 and 4 the development and the application of the new strategy will be 
discussed. According to the way the double bond of the dihydroxazine structure is 
transformed, a various number of morpholine-derivatives can be obtained. 
In the next chapter a simple catalytic reduction of the double bond is considered, in order 
to obtain an easy, high yielding access to the pharmacologically relevant Fmoc-3-
morpholine carboxylic acid. In chapter 4, the diastereoselective cyclopropanation of the 
double bond with diazo-acetates is explored, in order to access new, geometrically 
diversified and orthogonally protected scaffolds to be applied as peptidomimetics and 
templates for combinatorial synthesis.  
 
Scheme 1.17 Some applications of the new strategy to access the morpholine ring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In chapter 3, the previously synthesised Fmoc-3-morpholin-carboxylic acid is included, by 
means of solid phase synthesis, in the middle of two model tetrapeptides in order to study 
its attitude to act as a β-turn inducer. The conformational folding of the two tetrapeptides is 
studied with NMR techniques, IR and molecular modelling. 
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Fmoc-Morpholine-3-Carboxylic Acids 
from Serine and Threonine 
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Enantiopure Fmoc-protected morpholine-3-carboxylic acid was synthesized from 
dimethoxyacetaldehyde and serine methyl ester through a short and practical synthetic 
route. The preparation consisted of a five-step process based on reductive amination, 
intramolecular acetalization  and concomitant elimination of the anomeric methoxy 
substituent, followed by hydrogenation of the double bond and final acidic ester 
hydrolysis. The optical purity of both enantiomers of the title amino acid was demonstrated 
by HPLC analysis of the corresponding amide derivatives obtained from coupling with 
chiral (S)-(–)-1-phenyl-ethylamine. Moreover, the synthesis of a model tripeptide showed 
full compatibility of the title Fmoc-amino acid with Solid-Phase Peptide Synthesis, thus 
allowing the application of Fmoc-morpholine-3-carboxylic acid in peptidomimetic chemistry 
on solid-phase. The new synthetic approach was then extended to the synthesis of Fmoc 
protected 2-methyl-morpholine-3-carboxylic acid using threonine methyl ester in place of 
serine as starting material. 
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2.1 Introduction 
 
Over the years the synthesis and applications of cyclic amino acids has attracted 
considerable attention from synthetic and medicinal chemists, especially in the area of 
peptidomimetics.27 The incorporation of cyclic secondary amino acids28 has profound 
effects on the conformation of peptides, due to the inability of the nitrogen atom to act as a 
hydrogen bond donor unless it is located at the N-terminal position of the molecule, and to 
the conformational strain imparted by the cyclic structure. Also, cis/trans isomerism of the 
tertiary amide bond formed by cyclic amino acids is responsible for the modulation of the 
conformational preferences. Cyclic secondary amino acids have been applied in several 
biological issues, and their incorporation into bioactive peptides has been reported over 
the years.29 In particular, morpholine-3-carboxylic acid has been used to synthesize 
several bioactive molecules, such as TACE,30 MMP and TNF inhibitors,31 and a potent 
orally active VLA-4 antagonist.32 Also, it has been included in the core structure of tricyclic 
benzodiazepines,33 6-methylidene penems as -lactamase inhibitors,34 β-carbolines as IKK-
2 inhibitors,35 8,6-fused bicyclic peptidomimetic compounds as interleukin-1β converting 
enzyme inhibitors,36 and in the structure of benzoxazepines as stimulators of AMPA 
receptor.37  
 
 
 
 
 
                                               
27 (a) Giannis, A.; Kolter, T. Angew. Chem. Int. Ed. Engl. 1993, 32, 1244-1267. (b) Gante, J. Angew. Chem. 
Int. Ed. Engl. 1994, 33, 1699-1720. (c) Gibson, S. E.; Thomas, N.; Guillo, N.; Tozer, M. J. Tetrahedron 1999, 
55, 585-615. 
28 Hruby, V. J.; Al-Obeidi, F.; Kazmierski, W. Biochem. J. 1990, 268, 249-262. 
29 Goodman, M.; Ro, S. In Burger’s Medicinal Chemistry and Drug Design, Vol. 1; Wolff, M. E.,  Ed.; Wiley: 
New York, 1995. 
30Levin, J. I.; Chen, J. M.; Laakso, L. M.; Du, M.; Du, X.; Venkatesan, A. M.; Sandanayaka, V. ; Zask, A.; Xu, 
J.; Xu, W.; Zhang, Y.; Skotnicki, J. S. Bioorg. Med. Chem. Lett. 2005, 15, 4345-4349. 
31 (a) Almstead, N. G.; Bradley, R. S.; Pikul, S.; De, B.; Natchus, M. G.; Taiwo, Y. O.; Gu, F.; Williams, L. E.; 
Hynd, B. A.; Janusz, M. J.; Dunaway, C. M.; Mieling, G. E. J. Med. Chem. 1999, 42, 4547-4562. (b) Piscopio, 
A. D.; Rizzi, J. P. WO 96/33172, October 24, 1996. 
32 Chiba, J.; Machinaga, N.; Takashi, T.; Ejima, A.; Takayama, G.; Yokoyama, M.; Nakayama, A.; Baldwin, J. 
J.; McDonald, E.; Saionz, K. W.; Swanson, R.; Hussain, Z.; Wong, A. Bioorg. Med. Chem. Lett. 2005, 15, 41-
45. 
33 Matthews, J. M.; Dyatkin, A. B.; Evangelisto, M.; Gauthier, D. A.; Hecker, L. R.; Hoekstra, W. J.; Liu, F.; 
Poulter, B. L.; Sorgi, K. L.; Maryanoff, B. E. Tetrahedron: Asymmetry 2004, 15, 1259-1267. 
34 Venkatesan, A. M.; Agarwal, A.; Abe, T.; Ushirogochi, H.; Yamamura, I.; Ado, M.; Tsuyoshi, T.; Dos Santos, 
O.; Gu, Y.; Sum, F. –W.; Li, Z.; Francisco, G.; Lin, Y. –I.; Petersen, P. J.; Yang, Y.; Kumagai, T.; Weiss, W. J.; 
Shlaes, D. M.; Knox, J. R.; Mansour, T. S. J. Med. Chem. 2006, 49, 4623-4637. 
35 (a) Hepperle, M. E.; Liu, J. F.; Soucy, F.; Raman, P.; Little, J. D.; Fleming, P. E.; Reynolds, D.; Harriman, G. 
C. B. US2005/0239781 A1, October 27, 2005. (b) Hepperle, M. E.; Liu, J. F.; Soucy, F.; Ye, Y.; Murray, R. S.; 
Prakash, R.; Little, J. D.; Castro, A.; Mazdiyasni, H.; Fleming, P. E.; Reynolds, D. WO2004/092167 A1, 
October 28, 2004. 
36 O’Neil, S. V.; Wang, Y.; Laufersweiler, M. C.; Oppong, K. A.; Soper, D. L.; Wos, J. A.; Ellis, C. D.; Baize, M. 
W.; Bosch, G. K.; Fancher, A. N.; Lu, W.; Suchanek, M. K.; Wang, R. L.; De, B.; Demuth, Jr., T. P.  Bioorg. 
Med. Chem. Lett. 2005, 15, 5434-5438. 
37 Grove, S. J. A.; Zhang, M.; Shahid, M.; WO02/100865 A1, December 19, 2002. 
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Figure 2.1 Selected examples of bioactive compounds incorporating the morpholine-3-
carboxylic acid backbone. 
 
The first syntheses of morpholine-3-carboxylic acid were reported in 1981 by Anteunis et 
al. as a racemate,38 and by Brown et al. describing the preparation of the cyclic amino acid 
as the N-benzyl, ethyl ester derivative from serine in 6% overall yield.39 In the same years, 
Kogami and Ogawa reported the most convenient synthesis of morpholine-3-carboxylic,40 
which employed chiral benzyl N-Cbz-2-aziridine-carboxylate, derived from serine, to give 
the title amino acid after three steps in 66% overall yield. Recently, Dave and Sasaki 
reported the synthesis of enantiomerically pure Boc-morpholine-3-carboxylic acid from the 
corresponding alcohol derivative in 81% yield,41 which in turn was obtained from a 
protected serinol derivative in six steps and in 50% overall yield. In addition, an enzymatic 
synthesis of cyclic amino acids, including morpholine-3-carboxylic acid, has been 
proposed recently.42  
 
 
2.2 proposed synthesis 
 
During our ongoing research scheme in the field of cyclic acetals derived from amino 
acids precursors, we observed that morpholine-acetals 60, with the nitrogen atom 
protected as amide or carbamate, could undergo elimination of alcohol when treated with 
Lewis acids or dehydrating agents, to give 1,4-dihydro-oxazine species 62 (Scheme 2.2). 
 
Scheme 2.2: Synthesis of 1,4-dihydro-oxazine from morpholine-acetals. 
 
 
 
 
 
 
                                               
38 Asher, V.; Becu, C.; Anteunis, M. J. O.; Callens, R. Tetrahedron Lett. 1981, 22, 141-144. 
39 Brown, G. R.; Foubister, A. J.; Wright, B. J. Chem. Soc., Perkin Trans. 1 1985, 2577-2580. 
40 Kogami, Y.; Okawa, K. Bull. Chem. Soc. Jpn. 1987, 60, 2963-2965. 
41 Dave, R.; Sasaki, N. A. Tetrahedron: Asymmetry 2006, 17, 388-401. 
42 Yasuda, M.; Ueda, M.; Muramatsu, H.; Mihara, H.; Esaki, N. Tetrahedron: Asymmetry 2006, 17, 1775-1779. 
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We envisaged the possibility of exploiting this new reactivity in the asymmetric synthesis 
of Fmoc protected morpholine-3-carboxylic acid 66 and Fmoc protected 2-methyl-
morpholine-3-carboxylic acid 68. Our approach consisted in using serine and threonine 
methyl esters as precursor of morpholine-acetals 60a and 60b, which could then undergo 
elimination of alcohol to give 1,4-dihydro-oxazines 62. The latter are then easily converted 
to the target materials upon hydrogenation of the alkene and hydrolysis of the methyl 
ester.   
 
Scheme 2.3: Proposed synthesis of Fmoc-morpholine-3-carboxylic acids 66 and 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Synthesis of Fmoc-morpholine-3-carboxylic acid 
 
L-serine methyl ester hydrochloride was treated with dimethoxyacetaldehyde in a 
reductive amination step carried out under a hydrogen atmosphere in the presence of 
catalytic amounts of 5% Pd/C, giving compound 76a in 50% yield. Optimization of the 
reaction conditions consisted in the addition of one molar equivalent of triethylamine, thus 
furnishing clean adduct 76a in 98% yield after overnight stirring at room temperature 
(Scheme 2.4). 
Scheme 2.4 
  
 
 
 
 
 
 
 
 
 
Subsequent amine protection as Fmoc-urethane was achieved using Fmoc-Cl in water-
dioxane as solvent system, and in the presence of NaHCO3 as base, giving 77a in 97% 
yield. Acid-catalyzed cyclization by acetalization and in-situ elimination of the methoxy 
group was achieved in one-pot, by refluxing compound 77a in toluene in the presence of 
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catalytic quantities of p-toluenesulfonic acid, thus giving 62a as a single stereoisomer in 
85% yield. When the reaction was carried out without using molecular sieves, we 
observed a decrease of the yield to 67%, and the reaction time was prolonged to 4 h in 
order to achieve complete conversion of the starting material. Hydrogenation of the double 
bond at C-5 and C-6 carbon atoms of 78 was initially attempted by treatment with H2 and 
catalytic 10% Pd/C, leading to partial deprotection of the amine function (Table 2.1). The 
extent of such deprotection was found to be dependent on the choice of the solvent, as 
when 2:1 MeOH – CH2Cl2 was used as the solvent mixture the amount of deprotected 
amino ester increased, compared to MeOH (Table 2.1, entries 1 and 2). The use of 
Raney-Ni as catalyst was unsuccessful, as only starting material was recovered from the 
reaction mixture. 
 
Table 2.1 Optimization of reaction conditions for the double bond hydrogenation of 62a 
N
O
CO2Me
Fmoc
H2
catalyst
N
O
CO2Me
Fmoc
62a 78
solvent
 
 
Entry Catalyst Solvent Yield 
1 10% Pd/C MeOH 67a 
2 10% Pd/C 2:1 MeOH-CH2Cl2 25a 
3 Raney Ni MeOH - b 
4 10% Pt/C MeOH 91 
5 10% Pt/C 2:1 MeOH:CH2Cl2 95 
 
aPartial deprotection of the Fmoc group was observed. bOnly starting material 
 was recovered. 
 
Finally, 10% Pt/C catalyst gave clean reduction of the double bond and allowed 
preservation of the amine protecting group. The reaction proceeded in 91% using MeOH 
as solvent, and upon application of 2:1 MeOH – CH2Cl2 as solvent system, the yield was 
further optimized to 95% (Table 2.1, entry 5). Hydrolysis of the ester function to give the 
title Fmoc-protected amino acid was carried out in an acidic medium in order to preserve 
the base-labile Fmoc group. Optimization of the reaction conditions required several 
attempts in order to achieve high yield. Hydrolysis of 78 in 2:1 acetonitrile – 4M HCl with 
overnight stirring at room temperature resulted in poor conversion, giving 66 in 15% yield. 
Replacement of acetonitrile with dioxane, without altering the other reaction conditions, 
produced 66 in 29% yield. A marked improvement was obtained by raising the reaction 
temperature. In fact, the hydrolysis was carried out by refluxing the Fmoc-amino ester 78 
in a 0.07 M 1:1 dioxane – 4M HCl solution for 2.5 h, giving 66 in 69% yield. Further 
optimization gave 66 in 97% yield by overnight refluxing a 0.2 M solution of 78 in a 1:1 
mixture of 5M HCl – dioxane. Consequently, compound (S)-66 was obtained in five steps 
and an overall yield of 74%. Also, the synthesis of the corresponding enantiomeric (R)-
Fmoc-morpholine-3-carboxylic acid [(R)-66] was carried out starting from D-serine methyl 
ester, giving the title amino acid in 73% overall yield. 
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2.4 Enantiomeric purity 
 
Determination of the enantiomeric purity of (R)-66 and (S)-66  was performed by preparing 
and analyzing the corresponding diastereomeric amides obtained by reaction with a chiral 
amine, followed by HPLC analysis,43 according to methods reported for similar 
compounds.44 Thus, coupling between (S)-(–)-1-phenyl-ethylamine (98% pure) and (S)-66 
or (R)-66 was carried out using HBTU/HOBt and DIPEA in CH2Cl2 at room temperature for 
3 h, giving the corresponding diastereomeric amides in quantitative yields. Since the 1:1 
mixture of the two diastereoisomers could not be separated by reverse-phase HPLC due 
to similar retention times, we found it more convenient to deprotect a 1 mg/mL analytical 
sample of each of the two diastereomeric amides in acetonitrile with a drop of piperidine. 
The two deprotected samples showed different retention times, and the enantiomeric 
purity of the final product was measured by HPLC, giving a de>96%, without any 
detectable traces of the parent isomer in both cases. 
 
 
2.5 Compatibility with solid phase peptide synthesis 
 
Fmoc-3-morpholine carboxylic acid was applied in the Solid-Phase synthesis of a model 
tripeptide using Rink-HMBA resin, and DIC/HOBt as the activating mixture. The internal 
colorimetric Bromophenol Blue test, as reported by Krchnák et al.,45 was used to monitor 
the coupling efficiency on both amino and carboxylic functions of morpholine-3-carboxylic 
acid. Thus, Fmoc-Phe-morpholine-3S-CO-Leu-NH2 79 was synthesized. The coupling 
reactions proved to proceed slower on both functions compared to acyclic  -amino acids. 
The crude tripeptide was obtained in 90% yield after cleavage from the resin, and in 86% 
purity as determined by HPLC, thus showing full compatibility with solid-phase peptide 
chemistry.  
 
Scheme 2.5 Solid phase peptide synthesis using Fmoc-morpholine-3-carboxylic acid 
 
 
 
 
 
 
 
 
 
 
                                               
43 NMR analysis of the diastereomeric amides derived from (S)-66 and (R)-66 for assessing the enantiomeric 
purity of the Fmoc-amino acids was complicated by the presence of rotamers at the urethane bond. 
44 Souers, A. J.; Ellman, J. A. J. Org. Chem. 2000, 65, 1222-1224. 
45 Krchnák, V. ; Vágner, J. ; Sáfar, P. ; Lebl, M. Coll. Czech. Chem. Commun. 1988, 53, 2542-2548. 
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2.6 Strategy extension to threonine: synthesis of Fmoc-2-methyl-3-
morpholine-caroxylic acid 
 
The strategy described in this section and the strategy described in section 2.3 are both 
based on the key step of an acid catalyzed cyclization and a subsequent elimination of 
MeOH, in order to obtain the dihydroxazine structure. However, the synthesis of the 
dihydroxazine derived from threonine is not a mere extension of the strategy developed 
for serine and required much more experimental research, demonstrating the difference in 
reactivity of serine compared to threonine When the strategy developed with serine was 
extended to threonine, problems initially arose in the reductive amination step with 
dimethoxyacetaldehyde. In fact, upon treatment of threonine methyl ester hydrochloride 
with Pd/C-NEt3 under a hydrogen atmosphere, the only observed product was not the 
expected 76a, but 80 (Scheme 2.6). 
 
Scheme 2.6 Attempted synthesis of compound 80 
 
 
 
 
 
 
Protection of the hydroxyl group of threonine with TBSCl46 before performing the reductive 
amination proved essential and allowed the synthesis of the 82 in almost quantitative 
yield. Unfortunately amine 82 was found to be completely unreactive upon treatment with 
Fmoc-Cl under various reaction conditions. We reasoned that this poor reactivity was 
caused by high steric hindrance and so we decided to subject amine 82 to more harsh 
acid conditions, in order to deprotect the hydroxyl group and simultaneously obtain the 
trans-acetalyzation.   
 
Scheme 2.7 Synthesis of Fmoc-2-methyl-3-morpholine carboxylic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
46 Niu, Chuansheng; Pettersson, Teresia; Miller, Marvin J. J. Org. Chem. 1996, 61, 1014-1022. 
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The amino group of the resultant cyclic acetal 83 proved to be much more reactive than 
linear precursor 82 and the crude product deriving from trans-acetalyzation was easily 
protected upon treatment with Fmoc-Cl/NaHCO3 aq. Subsequent treatment of cyclic 
acetal 60b with p-TSOH/MS 4Å in refluxing toluene furnished the dihydroxazine scaffold 
62b in good overall yield, requiring only one purification through flash chromatography 
(Scheme 2.7). Schemes 2.4 and 2.7 are both based on the key step of an acid catalyzed 
cyclization and a subsequent elimination of MeOH, in order to obtain the dihydrozazine 
structure. However, the synthesis of the dihydroxazine derived from threonine is not a 
mere extension of the strategy developed for serine and required much more experimental 
research, demonstrating the difference in reactivity of serine compared to threonine. Final 
conversion of compound 62b to acid 67 was then achieved through catalytic 
hydrogenation using Pt/C, H2 and acid hydrolysis in refluxing dioxane-HCl 6M, using 
similar conditions to those previously described for the synthesis of 66 
 
 
2.7 Experimental for chapter 2 
 
General experimental methods 
Melting points are uncorrected. Chromatographic separations were performed on silica gel 
using flash-column techniques. Rf values refer to TLC carried out on 25 mm silica gel 
plates (Merck F254) with the same eluant indicated as for column chromatography. All the 
solid-phase reactions were carried out on a shaker, using solvents of HPLC quality. HPLC 
analyses were carried out on a HPLC system equipped with analytical C-18 10 µm, 250 × 
4.6 mm, reverse-phase column, using H2O – CH3CN eluant buffered with 0.1% TFA. 1H 
and 13C NMR spectra were recorded with NMR instruments operating at 400 MHz for 
proton and at 50 MHz for carbon, respectively, and using CDCl3 solutions unless 
otherwise stated. EI mass spectra were carried out at 70 eV ionizing voltage, and ESI-MS 
was carried out for peptide 79 using a linear ion-trap LC-MS spectrometer.  
 
(2S)-2-(2,2-Dimethoxy-ethylamino)-3-hydroxy-propionic acid methyl ester (76a) 
 
 
 
 
 
L-serine methyl ester hydrochloride (1.00 g, 6.47 mmol) was dissolved in MeOH (20 mL), 
then triethylamine (902 µL, 6.47 mmol), 60% aqueous solution of dimethoxyacetaldehyde 
(1.11 g, 6.47 mmol) and 10% Pd/C (90 mg) were successively added, and the resulting 
mixture was stirred overnight at room temperature under a hydrogen atmosphere. Then, 
the suspension was filtered on Celite and the organic solvent was removed under reduced 
pressure. The crude product was purified by flash column chromatography (CH2Cl2 – 
MeOH 12:1, Rf 0.43) to yield 76a as a colorless oil (1.31 g, 98%). [α]24D -28.5 (c = 1.0, 
CH2Cl2). 1H NMR (400 MHz, CDCl3) δ  4.44 (t, J = 4.5 Hz, 1 H), 3.77 (dd, J = 11.2, 4.5 Hz, 
1 H), 3.74 (s, 3 H), 3.59 (dd, J = 12.5, 8.0 Hz, 1 H), 3.40 (t, J = 4.5 Hz, 1 H), 3.36 (s, 6 H), 
2.84 (dd, J = 12.5, 4.5 Hz, 1 H), 2.65 (dd, J = 12.5, 4.5 Hz, 1 H), 2.39 (br, 1 H). 13C NMR 
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(50 MHz, CDCl3) δ 173.1 (s), 103.5 (d), 62.7 (d), 62.5 (t), 53.9 (q), 53.1 (q), 52.0 (q), 49.1 
(t). MS m/z 207 (M+, 26), 149 (13), 133 (18). Anal. calcd for C8H17NO5: C, 46.37; H, 8.27; 
N 6.76. Found: C, 46.40; H, 8.31; N 6.69. 
 
(2S)-2-[(2,2-Dimethoxy-ethyl)-(9H-fluoren-9-ylmethoxycarbonyl)-amino]-3-hydroxy-
propionic acid methyl ester (77a) 
 
 
 
 
 
To a solution of 76a (1.14 g, 5.5 mmol) in 2:1 water-dioxane (15 mL) was added NaHCO3 
(0.92 g, 11.0 mmol), and the mixture was cooled to 0 °C with an ice bath, then a solution 
of Fmoc-Cl (1.42 g, 5.5 mmol) in dioxane (15 mL) was added dropwise over 15 min. The 
ice bath was removed, and the reaction mixture was left stirring for 2.5 h. Successively, 
the mixture was partitioned between EtOAc (40 mL) and water (20 mL), and the organic 
phase was washed with 1M HCl, brine, and dried over Na2SO4. The organic solvents were 
then removed under reduced pressure, and the crude product was purified by flash 
column chromatography (EtOAc – hexanes 3:2, Rf 0.53), thus giving pure 77a as a 
colorless oil (2.29 g, 97%). [α]22D -31.6 (c = 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) 3:2 
Mixture of rotamers δ 7.76 (d, J = 7.2 Hz, 2 H), 7.60 (d, J = 6.0 Hz, 1 H), 7.55-7.53 (m, 1 
H), 7.42-7.39 (m, 2 H), 7.35-7.29 (m, 2 H), 4.76-4.69 (m, 2 H), 4.61-4.47 (m, 2 H), 4.24-
4.21 (m, 1 H), 3.97-3.94 (m, 1 H), 3.86-3.80 (m, 1 H), 3.69 and 3.61 (s, 3 H), 3.69-3.59 (m, 
1 H), 3.49 and 3.43 (2s, 2.4 H), 3.16 and 3.11 (2s, 3.6 H), 3.21-3.11 (m, 0.4 H),  2.97 (dd, 
J = 15.2, 7.2 Hz, 0.6 H). 13C NMR (50 MHz, CDCl3) δ 170.0 (s), 156.6 (s), 143.4 (s, 2 C), 
141.2 (s, 2 C), 127.6 (d, 2 C), 127.1 and 126.9 (d, 2 C), 124.6 and 124.5 (d, 2 C), 119.9 
(d, 2 C), 103.3 and 103.0 (d), 67.7 and 66.6 (t), 62.9 and 62.1 (d), 60.7 and 60.2 (t), 55.6 
(q), 54.7 (q), 52.2 (q), 49.1 and 48.9 (t), 47.3 and 47.0 (d). MS m/z 367 [0.2, M+- (OCH3)2], 
324 (0.2). Anal. calcd for C23H27NO7: C, 64.32; H, 6.34; N, 3.26. Found: C, 64.30; H, 6.39; 
N, 3.21. 
 
(3S)-2,3-Dihydro-[1,4]oxazine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester 3-
methyl ester (62a)  
 
 
 
 
 
A solution of compound 4 (1.1 g, 2.56 mmol) in toluene (25 mL) containing a catalytic 
amount of p-toluenesulfonic acid monohydrate (49 mg, 0.26 mmol) was placed in a single-
necked round-bottomed flask equipped with a reflux condenser and dropping funnel 
containing approximately 13 g of 4Å molecular sieves. The mixture was refluxed for 1.75 
h. Then it was cooled to room temperature and filtered through a thin layer of NaHCO3. 
Toluene was removed under reduced pressure, and the crude product was purified by 
flash column chromatography (hexanes-EtOAc 3:1, Rf 0.55) to yield compound 5 as a 
white foam (795 mg, 85%). [α]23D +6.2 (c = 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) 3:2 
Mixture of rotamers δ 7.77 (t, J = 8.0 Hz, 1 H), 7.61 (t, J = 8.0 Hz, 1 H), 7.50 (m, 1 H), 7.41 
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and 7.32 (m, 2 H), 6.42 (d, J = 5.2 Hz, 0.4 H), 6.36 (d, J = 5.2 Hz, 0.6 H), 6.02 (d, J = 5.2 
Hz, 0.4 H), 5.98 (d, J = 5.2 Hz, 0.6 H), 4.97 (s, 0.4 H), 4.68 (d, J = 11.2 Hz, 0.4 H), 4.60-
4.40 (m, 3.2 H), 4.32 (t, J = 7.2 Hz, 0.6 H), 4.23 (t, J = 7.2 Hz, 0.4 H), 3.99 (dd, J = 11.2, 
3.2 Hz, 0.6 H), 3.87 (dd, J = 11.2, 3.2 Hz, 0.4 H), 3.86 (s, 1.8 H), 3.71 (s, 1.2 H). 13C NMR 
(50 MHz, CDCl3) δ 168.2 (s), 151.9 and 151.2 (s), 143.4 and 143.2 (s, 2 C), 141.0 (s, 2 C), 
129.7 and 128.8 (d), 127.6 (d, 2 C), 126.9 (d, 2 C), 124.9 (d), 124.8 (d), 124.8 and 124.5 
(d), 119.9 (d, 2 C), 105.9 and 105.3 (d), 68.3 and 67.8 (t), 65.4 and 64.9 (t), 54.5 and 53.9 
(d), 52.8 (q), 47.0 and 46.9 (d). MS m/z 365 (M+, 7), 306 (0.4, M+-CO2Me), 179 (100). 
Anal. calcd for C21H19NO5: C, 69.03; H, 5.24; N, 3.83. Found: C, 69.16; H, 5.31; N, 3.80. 
 
(3S)-Morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester 3-methyl ester 
(78) 
 
 
 
 
 
Compound 62a (1.30 g, 3.3 mmol) was dissolved in a 2:1 mixture of MeOH-CH2Cl2 (30 
mL), and 10% Pt/C (166 mg) was added. The suspension was hydrogenated overnight at 
room temperature, and then filtered over Celite. The organic solvents were removed under 
reduced pressure and the crude product was purified by flash column chromatography 
(hexanes-EtOAc 2:1, Rf 0.48) to yield  pure 78 as a white foam (1.15 g, 95%). [α]24D -51.5 
(c = 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) mixture of rotamers δ 7.78-7.75 (t, J = 6.9 
Hz, 2 H), 7.60 (t, J = 6.5 Hz, 1 H), 7.50 (t, J = 7.1 Hz, 1 H), 7.43-7.38 (m, 2 H), 7.35-7.28 
(m, 2 H), 4.65 (m, 0.5 H), 4.56-4.46 (m, 1.5 H), 4.44-4.37 (m, 1 H), 4.33-4.28 (m, 1.5 H), 
4.24-4.20 (m, 0.5 H), 3.91-3.84 (m, 1.5 H), 3.78 and 3.73 (s, 3 H), 3.66 (dd, J = 12.0, 2.4 
Hz, 1.5 H), 3.58 (dd, J = 12.0, 2.4 Hz, 0.5 H), 3.50-3.40 (m, 1.5 H), 3.22 (td, J = 12.0, 4.0 
Hz, 1 H). 13C NMR (50 MHz, CDCl3) δ 169.9 (s), 143.7 and 143.5 (s, 2 C), 141.1 (s, 2 C), 
127.5 (d, 2 C), 126.9 (d, 2 C), 124.8 (d), 124.6 and 124.5 (d), 119.8 (d, 2 C), 67.8 and 
67.5 (t), 67.5 and 67.2 (t), 66.5 and 66.1 (t), 54.6 and 54.3 (d), 52.5 (q), 47.0 (d), 41.5 and 
41.0 (t). MS m/z 367 (M+, 0.6), 278 (0.8), 178 (9), 57 (100). Anal. calcd for C21H21NO5: C, 
68.65; H, 5.76; N, 3.81. Found: C, 68.70; H, 5.77; N, 3.82. 
 
(3S)-Morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester [(S)-66] 
 
 
 
 
 
Ester 78 (1.70 g, 4.6 mmol) was dissolved in dioxane (12 mL) and 5M HCl (12 mL) was 
added. The reaction was refluxed for 18 h and then diluted with 5% Na2CO3 (120 mL). The 
resulting solution was washed with diethyl ether and then the aqueous layer was acidified 
to pH=1 with concentrated HCl and the organic phase was extracted with CH2Cl2. The 
organic extracts were combined, dried over Na2SO4 and concentrated under reduced 
pressure to yield compound (S)-66 as a white solid (1.57 g, 97%). Mp = 128-130 °C. [α]24D 
-56.9 (c = 1, CH2Cl2). 1H NMR (400 MHz, CDCl3) mixture of rotamers δ 8.44 (br, 1 H), 
7.69-7.62 (m, 2 H), 7.52-7.50 (m, 1 H), 7.44-7.39 (m, 1 H), 7.33-7.17 (m, 4 H), 4.62 (s, 0.5 
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H), 4.51-4.41 (m, 1.5 H), 4.38-4.32 (m, 1 H), 4.25-4.11 (m, 2 H), 3.83-3.81 (m, 1 H), 3.71 
(d, J = 13.0 Hz, 0.5H), 3.65-3.50 (m, 1 H), 3.45 (dd, J = 11.8, 3.8 Hz, 0.5 H), 3.42-3.31 (m, 
1.5 H), 3.22-3.16 (td, J = 12.5, 3.4 Hz, 0.5 H). 13C NMR (50 MHz, CDCl3) δ 173.7 and 
173.5 (s), 156.1 and 155.5 (s), 143.5 and 143.3 (s, 2 C), 141.0 (s, 2 C), 127.5 (d, 2 C), 
126.8 (d, 2 C), 124.7 (d), 124.5 and 124.4 (d), 119.7 (d, 2 C),  67.9 and 67.4 (t), 67.4 and 
67.0 (t), 66.4 and 66.0 (t), 54.5 and 54.1 (d), 47.0 (d), 41.5 and 41.0 (t). ESI-MS m/z 
354.09 (M++H, 8), 376.18 (M++Na, 100), 392.18 (M++K, 46). Anal. calcd for C20H19NO5: C, 
67.98; H, 5.42; N, 3.96. Found: C, 67.90; H, 5.43; N, 3.98. 
 
(2R)-2-(2,2-Dimethoxy-ethylamino)-3-hydroxy-propionic acid methyl ester [(R)-76a]. 
D-serine methyl ester hydrochloride (2.50 g, 16 mmol) was treated as described for 76a, 
giving pure (R)-76a as a colorless oil (3.25 g, 98%), with spectroscopic data as for the 
enantiomer. [α]24D +27.7 (c = 1.0, CH2Cl2). Anal. calcd for C8H17NO5: C, 46.37; H, 8.27; N 
6.76. Found: C, 46.30; H, 8.41; N 6.79. 
 
(2R)-2-[(2,2-Dimethoxy-ethyl)-(9H-fluoren-9-ylmethoxycarbonyl)-amino]-3-hydroxy-
propionic acid methyl ester [(R)-77a]. Compound (R)-76a (2.33 g, 11.2 mmol) was 
treated as described for 77a, giving pure (R)-77a as a colorless oil (4.57 g, 95%), with 
spectroscopic data as for the enantiomer. [α]22D +32.5 (c = 1.0, CH2Cl2). Anal. calcd for 
C23H27NO7: C, 64.32; H, 6.34; N, 3.26. Found: C, 64.36; H, 6.31; N, 3.22. 
 
(3R)-2,3-Dihydro-[1,4]oxazine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester 3-
methyl ester [(R)-62a]. Compound (R)-62a (2.10 g, 4.89 mmol) was treated as described 
for 62a, giving pure (R)-62a as a white foam (1.54 g, 86%), with spectroscopic data as for 
the enantiomer. [α]23D -6.9 (c = 1.0, CH2Cl2). Anal. calcd for C21H19NO5: C, 69.03; H, 5.24; 
N, 3.83. Found: C, 69.06; H, 5.21; N, 3.78. 
 
(3R)-Morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester 3-methyl ester 
[(R)-78]. Compound (R)-78 (1.05 g, 2.87 mmol) was treated as described for 78, giving 
pure (R)-78 as a white foam (1.00 g, 95%), with spectroscopic data as for the enantiomer. 
[α]24D +51.1 (c = 1.0, CH2Cl2).  Anal. calcd for C21H21NO5: C, 68.65; H, 5.76; N, 3.81. 
Found: C, 68.60; H, 5.79; N, 3.77. 
 
(3R)-Morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester [(R)-66]. 
Compound (R)-66 (0.90 g, 2.45 mmol) was treated as described for (S)-66, giving pure 
(R)-66 as a white solid (0.83 g, 96%), with spectroscopic data as for the enantiomer. MP = 
128-129 °C. [α]24D +57.4 (c = 1, CH2Cl2). Anal. calcd for C20H19NO5: C, 67.98; H, 5.42; N, 
3.96. Found: C, 67.92; H, 5.39; N, 3.91. 
 
Enantiomeric purity. In two separate vessels, (S)-66 and (R)-66 (50 mg, 0.14 mmol) 
were each coupled with (S)-(–)-1-phenyl-ethylamine (36 µL, 0.28 mmol) using HBTU (106 
mg, 0.28 mmol) and HOBt (38 mg, 0.28 mmol) in CH2Cl2 (2 mL) and in the presence of 
DIPEA (96 µL, 0.56 mmol). After 3 h reacting at room temperature, the mixture was diluted 
with EtOAc and the organic phase was washed with 1M HCl, 5% Na2CO3, and brine. The 
organic phase was evaporated to yield the corresponding diastereomeric amides. A 1 
mg/mL analytical sample of the Fmoc-amides from (S)-66 and (R)-66 were further 
deprotected by addition of a drop of piperidine, followed by HPLC analysis using the 
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following gradient: 10% acetonitrile/5 min, then 10 – 25% acetonitrile/20 min, then 25 – 
30% acetonitrile/5 min, then 30 – 90% acetonitrile/15 min. Co-injection of the 1:1 mixture 
of diastereomeric amides from (S)-66 and (R)-66 resulted in two peaks of tR =  22.9 and 
21.8 min, respectively.  
 
Fmoc-Phe-(S)-Morph-Leu-NH2 (79). Solid-phase peptide synthesis was carried out using 
Fmoc-Leu, (S)-66, Fmoc-Phe, and Rink-HMBA resin (122 mg, 0.71 mmol/g). All amino 
acids and coupling reagents (DIC/HOBt) were used in 3-fold excess as 0.17 M DMF 
solutions. Coupling reactions were monitored using the internal Bromophenol Blue 
colorimetric indicator, as reported.20 Fmoc-deprotection was performed using a 30% 
solution of piperidine in DMF. Couplings on both functions of morpholine-3-carboxylic acid 
were completed within 24 h. After each coupling, the indicator was washed from the resin 
using 5% DIPEA in DMF, and successively the resin was washed thoroughly with DMF, 
CH2Cl2, and MeOH. Peptide was cleaved from the resin using 95% TFA in the presence of 
2.5% TIS and 2.5% H2O as scavengers. Peptide 79 was precipitated using cooled methyl-
t-butyl ether, and it was isolated after centrifugation. The crude product (48 mg) was 
analyzed by ESI-MS and by reverse-phase HPLC, resulting in 90% yield and 86% purity 
(10% acetonitrile/5 min, then 10 – 90% acetonitrile/20 min as gradient, 223 nm, tR = 18.80 
min). ESI-MS m/z 613.09 (M++H, 7), 635.36 (M++Na, 77), 651.27 (M++K, 62).  
 
(2R/S,4S,5R)-2-Dimethoxymethyl-5-methyl-oxazolidine-4-carboxylic acid methyl 
ester (80): synthesis of the Cbz-protected derivative of 80.  
 
 
 
 
 
 
Compound 80 was obtained as a by-product starting from L-threonine methyl ester 
(65) (2.42 g, 14.3 mmol) according to the reported procedure for the preparation of 
76a (Chapter 2 and ref. 14). The crude product 80 was then characterized as the 
corresponding Cbz-protected derivative, after treatment of crude 80 with Cbz-Cl 
according to procedure as for 87 (Chapter 4). Pure Cbz-protected compound (2.76 g, 
12.4 mmol) was obtained after chromatographic purification (Hexanes-EtOAc 1:3) in 
87% yield over two steps. (Found: C, 57.96; H, 6.61; N, 3.74. C17H23NO7 requires C, 
57.78; H, 6.56; N, 3.96%); 1H-NMR  (200 MHz, CDCl3) mixture of diastereomers 7.31 
(m, 5 H, Ph), 5.31 [s, 1 H, CH(OCH3)2], 5.15 (s, 2 H, CH2Ph), 4.58 (m, 1 H, OCHN), 
4.46 (m, 1 H, CHCH3), 4.07 (m, 1 H, NCHCO2), 3.69 (s, 3 H, CO2CH3), 3.46 (s, 6 H, 
OCH3), 1.39 (d, J = 5.6 Hz, 3 H, CHCH3); 13C-NMR (50 MHz, CDCl3) mixture of 
diastereomers 169.6 (s, CO2CH3), 135.6 (s, i-Ph), 128.2 (d, 2 C, Ph), 127.9 (d, 2 C, 
Ph), 127.5 (d, Ph), 104.2 [d, CH(OCH3)2], 88.6 (d, OCHN), 67.5 (t, CH2Ph), 64.4 (d, 
CHCH3), 55.7 (d, NCHCO2), 52.3 (q, CO2CH3), 19.5 (q, CHCH3).  
 
(2S,3R)-3-(t-Butyldimethylsilanyloxy)-2-(2,2-(dimethoxy)ethylamino)butyric acid 
methyl ester (82) 
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Compound 65 (3.70 g, 14.9 mmol) was dissolved in MeOH (45 mL), then 60% aqueous 
solution of dimethoxyacetaldehyde (75) (2.59 g, 14.9 mmol) and 10% Pd/C (329 mg) were 
successively added, and the resulting mixture was stirred overnight at room temperature 
under a hydrogen atmosphere. Then, the suspension was filtered on Celite and MeOH 
was removed under reduced pressure. The resulting mixture was partitioned between 
water and Et2O. The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure to yield compound 82 as a colourless 
oil (4.95 g, 99%). (Found: C, 53.86; H, 10.00; N, 4.22. C15H33NO5Si requires C, 53.70; H, 
9.91; N, 4.17%); [α]25D −11.4 (c 1.1, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 4.53 (t, J = 5.2 
Hz, 1 H, CH(OCH3)2], 4.18 (qui, J = 5.3 Hz, 1 H, OCHCH3), 3.73 (s, 3 H, CO2CH3), 3.37 (s, 
6 H, OCH3), 3.37 (m, 1 H, NCHCO2), 2.94 (dd, J = 12.2, 5.8 Hz, 1 H, CH2CH), 2.73 (dd, J 
= 12.2, 5.0 Hz, 1 H, CH2CH), 1.25 (d, J = 6.4 Hz, 3 H, CHCH3), 0.85 [s, 9 H, (CH3)3CSi], 
0.44 (s, 3 H, CH3Si), 0.14 (s, 3 H, CH3Si); 13C NMR (50 MHz, CDCl3) δ171.9 (s, CO2CH3), 
102.9 [d, CH(OCH3)2], 69.1 (d, OCHCH3), 66.8 (d, NCHCO2), 54.4 (q, OCH3), 53.6 (q, 
OCH3), 52.0 (q, CO2CH3), 48.9 (t, CH2CH), 25.7 [q, 3 C, (CH3)3CSi], 20.8 (q, CHCH3), 17.9 
[s, (CH3)3CSi], −4.2 (q, CH3Si), −5.1 (q, CH3Si); MS m/z 304 (M+ − CH3O, 8), 291 (15), 
278 (6), 246 (13), 159 (38), 73 (100). 
 
(2R,3S,6R/S)-6-Methoxy-2-methyl-morpholine-3-carboxylic acid methyl ester (83)  
 
 
 
 
 
SOCl2 (511 µL, 7 mmol) was added dropwise, at 0 °C, to 7 mL of MeOH. The resulting 
solution was used to dissolve compound 82 (600 mg, 1.79 mmol). The resulting 
mixture was refluxed for 4 h, and then concentrated under reduced pressure. The 
crude material was dissolved again in MeOH, neutralized with Amberlist A-21, and the 
solvent was evaporated to dryness. The product was directly used without further 
purification for the subsequent protection step. An analytical pure sample was 
obtained after purification through flash column chromatography (EtOAc). (Found: C, 
50.86; H, 8.08; N, 7.22. C8H15NO4 requires C, 50.78; H, 7.99; N, 7.40%); 1H-NMR (400 
MHz, CDCl3) 3:2 mixture of diastereomers α and β: δ 4.47 (s, 0.4 H, H-6 β), 4.40 (dd, J 
= 8.8, 2.4 Hz, 0.6 H, H-6 α), 3.88 (qd, J = 5.0, 1.8 Hz, 0.4 H, H-2 β), 3.74 and 3.73 (s, 
3 H, CO2CH3), 3.65 (qd, J = 4.2, 1.2 Hz, 0.6 H, H-2 α), 3.50 (s, 1.8 H, OCH3 α), 3.39 
(s, 1.2 H, OCH3 β), 3.27 (d, J = 9.4 Hz, 0.4 H, H-3 β), 3.18 (d, J = 9.4 Hz, 0.6 H, H-3 
α), 3.04 (dd, J = 12.4, 2.4 Hz, 0.6 H, H-5 α), 2.92-2.90 (m, 0.8 H, H-5 β), 2.59 (dd, J = 
12.4, 8.8 Hz, 0.6 H, H-5 α), 1.75-1.95 (br, 1 H, NH), 1.25 (d, J = 6.4 Hz, 1.8 H, CHCH3 
α), 1.15 (d, J = 6.0 Hz, 1.2 H, CHCH3 β); 13C NMR (50 MHz, CDCl3) mixture of 
diastereomers δ  171.1 (s, CO2CH3), 100.6 and 95.6 (d, C-6), 73.7 and 65.4 (d, C-2), 
63.6 and 62.8 (d, C-3), 56.1 and 54.5 (q, OCH3), 52.1 (q, CO2CH3), 47.9 and 47.2 (t, 
C-5), 18.2 (q, CHCH3).   
 
6-Methoxy-2-methyl-morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) 
ester 3-methyl ester (60b) 
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The crude cyclic acetal 83 was dissolved in H2O (13 mL) and NaHCO3 (1.33 g, 15.9 
mmol) was added. The mixture was stirred until complete dissolution of the salt and then 
dioxane (20 mL) was added. The flask was cooled at 0°C with an ice bath and solid Fmoc-
Cl (1.17 g, 4.55 mmol) was added portion wise. After 10 minutes the ice bath was 
removed and the reaction mixture was stirred 16 h at room temperature. After that EtOAc 
(30 mL) and water (20 mL) were added. The aqueous layer was discarded and the 
organic phase was washed with 5% citric acid, brine and dried over Na2SO4. The solvents 
were removed under reduced pressure and the crude material was purified through flash 
column chromatography (hexanes/AcOEt) to yield 1.778 g (95%) of 60b. (Characterization 
data refers to the first eluted diastereomer) [α]26D -3.40 (c = 1, CH2Cl2). 1H-NMR (200 MHz, 
CDCl3) (mixture of rotamers) δ 7.77 (d, J = 7.2 Hz, 2 H), 7.54 (bs, 2 H), 7.44-7-23 (m, 4 
H), 4.81-4.68 (m, 1 H), 4.45-4.00 (m, 6 H), 3.74 and 3.67 (2 overimposed singlets, 3 H), 
3.41 (s, 3 H), 3.20-3.97 (m, 1 H), 1.37 (s, 3 H). 13C-NMR (50 MHz, CDCl3) (mixture of 
rotamers) δ 170.6 (s), 155.1 (s), 143.3 (s), 141.1 (s), 127.5 (d, 2 C), 126.9 (d, 2 C), 124.7 
(d, 2 C), 119.8 (d, 2 C), 97.0 (d), 96.4 (d), 67.8 (t), 64.9 (d), 64.4 (d), 61.5 (d), 61.0 (d), 
55.3 (q), 52.3 (q), 47.1 (d), 42.9 (t), 42.0 (t), 19.1 (q). MS m/z 411 (M+, 8), 189 (3), 178 
(100), 165 (10), 152 (6). 
Anal. calcd for C23H25NO6: C, 67.14, H, 6.12, N, 3.40. Found: C, 67.65, H 6.18, N, 3.50. 
 
2-Methyl-2,3-dihydro-[1,4]oxazine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) 
ester 3-methyl ester (62b) 
 
 
 
A solution of compound 60b (736 mg, 1.79 mmol) in toluene (15 mL) containing a catalytic 
amount of p-toluenesulfonic acid monohydrate (34 mg, 0.18 mmol) was placed in a single-
necked round-bottomed flask equipped with a reflux condenser and dropping funnel 
containing approximately 10 g of 4Å molecular sieves. The mixture was refluxed for 1.45 
h. Then it was cooled to room temperature and filtered through a thin layer of NaHCO3. 
Toluene was removed under reduced pressure, and the crude product was purified by 
flash column chromatography (hexanes-EtOAc 7:2, Rf 0.50) to yield compound 62b as a 
white foam (598 mg, 88%). [α]27D 6.3 (c = 1.15, CHCl3). 1H-NMR (200 MHz, CDCl3) 
(mixture of rotamers) δ 7.77 (t, J = 7.2 Hz, 2 H), 7.74 (t, J = 4.4 Hz, 2 H), 7.53-7.26 (m, 4 
H), 6.37-6.32 (m, 1 H), 6.29-6.83 (m, 1 H), 4.88 (q, J = 6.6 Hz, 1 H), 4.72 (s, 1 H), 4.60-
4.21 (m, 4 H), 3.70 and 4.25 (2 singlets, 3 H), 1.33 (d, J = 6.6 Hz, 2 H), 1.24 (d, J = 6.6 
Hz, 1 H). 13C NMR (50 MHz, CDCl3) Mixture of rotamers δ 168.3 (s), 152.7 and 151.9 (s), 
143.5 and 143.2 (s, 2C), 141.1 (s, 2C), 127.6-124.5 (d, 7 C), 119.9 (d, 2C), 104.5 and 
104.0 (d), 69.8 and 69.2 (d), 68.3 and 67.8 (t), 57.9 and 57.4 (d), 52.7 (q), 47.1 and 47.0 
(d) 17.3 (q). MS m/z 379 (M+, 10), 179 (100), 157 (20), 98 (28). 
Anal. calcd for C22H21NO5: C, 69.64, H, 5.58, N, 3.69. Found: C, 69.65, H 5.98, N, 3.70. 
 
2-Methyl-morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester 3-methyl 
ester (84) 
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Compound 62b (530 mg, 1.40 mmol) was dissolved in a 2:1 mixture of MeOH-CH2Cl2 (15 
mL), and 10% Pt/C (63 mg) was added. The suspension was hydrogenated overnight at 
room temperature, and then filtered over Celite. The organic solvents were removed under 
reduced pressure and the crude product was purified by flash column chromatography 
(hexanes-EtOAc 3:1, Rf 0.41) to yield  pure 84 as a white foam (480 mg, 90%). [α]23D -33.6 
(c = 1.1, CHCl3). 1H-NMR (200 MHz, CDCl3) (mixture of rotamers) δ 7.76 (d, J = 7.0 Hz, 2 
H), 7.59 (bs, 2 H), 7.40-7.26 (m, 4 H), 4.60-4.40 (m, 3 H), 4.40-4.00 (m, 2 H), 3.75 (s, 3 
H), 3.80-3.20 (m, 4 H), 1.33 (d, J = 6.4 Hz, 3 H).13C NMR (50 MHz, CDCl3) Mixture of 
rotamers δ  169.8 (s), 156.3 (s), 143.4 and 143.3 (s, 2C), 141.0 (s, 2C), 127.4 (d, 2C), 
126.8 (d, 2C), 124.5 (d, 2C), 119.7 (d, 2C), 69.4 (d), 67.6 (t), 58.6 (1d and 1t, 2C), 52.4 
(q), 47.1 (d), 41.1 (t), 16.6 (q). MS m/z 322 (3), 178 (100), 165 (6), 152 (4). Anal. calcd for 
C22H23NO5: C, 69.28, H, 6.08, N, 3.67. Found: C, 69.45, H 5.98, N, 3.70. 
 
2-Methyl-morpholine-3,4-dicarboxylic acid 4-(9H-fluoren-9-ylmethyl) ester (67) 
 
 
 
 
 
Ester 84 (420 g, 1.1 mmol) was dissolved in dioxane (4 mL) and 5M HCl (4 mL) was 
added. The reaction was refluxed for 18 h and then diluted with 5% Na2CO3 (30 mL). The 
resulting solution was washed with diethyl ether and then the aqueous layer was acidified 
to pH=1 with concentrated HCl and the organic phase was extracted with CH2Cl2. The 
organic extracts were combined, dried over Na2SO4 and concentrated under reduced 
pressure to yield compound 67 as a white solid (390 mg, 96%). [α]24D -26.7 (c = 2, CHCl3). 
1H-NMR (200 MHz, CDCl3) (mixture of rotamers) δ 10.0 (bs, 1 H), 7.75 (d, J = 7.4 Hz, 2 
H), 7.57 (bs, 2 H), 7.40-7.25 (m, 4 H), 4.60-4.45 (m, 3 H), 4.40-4.26 (m, 2 H), 4.00-3.21 
(m, 4 H), 1.36 (d, J = 5.2 Hz, 3 H).13C NMR (50 MHz, CDCl3) Mixture of rotamers δ 174.0 
(s), 156.7 and 156.0 (s), 143.4 (s, 2C), 141.0 (s, 2C), 127.5 (d, 2C), 126.9 (d, 2C), 124.7 
(d, 2C), 119.7 (d, 2C), 69.3 and 68.4 (d), 67.7 (t), 58.2 (1d and 1t, 2C), 47.0 (d), 41.0 (t), 
16.4 (q). MS m/z 321 (2), 178 (100), 152 (16), 88 (19), 76 (24). 
Anal. calcd for C21H21NO5: C, 68.65, H, 5.76, N, 3.81. Found: C, 68.40, H, 5.66, N, 3.90. 
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L- or D-morpholine-3-carboxylic acids as β-turn 
nucleators 
 
 
“Trabocchi, A.; Sladojevich, F.; Guarna, A. 
Chirality, Early View” 
 
 
ABSTRACT 
 
The conformational analysis by NMR, IR and molecular modeling of tetrapeptides 
containing morpholine-3-carboxylic acid (Mor) as a proline surrogate is presented. The 
relationhip between the chirality of the cyclic amino acid at position i+1 and the turn 
propensity was maintained with respect to the reference proline-containing peptides, 
although marked differences in the type of folded structures were observed. The 
conformational profile of morpholine-containing turn peptides as a function of the chirality 
of the cyclic amino acid indicated that the heterochiral tetrapeptide containing the D-
isomer of the cyclic amino acid is more prone to nucleate compact folded structures, 
although with no resemblance to the β-turn structures of D-proline-containing peptides. 
Also, the solvation system proved to influence the organization of folded structures, as in 
the more interactive CD3CN the model peptides showed more compact conformations. L-
morpholine-3-carboxylic acid displayed two rotamers at the Val-Mor amide bond. The 
trans isomer of 85 did not experience any turn structures, nor any intramolecular 
hydrogen-bonds, whereas the cis isomer showed a strong preference for a type VI β-turn 
structure, thus providing a different conformational asset with respect to the β-turn 
structure as reported for the reference L-proline model peptide. 
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3.1 Introduction 
 
One of the relevant aspects in medicinal chemistry is related to the development of 
peptides and peptidomimetics as drugs, and to the comprehension of the role of small 
modified peptides in the development and cure of diseases. β-Turns play a crucial role in 
proteins and bioactive peptides for folding and generating compact structures,47 often 
being involved in molecular recognition processes,48 and so is for γ-turns, which are 
considered as rare turns among the types of secondary structures able to reverse the 
chain direction.49 Β-Turns are a subset of reverse turns and consist of a tetrapeptide 
sequence in a non-helical region in which the chain direction is reversed. These turns are 
often stabilized by an ten-membered ring intramolecular hydrogen-bond between the 
carbonyl oxygen of the first residue (i) and the amide proton of the fourth one (i+3) (Figure 
3.1, left). γ-Turns, which are less common than β -turns, are three residue sequences 
containing a seven-membered ring intramolecular hydrogen-bond between the carbonyl 
group of the first residue (i) with the amide proton of the third residue (i+2) (Figure 3.1, 
right). Further classification into classical or inverse γ-turns depends on the position of the 
side chain of the i+1 residue, being equatorial for the inverse type and axial for the 
classical γ-turn.50 
 
 
 
 
 
  
Figure 3.1: β- (left) and γ-turn (right) structures. 
 
β- And γ-turns mimetics have been taken into account for peptidomimetic design, as they 
allow to present in a stereocontrolled fashion two to four side chains of amino acids 
involved in biological interactions. Among the mimetics of γ-turns reported in the 
literature, the mimicry of such conformation by suitable γ-turn inducers is of special 
interest, which provide stabilization of  the turn motif by an intramolecular hydrogen-
bond.51 The majority of β -turn mimetics is based upon the replacement of the i+1 - i+2 
central dipeptidic sequence of a turn with dipeptide isosteres capable to preserve the 
intramolecular 10-membered ring hydrogen-bond.52 Also, the use of proline-mimetics has 
                                               
47 (a) Sibanda, B.L.; Blundell, T.L.; Thornton J.M.; J Mol Biol 1989, 206, 759-777. (b) Bell, J.E.; Bell, T.E.; 
Proteins and Enzymes. NJ, Prentice Hall: Englewood Cliffs; 1988. (c) Rose, G.D.; Gierasch, L.M.; Smith, J.A.; 
Adv Protein Chem 1985, 37, 1-109.  
48 (a) Creighton T.E. Proteins: Structure and Molecular Properties; Freeman: New York, 1983. (b) Rizo, J.; 
Gierasch, L.; Annu Rev Biochem 1992, 61, 387-418. (c) Ferguson, M.D.; Meara, J.P.; Nakanishi, H.; Lee, 
M.S.; Kahn, M.; Tetrahedron Lett. 1997, 38, 6961-6964 and references cited therein.  
49 F. A. Etzkorn, J. M. Travins, S. A. Hart in Rare Protein Turns: γ-turn, helix-turn-helix, and cis-proline mimics; 
(Advances in Amino Acid Mimetics and Peptidomimetics), JAI Press Inc., 1999, vol. 2, pp. 125–163. 
50 Statchel, S.J.; Hu, H.; Van, Q.N.; Shaka, A.J.; Van Vranken, D.L. Bioorg. Med. Chem. 1998, 6, 1439-1446. 
51 (a) Zhang, Y.L.; Marepalli, H.R.; Lu, H.; Becker, J.M.; Naider, F. Biochemistry 1998, 37, 12465-12476; (b) 
Burgess, K.; Lei, W.; Lim, D.; Moye-Sherman, D. Biopolymers 1997, 42, 439-453; (c) Curran, T.P.; Chandler, 
N.M.; Kennedy, R.J.; Keaney, M.T. Tetrahedron Lett. 1996, 37, 1933-1936; (d) Reetz, M.T.; Griebenow, N.; 
Goddard, R.; J. Chem. Soc., Chem. Commun. 1995, 1605-1606. 
52 (a) Alonso, E.; López-Ortiz, F.; Del Pozo, C.; Peralta, E.; Macías, A.; González, J. J. Org. Chem. 2001, 66, 
6333-6338; (b) Soth, M.J.; Nowick, J. S. J. Org. Chem. 1999, 64, 276-281;(c) Feng, Y.; Pattarawapan, M.; 
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been pursued and several scaffolds have been proposed, either having bicyclic structures 
or four to six-membered ring proline homologues, as among the naturally occurring amino 
acids, proline is known to play a central role in the nucleation of reverse turn structures 
like β -turns and β -hairpins, due to its ability to form cis peptide bonds and to undergo 
cis/trans isomerization.53 In fact, cis geometry of proline amide bond causes peptide 
backbone to fold in a type VI β -turn, in which proline occupies the i+2 position, although 
proline is often observed at the i+1 position of β -turn structures, generating a trans amide 
bond with the preceding amino acid at position i.54 In addition, it has been demonstrated 
that the cis/trans isomerization at Xaa-Pro peptide bond is accelerated by changing the 
proline ring in size and structure, and as an example, pipecolates have served as proline 
substitutes in structure-activity studies of biologically relevant peptides.55 Finally, whereas 
L-proline as the second residue (i + 1) is known to nucleate type I/II, β -turns in peptides 
involving an intramolecular hydrogen-bond between the C=O of the first (i) and NH of the 
fourth (i + 3) residue, its D-isomer favors antiparallel β-sheet formation via type I’/II’ β -
turns.56,57 As an additional unexplored proline analogue, morpholine-3-carboxylic acid 
(Mor) is of interest due to the oxygen atom in the ring which can modulate the polarity and 
the chair conformation profiles with respect to pipecolic acid. The relevance of such 
secondary amino acid in medicinal chemistry is remarkable, as morpholine-3-carboxylic 
acid has been used to synthesize several bioactive molecules, such as TACE,58 MMP and 
TNF inhibitors,59 and a potent orally active VLA-4 antagonist.60 In the previous chapter, 
we reported a new method for the synthesis of enantiopure Fmoc-protected morpholine-
3-carboxylic acid (66) from dimethoxyacetaldehyde and serine methyl ester through a 
short and practical synthetic route.61 This preliminar results opened the way to the 
synthesis of a new class of cyclic amino acids containing the morpholine nucleus, and 
also, with the aim to gain informations for the design of turn peptides containing the 
                                                                                                                                              
Wang, Z.; Burgess, K. Org. Lett. 1999, 1, 121-124; d) Krauthäuser, S.; Christianson, L.A.; Powell, D.R.; 
Gellman, S.H. J. Am. Chem. Soc. 1997, 119, 11719-11720; (e) Hanessian, S.; McNaughton–Smith, G.; 
Lombart, H.G.; Lubell, W.D. Tetrahedron 1997, 53, 12789-12854; (f) Gardner, R.R.; Liang, G.B.; Gellman, 
S.H. J. Am. Chem. Soc. 1995, 117, 3280-3281; (g) Virgilio, A.A.; Ellman, J.A. J. Am. Chem. Soc. 1994, 116, 
11580-11581; (h) Gardner, B.; Nakanishi, H.; Kahn, M. Tetrahedron 1993, 32, 1244-1267; (i) Nagai, U.; Sato, 
K.; Nakamura, R.; Kato, R. Tetrahedron 1993, 49, 3577-3592. 
53 (a) Kym, K.; Germanas, J.P. J. Org. Chem. 1997, 62, 2847-2852; (b) Lenman, M.M.; Lewis, A.; Gani, D. J. 
Chem. Soc., Perkin Trans. 1 1997, 2297-2311; (c) Genin, M.J.; Johnson, R.L. J. Am. Chem. Soc. 1992, 114, 
8778-8783; (d) Halab, L.; Lubell, W.D. J. Am. Chem. Soc. 2002, 124, 2474-2484; (e) Halab, L.; Lubell, W.D. J. 
Org. Chem. 1999, 64, 3312-3321. 
54 Breznik, M.; Golič S.; Grdadolnik, G. Giester, I. Leban, D. Kikelj, J. Org. Chem. 2001, 66, 7044-7050. 
55 (a) Kern, D.; Schutkowski, M.; Drakenberg, T. J. Am. Chem. Soc. 1997, 119, 8403-8408; (b) Ando, S.; 
Ikuhara, T.; Kamata, T.; Sasaki, Y.; Hisanga, S.I.; Kishimoto, T.; Ito, H.; Inagaki, M. J. Biochem. 1997, 122, 
409-414; (c) Wu, W.J.; Raleigh, D.P. J. Org. Chem. 1998, 63, 6689-6698. 
56 One of the earliest examples of the turn-forming ability of N-acyl proline dipeptides composed of amino 
acids of opposite configurations (“heterochiral sequences”) may be found in the structure of gramicidin: Hull, 
S.E.; Karlsson, R.; Main, P.; Woolfson, M.M.; Dodson, E.J. Nature 1978, 275, 206-275. 
57 Deber, C.M.; Madison, V.; Blout, E.R. Acc. Chem. Res. 1976, 9, 106-113. 
58 Levin, J.I.; Chen, J.M.; Laakso, L.M.; Du, M.; Du, X.; Venkatesan, A.M.; Sandanayaka, V.; Zask, A.; Xu, J.; 
Xu, W.; Zhang, Y.; Skotnicki, J.S.; Bioorg. Med. Chem. Lett. 2005, 15, 4345-4349. 
59 (a) Almstead, N.G.; Bradley, R.S.; Pikul, S.; De, B.; Natchus, M.G.; Taiwo, Y.O.; Gu, F.; Williams, L.E.; 
Hynd, B.A.; Janusz, M.J.; Dunaway, C.M.; Mieling, G.E. J. Med. Chem. 1999, 42, 4547-4562; (b) Piscopio, 
A.D.; Rizzi, J.P. WO 96/33172, October 24, 1996. 
60 Chiba, J.; Machinaga, N.; Takashi, T.; Ejima, A.; Takayama, G.; Yokoyama, M.; Nakayama, A.; Baldwin, 
J.J.; McDonald, K.W.; Hussain, R.; Wong, A; Bioorg. Med. Chem. Lett. 2005, 15, 41-45. 
61 Sladojevich, F.; Trabocchi, A.; Guarna, A. J. Org. Chem. 2007, 72, 4254-4257. 
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morpholine nucleus, we were interested in exploring the conformational role of such 
amino acid in model peptides. Specifically, in this chapter is reported the conformational 
analysis of model tetrapeptides containing either L- or D-morpholine-3-carboxylic acid 
(66) at position i+1, with the aim to assess the role of such amino acids in determining the 
conformational preferences of the peptide with respect to the parent peptide sequence 
bearing proline at the same position, as reported by Gellman et al.11g 
 
 
3.2 Synthesis of model tetrapeptides 
 
The synthesis of tetrapeptides 85 and 86 was achieved by means of Solid-Phase 
techniques using standard Fmoc protocol and HMBA (4-hydroxymethylbenzoic acid) resin, 
which allowed to perform a nucleophilic cleavage at the end of the synthesis, thus 
obtaining the title peptides with the C-terminus protected as methyl ester. Amino acid 
couplings were performed using DIPC (N,N’-diisopropylcarbodiimide)/HOBt (1-
hydroxybenzotriazole) as activating mixture and DMF as solvent. Completion of coupling 
reaction was monitored using bromophenol blue as internal standard, as described by 
Krchnák et al.62 In the case of valine coupling to the morpholine nucleus, reaction times 
were prolonged due to lowered reactivity at nitrogen atom of the latter. Despite the harsh 
conditions employed during the synthesis, the preparation of peptides afforded a mixture 
of the desired compound and Ac-Mor-Gly-Leu-OMe by-product, due to incomplete 
coupling. Truncated and title compounds were separated by semi-preparative HPLC, and 
peptides 85 and 86 were characterized by analytical HPLC, ESI-MS and NMR 
spectroscopy. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Model tetrapeptides containing L- (top) and D- (bottom) morpholine-3-
carboxylic acids. 
 
 
3.3 Conformational analysis 
 
The conformational analysis of peptides 85 and 86 was carried out by NMR and IR 
spectroscopy.63 As an additional aspect of the conformational study, the influence of 
                                               
62 Krchnák, V.; Vágner, J.; Sáfar, P.; Lebl, M. Collect. Czech. Chem. Commun. 1998, 53, 2542-2548. 
63 (a) Belvisi, L.; Gennari, C.; Mielgo, A.; Potenza, D.; Scolastico, C. Eur. J. Org. Chem. 1999, 389-400; (b) 
Yang, J.; Gellman, S.H. J. Am. Chem. Soc. 1998, 120, 9090-9091; (c) Liang, G.B.; Rito, C.J.; Gellman, S.H. J. 
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different solvents on the structural organization of morpholine-containing turn peptides 
was investigated.  The behaviour of amide protons was studied in CDCl3, a relatively non-
polar solvent, which is well-suited for evaluating intrinsic conformational propensities of 
small oligoamides, and CD3CN, being a moderate hydrogen-bond acceptor with enhanced 
solvating properties, was used to test the strength of intramolecular hydrogen-bonds of 
amide protons. The conformational analysis consisted in the examination of the hydrogen-
bonding pattern through the behaviour of amide proton chemical shifts as a function of the 
temperature and of increasing quantities of [D6]DMSO as a competitive solvent, and in the 
analysis of the 3D topology by 2D NMR experiments. 
 
 
3.3.1 Tetrapeptide containing L-morpholine-3-carboxylic acid 
 
The model tetrapeptide containing the L-isomer of morpholine-3-COOH [(L)-66] resulted in 
a 2:3 mixture of cis and trans rotamers at the Val-morpholine amide bond. The cis rotamer 
was more populated (55%) in the more interactive CD3CN solvent, in analogy with 
literature data indicating a growing amount of cis isomer of proline-containing peptides 
with increasing polarity of the solvent, as reported.64 Temperature dependence 
experiments in CDCl3 for amide protons belonging to the trans isomer showed medium 
temperature coefficients in absolute value (Table 3.1 and Figure 3.3, bottom left) and low 
chemical shift values (< 7 ppm), which suggested the absence of significant hydrogen-
bonded structures in such solvent. The termodinamic profile of amide proton chemical 
shifts in CD3CN showed little differences (Table 3.1 and Figure 3.3, bottom right), as Gly 
NH and Leu NH experienced lower temperature coefficient, and the chemical shifts 
suggested a non hydrogen-bonded profile for all the amide protons. This evidence was 
also supported by significant chemical shift deviations of the amide protons in CDCl3 with 
increasing amounts of [D6]DMSO as a competitive solvent (Figure 3.4, right), thus proving 
undoubtedly the absence of significant intramolecular hydrogen-bonding interactions for 
peptide 85, trans isomer. 
 
Table 3.1 Chemical shifts and temperature-dependent 1H-NMR data for amide protons of 
peptide 85.[a] 
 Amide Proton 
CDCl3 
 
Δδ/ΔT CD3CN 
 
Δδ/ΔT 
Cis ValNH     6.23 -5.57 6.67 -2.7 
 GlyNH 8.03 -0.4 7.99 -4.3 
 LeuNH 6.88 -4.76 7.17 -3.1 
Trans ValNH 6.32 -4.77 6.90 -4.1 
 GlyNH 6.70 -3.23 6.90 -1.8 
 LeuNH 6.39 -3.68 6.80 -0.7 
 
[a] Chemical shifts (δ) are reported in ppm, and temperature coefficients (Δδ/ΔT) in ppb/K. 
 
                                                                                                                                              
Am. Chem. Soc. 1992, 114, 4440-4442; (d) Gellman, S.H.; Dado, G.P.; Liang, G.B.; Adams, B.R. J. Am. 
Chem. Soc. 1991, 113, 1164-1173; (e) Boussard, G.; Marraud, M. J. Am. Chem. Soc. 1985, 107, 1825-1828. 
64 (a) Higashijima, T.; Tasumi, M.; Miyazawa, T. Biopolymers 1977, 16, 1259-1270; Madison, V.; Kopple, K.D. 
J. Am. Chem. Soc. 1980, 102, 4855-4863. 
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Figure 3.3 Variable temperature NH chemical shifts for L-peptide 85, cis-rotamer in CDCl3 
(top left) and CD3CN (top right), and trans-rotamer in CDCl3 (bottom left) and CD3CN 
(bottom right). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 [D6]DMSO titration of 1-2 mM CHCl3 solutions of peptide 85 (left: cis rotamer; 
right: trans rotamer). 
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The indication that the trans isomer of peptide 85 does not nucleate into ordered 
structures was confirmed by ROESY experiments, which showed the absence of any 
relevant cross peaks diagnostic of reverse turn motifs. ROESY peaks between Val H-α 
(4.90) and H-5 (3.87) of the morpholine ring allowed to assign the trans geometry at the 
Val-Mor amide bond. Thus, experimental data indicated that replacing L-proline with L-
morpholine causes the peptide to lose the equilibrating γ- and β-turn conformations, as 
suggested by Gellman et al. for the same rotamer of the model peptide Ac-Val-Pro-Gly-
Leu-OMe,11g and to fall into random conformations. 
The cis isomer of 85 displayed a more organized structure. 1D NMR data showed a 
deshielded chemical shift for Gly NH, which, in conjunction with a low temperature 
coefficient (Table 3.1), suggested the existence of a stable hydrogen-bonded structure in 
the less polar CDCl3, and of equilibrating hydrogen-bonded and non hydrogen-bonded 
conformations in the more interactive CD3CN, as indicated by higher Δδ/ΔT values (Table 
3.1, and Figure 3.3, top). Also, Leu NH proved to experience a slight deshield in CD3CN, 
indicating a greater tendency to experience equilibrating hydrogen-bonded conformations, 
whereas Val NH showed chemical shift values typical of non hydrogen-bonded 
conformations in both solvents. 1D experiments in the presence of increasing amounts of 
[D6]DMSO confirmed Gly NH as a strong intramolecular hydrogen-bond donor, as the 
chemical shift of such proton was not altered significantly within the range of 0.2 ppm 
(Figure 3.4, left). Also, Leu NH displayed a smaller deviation of the chemical shift as a 
function of increasing quantities of [D6]DMSO compared to the parent trans isomer, as a 
consequence of equilibrating hydrogen-bonding states. Although Val H-α and H-3 of the 
morpholine scaffold were almost isocronous in the ROESY spectrum, the absence of 
cross peaks between Val H-α and H-5 was diagnostic of the cis geometry at the Val-Mor 
amide bond. Nevertheless, ROESY data in CD3CN clearly showed a cross peak between 
Val H-α (4.38) and H-3 (4.61) which allowed to assign the cis rotamer. Also, this contact 
was consistent with the existence of a type VI β-turn stabilized by a ten-membered ring 
hydrogen bond between the acetyl group and Gly NH (Figure 3.5). This hydrogen-bond 
was in agreement with 1D experiments indicating a strong preference of Gly NH for 
hydrogen-bonded states, thus shifting the morpholine-based amino acid to the i+2 position 
of the turn. The equilibrating nature of Leu NH in hydrogen-bonding interactions was in 
agreement with interactions with either Mor C=O to generate a γ-turn or the acetyl group 
(Figure 3.5). 
 
 
 
 
 
 
 
 
Figure 3.5 Reverse turn conformations of peptide 85, cis isomer: the arrows indicate 
diagnostic ROESY peaks. 
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3.3.2 Tetrapeptide containing D-morpholine-3-carboxylic acid 
 
1D NMR data of peptide 86 showed a single set of signals, indicating the existence of a 
unique rotamer. Sequential ROESY peaks between Val H-α and H-5 protons of the 
morpholine nucleus allowed to assign this structure as the trans isomer. Temperature 
dependence data showed a different behaviour of amide protons of peptide 86 with 
respect to the trans rotamer of diastereoisomer 85, (Table 3.2 and Figure 3.6). The 
analysis of the chemical shifts of amide protons suggested marked differences with 
respect to the reference D-proline-containing peptide as reported by Gellman et al.,11g as 
Gly NH showed higher deshield of its chemical shift and higher propensity to establish 
hydrogen-bonds with respect to Leu NH, whereas Val NH did not display any hydrogen-
bonding preference, in analogy with both rotamers of peptide 85. 
 
Table 3.2 Chemical shifts and temperature-dependent 1H NMR data for amide protons of 
peptide 85[a] 
Amide 
proton 
CDCl3 
   δ 
Δδ/ΔT CD3CN 
    Δ 
Δδ/ΔT 
ValNH 6.68 -3.14 7.01 -4.2 
GlyNH 7.45 -4.57 7.74 -3.3 
LeuNH 6.78 -2.36 6.82 -1.1 
 
[a] Chemical shifts (δ) are reported in ppm, and temperature coefficients (Δδ/ΔT) in ppb/K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Variable temperature NH chemical shifts in CDCl3 (left) and CD3CN (right) for 
peptide 86. 
 
Temperature coefficient and chemical shift values of Gly NH indicated an equilibrium 
between hydrogen-bonded and non hydrogen-bonded states, suggesting the capability of 
nucleating reverse turn structures. [D6]DMSO competition studies confirmed the marked 
tendency of Gly NH to act as a hydrogen-bond donor, as the conservation of the chemical 
shift within 0.2 ppm upon increasing quantities of the competitive solvent was observed 
(Figure 3.7). Also, Leu NH, although displaying lower chemical shift values compared to 
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Gly NH, showed a similar stability of the chemical shift in the presence of increasing 
amounts of [D6]DMSO, whereas Val NH showed high deviation of the chemical shift in the 
presence of [D6]DMSO, in accordance with δ and Δδ/ΔT values suggesting the absence of 
any involvement in intramolecular hydrogen-bonds. These data proved peptide 86 to fold 
into equilibrating γ- and β-turn structures stabilized by seven- and ten-membered ring 
intramolecular hydrogen-bonds established by Gly NH and Leu NH. 
 
Figure 3.7 [D6]DMSO titration of peptide 86. 
 
ROESY data of 86 in CDCl3 showed a correlation between Val H-α (4.37) and H-5 (3.94), 
diagnostic of the trans configuration at the Val-Mor amide bond. Taking into account the 
behaviour of amide protons in 1D experiments, the absence of other relevant ROESY 
peaks were in agreement with turn conformations having the morpholine scaffold at i+2 
position to give a type II β-turn, and at i+1 giving a type I’ β-turn, as a consequence of the 
absence of the correlation between Gly NH with H-3 (Figure 3.8), in analogy with 85, cis 
rotamer.  
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Figure 3.8 Reverse turn conformations of peptide 86 in CDCl3: the arrows indicate 
selected ROESY peaks. 
 
Thus, the replacement of D-pro with D-morpholine-3-COOH proved to alter completely the 
conformational preferences of the peptide, by destabilizing completely the β-hairpin 
structure typical of peptides containing D-proline at i+1 position of the turn in favour of 
conformations stabilized by Gly NH as a hydrogen-bond donor.  
2D NMR data in CD3CN suggested peptide 86 to assume a more compact structure, as a 
consequence of the modulation of the conformational asset moving towards a more 
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interactive solvent. Temperature dependence experiments showed higher hydrogen-
bonding propensity for Leu NH, suggested by the smaller temperature coefficient in 
CD3CN (Table 3.2 and Figure 3.6, right), whereas Val NH data did not exhibit any 
hydrogen-bonding preference, in analogy with both rotamers of peptide 85. ROESY 
experiments in CD3CN showed cross peaks typical of β-turn structures, as outlined in 
Figure 3.9. 
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Figure 3.9  Reverse turn conformation of peptide 86 in CD3CN: the arrows indicate 
selected ROESY peaks. 
 
In particular, the correlation between Gly NH (7.72) and Leu NH (6.82), although weak, 
and the strong H-3 (4.80) / Gly NH cross peak suggested the existence of a β-turn 
stabilized by a ten-membered ring hydrogen-bond between Val carbonyl group and Leu 
NH in equilibrium with a γ-turn stabilized by a 7-membered ring hydrogen-bond between 
Gly NH and Val C=O. Also, a key cross strand ROESY peak between Leu NH and Gly NH 
was observed, indicating the proximity of the two amides as a consequence of the folded 
b-turn conformations. The conformational preferences of peptide 86 for turn structures in 
CD3CN were thus different than in CDCl3, probably by virtue of the more interactive 
solvent, and this conformational profile was not completely similar to the reference D-
proline-containing peptide, as the replacement with D-morpholine-3-COOH caused the 
peptide to lose the β-hairpin structure and to equilibrate between γ- and β-turn structures 
as a function of the solvent. 
The conformational preferences of D-morpholine-3-carboxylic acid-containing tetrapeptide 
86 were also studied in a [D6]DMSO solution, so as to detect any intramolecular 
hydrogen-bond in a solvent able to disrupt the intramolecular interactions in flexible 
peptidomimetics. 1D NMR data showed a minimal amount of the cis isomer, consistent 
with the higher polarity of the solvation system. Also, 2D spectra indicated the existence of 
equilibrating reverse turn structures in line with the conformational behaviour as observed 
in CD3CN (see Figure 3.9). Specifically, ROESY data suggested tetrapeptide 86 to fold 
into a β-turn conformation having D-Mor at i+1 position of the turn, as showed by the key 
correlations of Gly NH (7.93) with H-3 (4.75) and  Leu NH (8.10), and of Gly H-α with Leu 
NH.    
 
 
3.3.3 IR data 
 
IR experiments supported the evidences that D-Mor is more prone to nucleate folded 
structures with respect to the corresponding enantiomer. In fact, peptide 85 showed a 
sharp peak at 3400 cm-1 typical of non hydrogen-bonded states, and exhibiting a small 
shoulder in the 3300 cm-1 attributable to the well organized hydrogen-bonded cis isomer 
(Figure 3.10). On the contrary, peptide 86 showed a stronger stretch peak in the region 
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typical of hydrogen-bonded states, with a minor shoulder attributable to Val NH proton. 
Thus, IR experiments confirmed the different conformational profile of the same model 
peptide having embedded two morpholine-based amino acids of opposite configurations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 IR expansion of the amide proton stretch regions for peptide 85 (left) and 86 
(right). 
 
 
3.4 Molecular modelling 
 
Initially, the conformational preference of the monomeric acetyl-morpholine-3-methylamide 
as a model compound was investigated by computational methods to assess the most 
stable structures of the morpholine nucleus, thus both cis and trans configuration at the 
acetyl-morpholine amide bond were evaluated in the case of the 3-methylamide group at 
equatorial or axial position. AM1 semiempirical method was used to optimize the global 
minimum conformer. The geometry of the most abundant minimum energy conformer was 
successively subjected to ab initio single point energy calculation at the 6-31G*/ HF level 
of quantum chemical theory. In both cis and trans structures, the axial orientation of the 
methylamide group was found to be more stable than the corresponding equatorial of 
about 8 kcal/mol, indicating a favourable stereoelectronic effect irrespective of the type of 
rotameric structure. A lower energetic difference of about 3.2 kcal/mol in absolute value 
was observed between the cis and trans structures as a consequence of strain relief for 
the latter case. These calculations indicated the morpholine ring to show a lower steric 
hindrance in the conformation having the carboxamido group at the axial position by virtue 
of the relief of diaxial destabilizing interactions given by the presence of the oxygen atom 
at position 4.  
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Figure 3.11 Top right: axial, cis conformer, Erel = +3.16 kcal/mol; Top left: equatorial, cis 
conformer, Erel  = +12.14 kcal/mol; axial, trans conformer, Erel = 0 kcal/mol; equatorial, 
trans conformer, Erel = +8.89 kcal/mol. 
 
Molecular mechanics calculations using OPLSA*65 as a force field were carried out to gain 
further insights into the conformational space accessible for peptides 85 and 86, using full 
unconstrained Monte Carlo conformational search.66 The cis rotamer of compound 85 was 
sampled using the implicit CDCl3 GB/SA solvation system. The global minimum conformer 
(Figure 3.11) resulted in a folded structure having the morpholine nucleus shifted at 
position i+2 of a β-turn and bearing the C=O group at position 3-axial, in analogy with the 
folding propensity of pipecolic and azapipecolic acid-containing peptides, as reported.67 
The β-turn structure was stabilized by a 10-membered ring hydrogen-bond between Gly 
NH and the acetyl group, in accordance with NMR data for such amide proton, and also 
an additional hydrogen-bonding interaction with acetyl C=O was found for Leu NH, in 
agreement with NMR data of this amide proton indicating a partial hydrogen-bonding 
character. Also, dihedral angles of the global minimum conformer corresponding to φ and 
ψ values at positions i+1 and i+2 suggested L-morpholine-3-COOH to induce a type-VIa 
β-turn (see Table 3.3, entries 1 and 9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Global minimum conformer of 85, cis isomer. 
 
 
                                               
65 Jorgensen, W.L.; Tirado-Rives, J. J. Am. Chem. Soc. 1988, 110, 1657-1666. 
66 Chang, G.; Guida, W.C.; Still, W.C. J. Am. Chem. Soc. 1989, 111, 4379-4386 
67 Didierjean, C.; Aubry, A.; Wyckaert, F.; Boussard, G. J. Peptide Res. 2000, 55, 308–317. 
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Table 3.3 Dihedral angle values for 85 and 86, low-energy conformers of different GB/SA 
solvation systems and reference values of β-turn types 
 
Entry   φi+1 ψi+1 φi+2 ψi+2 
1 85, CHCl3 -65.5 140.4 -99.0 28.8 
2 86, CHCl3[a] 66.0 3.6 105.0 -14.3 
3 86, CHCl3[b] -71.6 115.7 66.0 3.6 
4 86, H2O[c] 74.3 -128.5 -114.1 14.3 
5 86, H2O[d] -67.3 129.8 87.9 -8.2 
6 Type I’ 60 30 90 0 
7 Type II -60 120 80 0 
8 Type II’ 60 -120 -80 0 
9 Type Via -60 120 -90 0 
 
[a] Lowest-energy conformer having D-Mor at position i+1. [b] Global minimum conformer having D-Mor at 
position i+2. [c] Global minimum conformer having D-Mor at position i+1. [d] Lowest-energy conformer having 
D-Mor at position i+2. 
. 
Conformational preferences of the trans isomer of tetrapeptide 86 were evaluated using 
both the chloroform and water GB/SA solvation system. The calculation using the 
chloroform parameters resulted in a global minimum conformer displaying a compact 
organization stabilized by multiple hydrogen-bonds. 
 
 
 
 
 
 
 
 
 
Figure 3.13. Global minimum conformer of 86, trans isomer after MCMM calculation using 
CHCl3 GB/SA solvation system (left), and 90° clockwise rotated view (right). 
 
Dihedral angles of the global minimum conformer indicated a type II β-turn, whereas low-
energy conformer having D-Mor at i+1 position folded into a type I’ β-turn, in perfect 
accordance with the hypothesis, as shown in Figure 3.8. Interestingly, when the 
calculation was carried out using implicit water GB/SA solvation system, the global 
minimum conformer consisted in a β-turn structure having the morpholine nucleus at 
position i+1 of a 10-membered ring hydrogen-bonded β-turn, in accordance with NMR 
data in CD3CN and [D6]DMSO as solvent. Thus, the calculation was consistent with the 
observation that moving to more interactive solvents the heterochiral peptide folded in a β-
turn conformation similar to D-proline β-turns.  
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Figure 3.14 Global minimum conformer of 86, trans isomer after MCMM calculation using 
H2O GB/SA solvation system. 
 
The dihedral angles corresponding to φ and ψ values at positions i+1 and i+2 suggested 
D-Mor to induce a distorted type-II’ β-turn structure, as a consequence of the axial 
orientation of the carbonyl group at position 3 of the morpholine ring. The second low-
energy conformer found in water GB/SA solvation system resulted in a structure having 
the morpholine ring at position i+2 of a β-turn stabilized by a 10-membered ring between 
Gly NH and the acetyl group, in analogy with the results found in CHCl3 
 
 
3.5 Conclusions 
 
The conformational analysis of the diastereomeric peptides 85 and 86, differing by the 
configuration of the morpholine-3-COOH component at the i+1 position of the designed 
model structure, indicated the nucleation of turn conformations to be influenced by the 
configuration of the cyclic amino acid acting as the turn inducer and by the solvent 
polarity. Although for peptides 85 and 86 the relationship between the configuration of the 
cyclic amino acid at position i+1 and the turn propensity was maintained with respect to 
the reference proline-containing peptides, marked differences in the type of folded 
structures were observed. Specifically, L-morpholine-3-carboxylic acid displayed two 
rotamers at the Val-Mor amide bond. The trans isomer of 1 did not experience any turn 
structures, nor any intramolecular hydrogen-bonds, whereas the cis isomer showed a 
strong preference for a type VI β-turn structure, thus providing a different conformational 
asset with respect to the β-turn structure as reported for the reference L-proline model 
peptide. Peptide 85, having D-morpholine-3-carboxylic acid at the i+1 position, in analogy 
with the reference D-proline model peptide, proved to nucleate a more organized turn 
structure, although with significant differences. In fact, Val NH of peptide 86 never 
experienced any intramolecular hydrogen-bond necessary to stabilize a β-hairpin motif, as 
reported for the reference peptide. Moreover, peptide 86 showed equilibrating 
conformations ranging from γ- to β-turns as a function of solvent polarity, indicating D-
morpholine-3-COOH as the more effective enantiomer in the turn inducing capability. The 
marked differences to D-proline in provoking structural organization of model peptides, as 
a consequence of the six-membered ring structure containing two heteroatoms, were not 
entirely predictable, and are of special importance as a guide for the design of reverse 
turn mimetics having the morpholine scaffold embedded in the peptide backbone 
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3.6 Experimental for chapter 3 
 
IR methods. IR spectra were recorded on 1-2 mM chloroform solutions with a Perkin FT-
IR spectrophotometer, using 128 scans. The pure solvent spectrum for a particular 
solution was subtracted from the sample spectrum prior to analysis. Peaks in the amide 
NH stretch region were baseline corrected, and analyzed without further manipulation. 
NMR methods. NMR spectra were performed on a Varian Mercury 400Plus spectrometer 
operating at 400 MHz for 1H. The spectra were obtained in 3-5 mM CDCl3 or CD3CN 
solutions where aggregation was not significant. One-dimensional 1H NMR spectra for 
determining temperature coefficients were obtained at 295-325 K with increments of 5-10 
K. Sample temperatures were controlled with the variable-temperature unit of the 
instrument. Proton signals were assigned via TOCSY spectra, and ROESY spectra 
provided the data used in the conformational analyses. TOCSY spectra were recorded 
with 2048 points in t1, 256 points in t2, and 8 scans per t2 increment. ROESY spectra 
were recorded with a similar number of t1 and t2 points unless otherwise noted, and 32 
per t2 increment. Sample concentrations for two-dimensional spectra were respectively for 
85 and 86: 3.8 and 4.4 mM in CDCl3, 4.4 and 6.6 mM in CD3CN, and 4.4 mM in [D6]DMSO 
for peptide 2. 
Computational methods. Molecular mechanics calculations were carried out on a SGI 
IRIX 6.5 workstation, using MacroModel (v6.5) molecular modelling software,68 with 
OPLSA* as a force field19 and the implicit chloroform GB/SA solvation system.69 Monte 
Carlo conformational search20 was carried out without imposing any constraint and 
including amide bonds among all rotatable bonds. A ring closure was defined for the six- 
and seven-membered ring of BGS and Bgs scaffolds. 2000 structures were generated and 
minimised until the gradient was less than 0.05 kJ/Å·mol using the TNCG gradient 
implemented in MacroModel.70 All the conformers having an energy of 6 kcal/mol above 
the global minimum conformer were discarded. Cis and trans isomers of peptide 85 were 
separately analyzed. Calculations on the model compound were performed using 
SPARTAN version 5.147 running on a SGI IRIX 6.5 workstation. Conformational searches 
of Ac-Mor-NHEt were carried out using Monte Carlo method within MMFF94 force field,71 
and the AM1 semiempirical method72 was used to optimize the global minimum 
conformer. The geometry of the most abundant minimum energy conformer was 
successively subjected to ab initio single point calculation of the electronic properties at 
the 6-31G*/HF level73 of quantum chemical theory.  
 
                                               
68 Mohamadi, F.; Richards, N.G.J.; Guida, W.C:; Liskamp, L.; Lipton, M.; Caufield, C.; Chang, G.; 
Hendrickson, T.; Still, W.C. J. Comput. Chem. 1990, 11, 440-467. 
69 Still, W.C.; Tempczyk, A.; Hawley, R.C.; Hendrickson, T. J. Am. Chem. Soc. 1990, 112, 6127-6129. 
70 Ponder, J.W.; Richards, F.M. J. Comput. Chem. 1987, 8, 1016-1024. 
71 (a) Halgren, T.A: J. Comput. Chem. 1996, 17, 490-519; (b) Halgren, T.A. J. Comput. Chem. 1996, 17, 520-
552; (c) Halgren, T.A. J. Comput. Chem. 1996, 17, 553-586; (d) Halgren, T.A.; Nachbar, R.B. J. Comput. 
Chem. 1996, 17, 587-615; (e) Halgren, T.A. J. Comput. Chem. 1996, 17, 616-641. 
72 Dewar, M.J.S; Zoebisch, E.G.; Healy, E.F.; Stewart, J.J. J. Am. Chem. Soc. 1985, 107, 3902-3909. 
73 Hehre, W.J.; Radam, L.; Schleyer, P.R:; Pople, J.A. Ab initio Molecular Orbital Theory; Wiley: New York, 
1986. 
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Ac-Val-l-Mor-Gly-Leu-OMe (85). Pure peptide showed HPLC peak at tR = 16.2 min (93% 
HPLC purity) using 0% acetonitrile/5 min, 0 – 10% acetonitrile/5 min, then 10 – 90% 
acetonitrile/20 min as gradient and ESI-MS peaks of m/z 457.09 (M+ + 1, 8), 479.27 (M+ + 
Na, 100), 495.27 (M+ + K, 35). 1H NMR data of the cis and trans conformers are shown in 
Table 3.4. 
Ac-Val-d-Mor-Gly-Leu-OMe (86). Pure peptide showed HPLC peak at tR = 16.7 min (96% 
HPLC purity) using 0% acetonitrile/5 min, 0 – 10% acetonitrile/5 min, then 10 – 90% 
acetonitrile/20 min as gradient and ESI-MS peaks of m/z 457.09 (M+ + 1, 6), 479.27 (M+ + 
Na, 100), 495.27 (M+ + K, 41). 1H NMR data of the unique conformer is shown in Table 
3.5. 
 
Table 3.4 Proton chemical shifts of 85, cis and trans conformers in CDCl3 and CD3CN at 
298 K 
 Cis Trans 
 δ (CDCl3) δ (CD3CN) δ( CDCl3) δ (CD3CN) 
H-2 4.74, 3.49 4.55, 3.48 4.41, 3.65 4.30, 3.58 
H-3 4.46 4.61 4.98 4.93 
H-5 4.48, 3.05 4.35, 2.92 3.92, 3.87 4.42, 3.53 
H-6 3.95, 3.43 3.85, 3.54 4.40, 3.56 4.38, 3.43 
Gly NH 7.97 7.98 6.65 6.90 
Leu NH 6.89 6.80 6.32 7.21 
Val NH 6.19 6.91 6.37 6.72 
Gly H-α 4.05, 4.01 3.85 4.10, 3.91 3.83 
Leu H-α 4.63 4.47 4.63 4.45 
Leu H-β 1.63, 1.53 1.65, 1.60 1.65, 1.55 1.64, 1.61 
Leu H-γ 1.63 1.65 1.65 1.64 
Leu H-δ 0.94 0.96 0.94 0.91 
Val H-α 4.47 4.38 4.90 4.70 
Val H-β 2.01 2.01 2.10 2.02 
Val H-γ 1.06 1.05 1.01, 0.91 0.99 
-OCH3 3.70 3.66 3.74 3.68 
CH3CO 2.02 1.95 2.07 1.98 
 
Table 3.5 Proton chemical shifts of 86, trans conformer in CDCl3 and CD3CN at 298 K. 
 
 
 δ (CDCl3) δ (CD3CN) δ (DMSO-d6) 
H-2 4.62, 3.58 4.48, 3.52 4.28 
H-3 4.89 4.80 4.75 
H-5 4.02, 3.72 3.94, 3.52 3.85, 3.22 
H-6 3.84, 3.51 3.89, 3.46 3.82, 3.40 
Gly NH 7.48 7.72 7.93 
Leu NH 6.69 6.82 8.10 
Val NH 6.79 7.00 8.18 
Gly H-α 4.09, 3.91 3.81 3.85, 3.78 
Leu H-α 4.60 4.40 4.44 
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Leu H-β 1.62 1.60 1.60, 1.46 
Leu H-γ 1.62 1.60 1.60 
Leu H-δ 0.91 0.94, 0.91 0.93, 0.90 
Val H-α 4.42 4.37 4.22 
Val H-β 2.07 1.99 1.96 
Val H-γ 1.08, 1.03 1.05, 1.01 0.91 
-OCH3 3.72 3.68 3.78 
CH3CO 2.05 2.11 1.84 
 
Table 3.6 Variable temperature 1D experiments for Ac-Val-L-morph-Gly-Leu-OMe 
 
 
  CDCl3 CD3CN 
 Temp,°K Δ NHV Δ NHG δ NHL δ NHV δ NHG δ NHL 
 295 6.39 6.70 6.32 6.90 6.90 6.80 
 298 6.35 6.68 6.30 - - - 
Trans 305 6.32 6.67 6.30 6.78 6.86 6.78 
 315 6.27 6.63 6.24 6.76 6.83 6.80 
 325 6.24 6.60 6.21 6.77 6.85 6.77 
        
 295 6.23 8.03 6.88 6.67 7.99 7.17 
 298 6.20 8.03 6.86 - - - 
Cis 305 6.15 8.03 6.83 6.64 7.94 7.14 
 315 6.10 8.02 6.77 6.61 7.90 7.10 
 325 6.06 8.02 6.74 6.59 7.86 7.08 
 
Calculation of Δδ(NH)/ΔT of trans-rotamer in CDCl3 
δ NHV = -0.00477 (T) + 7.78 (R = -0.981) Δδ(ΝΗ)/ΔΤ = -4.77 ppb / °K 
δ NHG = -0.00323 (T) + 7.65 (R = -0.993) Δδ(ΝΗ)/ΔΤ = -3.23 ppb / °K 
δ NHL = -0.00368 (T) + 7.41 (R = -0.977) Δδ(ΝΗ)/ΔΤ = -3.68 ppb / °K 
Calculation of Δδ(NH)/ΔT of trans-rotamer in CD3CN 
δ NHV = -0.0041 (T) + 8.07 (R = -0.808) Δδ(ΝΗ)/ΔΤ = -4.1 ppb / °K 
δ NHG = -0.0018 (T) + 7.42 (R = -0.789) Δδ(ΝΗ)/ΔΤ = -1.8 ppb / °K 
δ NHL = -0.0007 (T) + 7.00 (R = -0.602) Δδ(ΝΗ)/ΔΤ = -0.7 ppb / °K 
Calculation of Δδ(NH)/ΔT of cis-rotamer in CDCl3 
δ NHV = -0.00557 (T) + 7.86 (R = -0.989) Δδ(ΝΗ)/ΔΤ = -5.57 ppb / °K 
δ NHG = -0.00040 (T) + 8.15 (R = -0.913) Δδ(ΝΗ)/ΔΤ = -0.40 ppb / °K 
δ NHL = -0.00476 (T) + 8.28 (R = -0.993) Δδ(ΝΗ)/ΔΤ = -4.76 ppb / °K 
Calculation of Δδ(NH)/ΔT of cis-rotamer in CD3CN 
δ NHV = -0.0027 (T) + 7.46 (R = -0.996) Δδ(ΝΗ)/ΔΤ = -2.7 ppb / °K 
δ NHG = -0.0043 (T) + 9.26 (R = -0.998) Δδ(ΝΗ)/ΔΤ = -4.3 ppb / °K 
δ NHL = -0.0031 (T) + 8.08 (R = -0.993) Δδ(ΝΗ)/ΔΤ = -3.1 ppb / °K 
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Table 3.7 Variable temperature 1D experiments for Ac-Val-D-morph-Gly-Leu-OMe 
 
 
 CDCl3 CD3CN 
Temp, °K δ NHV δ NHG δ NHL δ NHV δ NHG δ NHL 
295 6.38 7.45 6.68 7.01 7.74 6.82 
300 6.37 7.44 6.67    
305 6.35 7.42 6.66 6.96 7.71 6.78 
310 6.33 7.40 6.64    
315 6.32 7.37 6.64 6.93 7.68 6.79 
320 6.30 7.34 6.62    
325 6.29 7.32 6.61 6.88 7.64 6.78 
 
Calculation of Δδ(NH)/ΔT in CDCl3 
δ NHV = -0.00314 (T) + 7.31 (R = -0.996) Δδ(ΝΗ)/ΔΤ = -3.14 ppb / °K 
δ NHG = -0.00457 (T) + 8.81 (R = -0.991) Δδ(ΝΗ)/ΔΤ = -4.57 ppb / °K 
δ NHL = -0.00236 (T) + 7.38 (R = -0.990) Δδ(ΝΗ)/ΔΤ = -2.36 ppb / °K 
Calculation of Δδ(NH)/ΔT in CD3CN 
δ NHV = -0.0042 (T) + 8.25 (R = -0.996) Δδ(ΝΗ)/ΔΤ = -4.2 ppb / °K 
δ NHG = -0.0033 (T) + 8.72 (R = -0.997) Δδ(ΝΗ)/ΔΤ = -3.3 ppb / °K 
δ NHL = -0.0011 (T) + 7.13 (R = -0.752) Δδ(ΝΗ)/ΔΤ = -1.1 ppb / °K 
 
Table 3.8 1D competition studies with [D6]DMSO for Ac-Val-L-morph-Gly-Leu-OMe 
 
 µL [D6]DMSO Cis  Trans 
 δ NHV Δ NHG δ NHL  δ NHV δ NHG δ NHL 
0 6.19 7.97 6.88  6.19 6.65 6.32 
6 6.44 8.03 6.96  6.68 6.91 6.32 
12 6.68 8.06 7.04  6.88 7.05 6.41 
18 6.85 8.07 7.1  7.00 7.13 6.47 
24 6.97 8.08 7.15  7.09 7.19 6.54 
30 7.06 8.09 7.18  7.15 7.23 6.58 
36 7.14 8.08 7.19  7.19 7.24 6.64 
42 7.22 8.08 7.2  7.24 7.24 6.68 
48 7.26 8.08 7.26  7.27 7.28 6.72 
54 7.28 8.08 7.28  7.29 7.28 6.75 
60 7.28 8.07 7.28  7.30 7.30 6.77 
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Figure 3.15 Stacked 1H NMR plots of 85. 
 
 
Table 3.9 1D competition studies with [D6]DMSO for Ac-Val-D-morph-Gly-Leu-OMe 
 
µL [D6]DMSO δ NHV δ NHG δ NHL 
0 6.68 7.49 6.79 
5 6.69 7.54 6.77 
10 6.93 7.61 6.86 
15 7.08 7.64 6.9 
20 7.17 7.65 6.93 
25 7.17 7.66 6.92 
30 7.33 7.67 6.95 
35 7.37 7.67 6.97 
40 7.42 7.67 6.97 
45 7.42 7.67 6.97 
50 7.47 7.67 6.98 
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Figure 3.16 Stacked 1H NMR plots of 86. 
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A general strategy for the synthesis of novel, orthogonally protected scaffolds based on 
the unique 2-oxa-5-azabicyclo[4.1.0]heptane structure is presented. The described 
reaction sequence takes advantage of easily available starting materials such as serine 
and threonine and leads to stereochemically dense structures in few, high-yielding 
synthetic steps. We show how the stereochemistry can be easily tuned by starting from 
different β-hydroxy-α-amino acids and also by means of a transition metal-catalyzed 
cyclopropanation step. These compounds find application as constrained templates for 
the construction of geometrically diversified libraries of compounds. 
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4.1 Introduction 
 
One of the initial steps in the drug discovery process is the identification of leads which 
bind to receptors or other targets of interest. To address this, a common and established 
approach is the screening of libraries of compounds. While combinatorial chemistry 
initially tended towards the synthesis of very large libraries of structurally similar products, 
nowadays this initial emphasis on creating mixtures of very large numbers of structures is 
giving way to a more measured approach based on arrays of fewer, well-characterized 
compounds.74  This is particularly noticeable in the move towards the synthesis of 
complex and highly diversified mixtures of molecules that bear a structural resemblance to 
approved natural-product-based drugs75 or to “privileged medicinal scaffolds”.76 There is a 
strong drive towards the generation of new chemo-types, displaying increasing complexity 
and possessing features that can be related to pharmacologically relevant structures.77 
Among the possible alternatives, nitrogen-containing-heterocycles with a saturated 
backbone have attracted considerable attention in the design of biologically active 
products.78,79 Most marketed compounds and several promising leads fall into this 
category, and the discovery of small-molecular-weight scaffolds with a high degree of 
diversity belonging to this family is a tool of primary importance in the drug discovery 
process.80 Among the various structures proposed by medicinal chemists, the morpholine 
ring represents a common motif.81 Many carbon-substituted morpholines display biological 
                                               
74 For discussions about new trends in combinatorial chemistry, see: (a) Schmuck, C.; Wich, P.; New J. Chem. 
2006, 30, 1377-1385. (b) R. Breinbauer, I. R. Vetter and H. Waldmann, Angew. Chem., Int. Ed. 2002, 41, 
2878–2890. (c) Ganesan, A. 2002, 7, 47-55 (c) A. Golebiowski, S. R. Klopfenstein, D. E. Portlock, Curr. Opin. 
Chem. Biol. 2001, 5, 273-284. 
75 Arya, P.; Joseph, R.; Gan, Z.; Rakic, B. Chemistry & Biology 2005, 12, 163-180 (a) Arya, P.; Joseph, R.; 
Chou, D. T. H. Chemistry & Biology 2002, 9, 145-156. (b) Arya, P.; Chou, D. T. H.; Baek, M.-G. Angew. Chem. 
Int. Ed. 2001, 40, 339-346. 
76 (a) Evans, B. E.; Rittle, K. E.; Bock, M. E.; Di Pardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; 
Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. 
A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, 2235-2246. 
For recent reviews, see: 
(b) Duarte, Carolina D.; Barreiro, Eliezer J.; Fraga, Carlos A. M. Privileged structures: a useful concept for the 
rational design of new lead drug candidates. Mini-Reviews in Medicinal Chemistry 2007, 7 (11), 1108-1119. 
(c) Costantino, L.; Barlocco, D.; E. Curr. Med.Chem. 2006, 13, 65-85. 
77 Schreiber, S. L. Science (Washington, D. C.) 2000, 287, 1964-1969. 
78 Dewick, P.M.; Medicinal Natural Products, a biosynthetic approach. John Wiley & Sons: New York, 1997. 
79 O'Hagan D.; Nat. Prod. Rep. 2000, 17, 435-446. Singh; S. Chem. Rev. 2000., 100, 925-1024. 
80 For recent exemples of saturated, nitrogen-containing scaffolds, see:  
(a) Machetti, F.; Bucelli, I.; Indiani, G.; Kappe, C. O.; Guarna, A. J. Comb. Chem. 2007, 9, 454-461. (b) 
Dandapani, S.; Lan, P.; Beeler, A. B..; Beischel, S.; Abbas, A.; Roth, B. L.; Porco, J. A., Jr.; Panek, J. S.,  J. 
Org. Chem.,  2006, 71, 8934-8945. (c) Nilsson, J. W.; Thorstensson, F.; Kvarnstroem, I.; Oprea, T.; 
Samuelsson, B.; Nilsson, I. J. Comb. Chem. 2001, 3, 546-553. (d) Quirante J.; Vila X.; Bonjoch J.; Kozikowski 
A. P.; Johnson K. M. Bioorganic & medicinal chemistry, 2004, 12, 1383-91. (e) Simonsen, K. B.; Ayida, B. K.; 
Vourloumis, D.; Winters, G. C.; Takahashi, M.; Shandrick, S.; Zhao, Q.; Hermann, T. ChemBioChem 2003, 4, 
886-890. 
81 For a recent review on the biological relevance and synthesis of C-substituted morpholine derivatives, see: 
Wijtmans, R.; Vink, M. K. S.; Schoemaker, H. E.; van Delft, F. L.; Blaauw, R. H.; Rutjes, F. P. J. T. Synthesis 
2004, 22, 641-662. 
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activity and can find application as antidepressants,82 appetite suppressants,83 
antioxidants,84 etc. Some selected examples are reported in Figure 4.1 
 
 
 
 
 
 
 
Figure 4.1 Selected, biologically relevant, morpholine-based compounds 
 
During our ongoing research program toward the development of costrained, morpholine-
based platforms for medicinal chemistry,85 we developed the idea of rigidifying a chiral 
morpholine structure through fusion to a functionalized cyclopropane ring. This approach 
provides access to a stereochemically-rich and rigid backbone, allowing us to generate 
different scaffolds by means of geometric variation of the scaffold itself.86 Herein we 
present the new template 2-oxa-5-aza-bicyclo[4.1.0]heptane heterocycle (Scheme 4.1) 
and we demonstrate a general synthetic strategy which can guarantee the introduction of 
diversification positions with a high degree of diastereocontrol. The concomitant presence 
of an oxygen and a nitrogen in the morpholine ring can be exploited in a wide range of 
retrosynthetical analysis which allow easy control of the stereochemistry of the carbon 
atoms, especially starting from readily available amino acid derivatives. In order to obtain 
the 2-oxa-5-aza-bicyclo[4.1.0]heptane skeleton we planned to use amino acid-derived 
dihydroxazine structures87 (Scheme 4.1) as substrates for a diastereoselective, transition 
                                               
82 (a) Melloni, P.; Della Torre, A.; Lazzari, E.; Mazzini, G.; Meroni, M.; Tetrahedron 1985, 41, 1393 (b) Fang, 
Q.K., Han, Z.; Grover, P.; Kessler, D.; Senamanayake, C.H.; Wald, S.A. Tetrahedron: Asymmetry 2000, 11, 
3659. (c) Kelley, J.L; Musso, D.L.; Boswell, G.E.; Soroko, F.E.; Cooper, B.R. J.Med.Chem. 1996, 39, 347-349. 
83 Common appetite suppressants are Phendimetrazine and Phenmetrazine. 
84 (a) Guilloneau, C.; Charton, Y.; Ginot, Y.; Fouquier-d’Herouel, M.; Bertrand, M.; Lockhart, B.; Lestage, P., 
Goldstein, S.; Eur. J. Med. Chem. 2003, 38, 1-11. (b) Chrysselis, M.C.; Rekka, E.A.; Siskou, I.C.; 
Kourounakis, P.N. J. Med. Chem. 2002, 45, 5406. (c) Chrysselis, M.C.; Rekka, E.A.; Kourounakis, P.N. J. 
Med. Chem. 2000, 43, 609-612. 
85 (a) Cini, N.; Danieli, E.; Menchi, G.; Trabocchi, A.; Bottoncetti, A.; Raspanti, S; Pupi, A; Guarna, A. 
Bioorganic & Medicinal Chemistry 2006, 14, 5110-5120. (b) Mannino, C.; Nievo, M.; Machetti, F.; 
Papakyriakou, A.; Calderone, V.; Fragai, M.; Guarna, A. Bioorganic & Medicinal Chemistry  2006 14 (22), 
7392-7403. (c) Guarna, A.; Cozzolino, F.; Torcia, M.; Garaci, E. Pharmaceutical compositions for the 
treatment of diseases related to neurotrophins. PCT Int. Appl. (2003). (d) Guarna, A.; Guidi, A.; Machetti, F.; 
Menchi, G.; Occhiato, E. G.; Scarpi, D.; Sisi, S.; Trabocchi, A. J. Org. Chem. 1999,  64 , 7347-7364. 
86 For examples of the concept of geometrical diversity, see: (a) Burke, M.D., Berger E.M., Schreiber, S.L.; J. 
Am. Chem. Soc., 2004, 126, 14095-14104. (b) Gierasch; T.M., Shi Z.; Verdine, G.L.; Org. Lett., 2003, 5, 621-
624. (c) Paterson, I.; Temal-Laieb, T. Org. Lett. 2002, 4, 2473-2476. (d) Misske, A. M.; Hoffmann, H. M. R. 
Chem. Eur. J. 2000, 6, 3313-3320. (e) Paterson, I.; Scott, J. P. J. Chem. Soc., Perkin Trans. 1 1999, 1003-
1014. Annis, D. A.; Helluin, O.; Jacobsen, E. N Angew. Chem. Int. Ed. Engl. 1998, 37, 1907-1909. Sutherlin, 
D. P.; Armstrong, R. W. J. Org. Chem. 1997, 62, 5267-5283. 
87 (a) F. Sladojevich, A.Trabocchi and A. Guarna, J.Org. Chem., 2007, 72, 110 4254; (b) A. Guarna, A. 
Trabocchi, G. Menchi, C. Lalli, F. Sladojevich and N. Cini, Eur Pat. Appl. PCT/EP2008/054750, April 18th 
2008. 
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metal catalyzed cyclopropanation using diazo-acetates. The cyclopropanation creates 
three new adjacent stereocenters and at the same time introduces a strong 
conformational constraint. This approach allows the synthesis of structures bearing 
functionalizable groups in different, reciprocal stereochemical relationship. Chirality is first 
introduced using readily available, enantiomerically pure β-hydroxy-α-amino acids as 
starting materials and, in second instance, through a cyclopropanation step, whose 
stereochemical outcome is generally governed by the stereochemistry of the ligand used.  
 
Scheme 4.1 Retrosynthetic analysis of 2-oxa-5-aza-bicyclo[4.1.0]heptane scaffolds 
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4.2 Preparation of dihydroxazine scaffolds 
 
The strategy was developed using serine and threonine as starting materials and the Cbz 
as nitrogen protecting group. The serine derived dihydroxazine 62c was prepared starting 
from amine 76a,14 which was protected using Cbz-Cl and then cyclized after treatment 
with p-TSOH/MS 4Å in refluxing toluene, in order to promote acid catalyzed trans-
acetalyzation and subsequent elimination of MeOH (Scheme 4.2). 
 
Scheme 4.2 Synthesis of serine-derived dihydroxazine (S)-62c 
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When the above reported strategy was extended to threonine, problems initially arose in 
the reductive amination step with dimethoxyacetaldehyde. In fact, upon treatment of 
threonine methyl ester hydrochloride with Pd/C-NEt3 under a hydrogen atmosphere, the 
only observed product was not the expected 76a, but 80 as reported in Scheme 4.3 (See 
discussion in Chapter 2, Section 2.6). 
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Scheme 4.3 Attempted synthesis of compound 76a 
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Protection of the hydroxyl group of threonine with TBSCl88 before performing the reductive 
amination proved essential and allowed the synthesis of the 82 in almost quantitative 
yield. Unfortunately amine 82 was found to be completely unreactive upon treatment with 
Cbz-Cl, in analogy to the attempted protection with Fmoc-Cl discussed in chapter 2, 
Section 2.6. The problem was solved using the same strategy developed in chapter 2, 
section 6, subjecting amine 82 to more harsh acid conditions, in order to deprotect the 
hydroxyl group and simultaneously obtain the trans-acetalyzation. The amino group of the 
resultant cyclic acetal 83 proved to be much more reactive than linear precursor 82 and 
the crude product deriving from trans-acetalyzation was easily protected upon treatment 
with Cbz-Cl/NaHCO3 aq. Subsequent treatment of cyclic acetal 88 with p-TSOH/MS 4Å in 
refluxing toluene furnished the dihydroxazine scaffold 62d in good overall yield, requiring 
only one purification through flash chromatography (Scheme 4.4). 
 
Scheme 4.4 Synthesis of threonine-derived dihydroxazine 62d 
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4.3 Cyclopropanation studies 
 
We then focused on the study of the cyclopropanation reaction of the dihydroxazine 
scaffolds using diazoacetates. We performed some preliminary studies using ethyl 
diazoacetate, in order to determine the most effective metal catalyst and the best reaction 
conditions (Table 4.1). We found that Rh2(OAc)4 and Cu(I)(OTf) were both effective and 
gave comparable yields. Slow addition of ethyl diazo acetate was necessary to maintain a 
low “active carbene” concentration in solution, therefore preventing dimerization of the 
                                               
88 Niu, Chuansheng; Pettersson, Teresia; Miller, Marvin J. J. Org. Chem. 1996, 61, 1014-1022. 
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carbene.89 The best experimental conditions identified using ethyl diazoacetate were then 
extended to the cyclopropanation using tert-butyl diazoacetate, in order to obtain 
orthogonality between the two ester groups. The introduction of a more hindered ester did 
not affect yield or diastereoselectivity (Table 4.1, entry 6), and cyclopropanation products 
could be isolated in good yield. Low diastereoselectivity between the two diastereomers 
69 and 70 was observed, and only traces of the other two possible diastereomers were 
detected. Although diastereomers 69 and 70 could be separated by standard 
chromatography, the use of suitable chiral ligands was taken into account to enhance the 
diastereocontrol. 
 
Table 4.1 Cyclopropanation conditions for dihiydroxazine (S)-62c 
 
N
O
CO2Me
Cbz
RO2C
H
HN
O
CO2Me
Cbz
RO2C
H
HN
O
CO2Me
Cbz
Catalyst, Ligand
N2 CO2R
(+)-(S)-62c (-)-(1S,4S,6R,7R)-69a, R = Et
(-)-(1S,4S,6R,7R)-69b, R = t-Bu
(+)-(1R,4S,6S,7S)-70a, R = Et
(+)-(1R,4S,6S,7S)-70b, R = t-Bu 
 
R Catalyst Ligand EDA eq. 
Time of 
Addition 
Combined 
Yield 69+70 
Ratio 
69:70 
Et Rh2(OAc)4 - 2 10 min. 41 % 1.6:1 
Et Rh2(OAc)4 - 3 5 h 72 % 1.6:1 
Et Cu(OTf)2/PhNHNH2 - 3 5 h 75 % 1.5:1 
Et Cu(OTf)2/PhNHNH2 - 4.5 6 h 86 % 1.5:1 
Et Cu(OTf)2/PhNHNH2 (S-S)-t-BuBOX 4.5 6 h 73 % 1:6 
t-Bu Cu(OTf)2/PhNHNH2 (S-S)-t-BuBOX 4.5 5 h 67 % 1:5 
t-Bu Cu(OTf)2/PhNHNH2 (S-S)-t-BuBOX 4.5 6 h 80 % 1:6 
       a Estimated by 1H-NMR. 
 
The bisoxazoline ligand (S,S)-2,2-methylenebis(4-t-butyl-2-oxazoline), (S,S)-t-BuBOX),90 
proved to be effective when used in combination with copper(I) triflate.We observed that 
the stereochemistry of the cyclopropanes formed was mainly controlled by the ligand 
chirality, regardless of the stereochemistry of the dihydroxazine scaffold, suggesting in 
each case that the chiral ligand orients the attacking carbene to the same alkene face. In 
fact, when dihydroxazine (S)-62c (derived from L-serine) was treated with t-butyl 
diazoacetate and (S,S)-t-BuBOX, the ratio between the diastereomers 69b and 70b was 1 
: 6, whereas when the enantiomeric dihydroxazine (derived from D-serine) was used, the 
ratio of the two diastereomers [enantiomeric to (-)-69b and (+)-70b, respectively] was 
reversed, giving a 9:1 mixture in favour of compound (+)-69b (scheme 4.5). Comparison 
of these data with the diastereomeric ratios obtained in the absence of the chiral ligand 
(Table 4.1, entries 3, 4 and 6) suggested that the combination of (S,S)-t-BuBOX with 
                                               
89  Eric N. Jacobsen · Andreas Pfaltz · Hisashi Yamamoto, Comprehensive Asymmetric Catalysis vol. II, 
Springer-Verlag: Berlin-Heidelberg-New York 2000, pp 513-539.  
90 D. A. Evans, K. A. Woerpel, M. M. Hinman and M. M. Faul, J. Am.Chem. Soc., 1991, 113, 726. 
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dihydroxazine (R)-62c is the matched pair, whereas the same chiral ligand in combination 
with (S)-62c is the mismatched pair. 
 
Scheme 4.5 (S,S)-t-BuBOX-Cu(OTf) catalyzed cyclopropanation of dihydroxazines (R)-
62c and (S)-62c 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cyclopropanation of dihydroxazine 62d, derived from L-threonine methyl ester, with (S,S)-
t-BuBOX and t-butyl diazoacetate resulted in compound 71 as the major stereoisomer and 
only traces of a second stereoisomer (Scheme 4.6), indicating an additional effect of the 
methyl group at C-2 of dihydroxazine 62d on the stereoselectivity. 
 
Scheme 4.6 Cyclopropanation of dihydroxazine 62d with (S,S)-t-BuBOX-Cu(OTf) 
N
O
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H
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O
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Cu(OTf)2, PhNHNH2,
(S,S)-t-Bu-BOX,
71
 
 
 
4.4 Structural assignament 
 
The structural assignment of the two major diastereomers was accomplished analyzing 
the values of the coupling constants for the hydrogens in the cyclopropane ring and by 
means of NOE experiments. We based on the assessment that coupling constants less 
than 7 Hz are associated with a trans relationship between two protons in a cyclopropane 
ring.91  In all the isolated diastereomers, J couplings of proton H7 (see Table 4.2) with the 
other two protons of the cyclopropane ring are comprised between 2.4 and 3.6 Hz (Table 
4.2).  
                                               
91 Morris, D. G. Nuclear Magnetic Resonance and Infrared Spectra of Cyclopropanes and Cyclopropenes. In 
The Chemistry of the Cyclopropyl Group; Patai, S., Rappoport Z., Eds.; John Wiley and Sons: New York, 
1987; Chapter 3, pp 101-172. 
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Table 4.2 Coupling constants for the hydrogens of the cyclopropane ring in the scaffolds 
synthesized 
 
 
 
 
 
 
 
A definitive structure elucidation was based on NOE spectra for the bicyclic morpholine-
based scaffolds deriving from cyclopropanation 5 with t-butyl diazoacetate. In particular, a 
diagnostic NOE effect between H-4 and H-7 was observed for compound 69b (Fig. 3). For 
compound 70b,H-7 provided only a weak NOE effect with the methyl ester protons at C-4, 
and a strong NOE effect was observed between H-7 and one of the two methylenic 
protons at C-3 of the morpholine ring (Fig. 3).NOE spectra of compound 71 deriving from 
L-threonine resulted in NOE interactions between the protons of the methyl group at C-3 
and the two protons H-1 and H-6. This strongly supported the structure in Fig. 3, with the 
two esters in a trans relationship. 
69b
O
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Figure 4.2 Most significant NOEs observed for structures 69b and 70b and 71 
 
4.5 Modeling studies  
 
Molecular modeling calculations were carried out on compound 71 so as to assess the 
most stable conformation and to gain insight into the detailed structure of the bicyclic 
scaffold. Energy-minimized conformations of the 2-oxa-5-azabicyclo[4.1.0]heptane-based 
scaffold 71 were achieved using SPARTAN Version 5.1192 running on a SGI IRIX 6.5 
workstation. Conformational searches of 71 were carried out using a Monte Carlo method 
within the MMFF94 force field,93 and the AM1 semiempiricalmethod94 was used to 
optimize the globalminimum conformer. The geometries of the most abundant 
minimumenergy conformers were successively subjected to ab initio single-point energy 
calculation at the 3-21G*/HF level95 of quantum chemical theory. The conformation having 
axial C-2 and C-3 substituents resulted in a twisted half-chair structure for the morpholine 
                                               
92 SPARTAN Version 5.1, Wavefunction, Inc., Irvine, CA 
93 (a) T. A. Halgren, J. Comput. Chem., 1996, 17, 490; (b) T. A. Halgren, J. Comput. Chem., 1996, 17, 520; (c) 
T. A. Halgren, J. Comput. Chem., 125, 1996, 17, 553; (d) T. A. Halgren and R. B. Nachbar, J. Comput. Chem., 
1996, 17, 587; (e) T. A. Halgren, J. Comput. Chem., 1996, 17, 616. 
94 M. J. S. Dewar, E. G. Zoebisch, E. F. Healy and J. J. P. Stewart, J. Am. Chem. Soc., 1985, 107, 3902. 
95 W. J. Hehre, L. Radam, P. R. Schleyer and J. A. Pople, Ab initio 130 molecular orbital theory, Wiley, New 
York, 1986 
Product J6,7 J1,7 J1,6 
69a 3.2 3.2 7.2 
69b 3.6 2.4 7.2 
70a 3.6 2.4 7.2 
70b 3.2 3.2 7.2 
 71 3.2 3.2 7.2 
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moiety, whereas a twisted half-boat structure was obtained for the conformation having 
the same substitutents in equatorial position. Also, the conformation with axial C-2 and C-
3 substituents proved to be more stable by about 2.3 kcal mol−1 (Eax = −232.14 kcal 
mol−1; Eeq = −229.86 kcal mol−1). Computation of the dihedral angle formed by H-2, C-2, 
C-3, H-3 atoms for the axial and equatorial conformations resulted in −73.6◦ and −144.6◦, 
respectively, which, in conjunction with 1H-NMR data indicating absence of coupling 
between H-2 and H-3, suggested the axial conformer as the more favourable in 
chloroform solution (Fig. 4).  Further corroboration of the preferential axial conformation 
for 71 was given by NOE experiments, which showed NOE correlation of H-7 with methyl 
ester protons (and not H-2), and of H-6 with the methyl group at C-2. 
 
 
4.6 Further diversifications of 2-oxa-5-azabicyclo[4.1.0]heptane 
 
In order to extend the versatility of the bicyclic structures reported herein, the selective 
transformation of the t-butyl ester into a primary alcohol using compound 70b as substrate 
was carried out. Specifically, the orthogonality of the two esters was used for selective 
deprotection of the t-butyl ester under standard acid conditions, followed by reduction of 
the resulting acid with isobutyl chloroformate/NaBH4 (Scheme 4.7). Both transformations 
proved to be completely stereoselective, and no epimerization at C-7 was observed by 1H-
NMR, giving the corresponding alcohol 90 in overall 69% yield from 70b, and 
demonstrating the feasibility of such scaffold as a template for subsequent appendage 
diversity. 
Scheme 4.7 Synthesis of compound 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.7 Conclusions 
 
In summary we have developed an efficient strategy which gives access to a new series 
of scaffolds based on the unique heterocyclic structure of the 2-oxa-5-
azabicyclo[4.1.0]heptane. The strategy allows the generation of compounds with up to five 
stereogenic centers in enantiopure form starting from readily available β-hydroxy-α-amino 
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acids and by means of a diastereoselective cyclopropanation achieved using 
diazoacetates in conjunction with Cu(I)OTf and a chiral t-BuBOX ligand. The 
cyclopropanation outcome proved to be mainly controlled by the stereochemistry of the 
bis-isoxazolidine ligand. A variety of scaffolds can be obtained using this strategy, each of 
them differing for the spatial orientation of the orthogonally protected diversification sites. 
Some final manipulations of the synthesized structures have been presented, in order to 
prove the versatility and the orthogonal relationship between the various protecting groups 
introduced. 
 
 
4.8 Experimental for chapter 4 
General Experimental 
Chromatographic separations were performed on silica gel using flash-column 
techniques. Rf values refer to TLC carried out on 25 mm silica gel plates (Merck F254) 
with the same eluant indicated as for column chromatography. 1H and 13C NMR 
spectra were recorded with NMR instruments operating at 200 MHz and 400 MHz for 
proton and at 50 MHz for carbon, and using CDCl3 solutions unless otherwise stated. 
EI mass spectra were carried out at 70 eV ionizing voltage. 
 
(S)-2-[Benzyloxycarbonyl-(2,2-dimethoxy-ethyl)-amino]-3-hydroxy-propionic acid 
methyl ester [(S)-87].  
 
 
 
 
 
 
L-serine methyl ester hydrochloride (64) (5.34 g, 34.3 mmol) was dissolved in MeOH 
(110 mL), then triethylamine (4.79 mL, 34.3 mmol), 60% aqueous solution of 
dimethoxyacetaldehyde (75) (5.95 g, 34.3 mmol) and 10% Pd/C (477 mg) were 
successively added, and the resulting mixture was stirred overnight at room 
temperature under a hydrogen atmosphere. Then, the suspension was filtered over 
Celite and the organic solvent was removed under reduced pressure. The crude 
reaction mixture was dissolved in H2O (60 mL) and NaHCO3 (5.76 g, 68.6 mmol) was 
added. EtOAc (75 mL) was added and the mixture was cooled at 0 °C with an ice bath. 
Cbz-Cl (4.80 mL, 33.61 mmol) was added dropwise, then, after 1 h stirring, the ice 
bath was removed and the mixture was stirred overnight. The reaction was diluted with 
EtOAc (200 mL) and the aqueous layer was discarded. The organic phase was 
washed with 1M HCl, brine, dried over Na2SO4, concentrated and purified through 
flash chromatography (EtOAc-Hexanes 3:2) to provide compound (S)-87 as a 
colourless oil (10.01 g, 85%).  (Found: C, 56.40; H, 6.95; N 4.01. C16H23NO7 requires 
C, 56.30; H, 6.79; N, 4.10%); [α]26D -42.9 (c 1.0, CHCl3); 1H-NMR (400 MHz; CDCl3) 
1:1 mixture of rotamers 7.36-7.29 (m, 5 H, Ph), 5.21 (AB, part A, J = 6.0 Hz, 0.5 H, 
CH2Ph), 5.13 (s, 1 H, CH2Ph), 5.13 (AB, part B, J = 6.0 Hz, 0.5 H, CH2Ph), 4.70 (dd, J 
= 7.2, 4.0 Hz, 0.5 H), 4.65-4.58 (m, 1 H), 4.49 (dd, J = 7.2, 4.0 Hz, 0.5 H), 4.05-3.77 
(m, 2 H), 3.71 (s, 1.5 H, CO2CH3), 3.58 (s, 1.5 H, CO2CH3), 3.68-3.54 (m, 2 H) 3.45 (s, 
1.5 H, OCH3), 3.43 (s, 1.5 H, OCH3), 3.31 (s, 1.5 H, OCH3), 3.28 (s, 1.5 H, OCH3), 
3.26-3.21 (m, 1 H); 13C-NMR (50 MHz; CDCl3) mixture of rotamers 170.0 (s, CO2CH3), 
156.3 and 156.1 (s, NCO2), 135.7 (s, i-Ph), 128.2-127.6 (d, 5 C, Ph), 103.5 and 102.9 
OHC
OMe
OMe
H2, 10% Pd/C
Cbz-Cl, NaHCO3
dioxane-H2O
N CO2Me
HO
MeO
OMe Cbz
751)
2)
NH2MeO2C HCl
HO
8764
PART I - Stereoselective Cyclopropanation of Oxazines                                      CHAPTER 4 
 68 
[d, CH(OCH3)2], 67.7 and 67.5 (t, PhCH2), 62.8 and 62.3 (d, NCH), 60.7 and 60.4 (t, 
CH2OH), 55.1 and 54.8 (q, CO2CH3), 54.3 and 52.0 (q, 2 C, OCH3), 49.2 (t, NCH2); MS 
m/z 309 (M+-CH3OH, 1.9), 277 (0.7), 264 (0.7), 250 (0.6), 234 (0.5), 220 (0.1), 91 
(100).  
 
(R)-2-[Benzyloxycarbonyl-(2,2-dimethoxy-ethyl)-amino]-3-hydroxy-propionic acid 
methyl ester [(R)-87]. Compound (R)-87  was prepared as for (S)-87 starting from D-
serine methyl ester hydrochloride and (64), with identical NMR data to the 
enantiomeric compound (S)-87. (Found: C, 56.20; H, 6.84; N 4.02. C16H23NO7 requires 
C, 56.30; H, 6.79; N, 4.10%); [α]25D 41.7 (c 1.0, CHCl3).  
 
(S)-2,3-Dihydro-[1,4]oxazine-3,4-dicarboxylic acid 4-benzyl ester 3-methyl ester 
[(S)-62c].  
 
 
 
 
 
 
A solution of compound (S)-87 (1.12 g, 3.28 mmol) in toluene (45 mL) containing a 
catalytic amount of p-toluenesulfonic acid monohydrate (63 mg, 0.33 mmol) was 
placed in a single-necked round-bottomed flask equipped with a reflux condenser and 
a dropping funnel containing approximately 16 g of 4Å molecular sieves. The mixture 
was refluxed for 2.5 h, then cooled to room temperature and filtered through a thin 
layer of NaHCO3. Toluene was removed under reduced pressure, and the crude 
product was purified by flash column chromatography (Hexanes-EtOAc 3:1) to yield 
compound (S)-62c as a colourless oil (729 mg, 78%). (Found: C, 60.81; H, 5.55; N, 
5.01. C14H15NO5 requires C, 60.64; H, 5.45; N, 5.05%); [α]25D 8.6 (c 1.0, CHCl3); 1H- 
NMR  (400 MHz, CDCl3) 3:2 mixture of rotamers α and β 7.39-7.30 (m, 5 H, Ph), 6.45 
(d, J = 2.4 Hz, 0.4 H, H-6 β), 6.33 (d, J = 2.6 Hz, 0.6 H, H-6 α), 6.03 (d, J = 2.4 Hz, 0.4 
H, H-5 β), 5.90 (d, J = 2.6 Hz, 0.6 H, H-5 α), 5.29-5.15 (m, 2 H, CH2Ph), 4.95 (s, 0.6 H, 
H-2 α), 4.83 (s, 0.4 H, H-2 β), 4.65 (dd, J = 10.8, 0.8 Hz, 0.6 H, H-2  α), 4.57 (d, J = 
10.8, 0.8 Hz, 0.4 H, H-2 β), 3.97-3.92 (m, 1 H, H-3), 3.78 (s, 1.8 H, OCH3 α), 3.71 (s, 
1.2 H, OCH3 β); 13C-NMR (50 MHz, CDCl3) mixture of rotamers 168.2 and 168.0 (s, 
CO2CH3), 151.7 and 151.0 (s, NCO2), 135.4 (s, i-Ph), 129.4 and 128.2 (d, C-6), 128.1-
127.6 (d, 5 C, Ph), 105.8 and 105.3 (d, C-5), 67.7 and 67.5 (t, CH2Ph), 65.1 and 64.7 
(t, C-2), 54.4 (q, CO2CH3), 53.7 and 52.5 (d, C-3); MS m/z 277 (M+, 4), 249 (11), 91 
(100).  
 
(R)-2,3-Dihydro-[1,4]oxazine-3,4-dicarboxylic acid 4-benzyl ester 3-methyl ester 
[(R)-62c]. Compound (R)-62c was prepared as for (S)-62c starting from (R)-87, with 
identical NMR data to the enantiomeric compound (S)-87. (Found: C, 60.78; H, 5.51; 
N, 5.09. C14H15NO5 requires C, 60.64; H, 5.45; N, 5.05%); [α]25D -7.2 (c 2.5, CHCl3). 
  
(2R/S,4S,5R)-2-Dimethoxymethyl-5-methyl-oxazolidine-4-carboxylic acid methyl 
ester (80): synthesis of the Cbz-protected derivative of 80.  
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Compound 80 was obtained as a by-product starting from L-threonine methyl ester 
(65) (2.42 g, 14.3 mmol) according to the reported procedure for the preparation of 
76a (Chapter 2 and ref. 14). The crude product 80 was then characterized as the 
corresponding Cbz-protected derivative, after treatment of crude 80 with Cbz-Cl 
according to procedure as for 87. Pure Cbz-protected compound (2.76 g, 12.4 mmol) 
was obtained after chromatographic purification (Hexanes-EtOAc 1:3) in 87% yield 
over two steps. (Found: C, 57.96; H, 6.61; N, 3.74. C17H23NO7 requires C, 57.78; H, 
6.56; N, 3.96%); 1H-NMR  (200 MHz, CDCl3) mixture of diastereomers 7.31 (m, 5 H, 
Ph), 5.31 [s, 1 H, CH(OCH3)2], 5.15 (s, 2 H, CH2Ph), 4.58 (m, 1 H, OCHN), 4.46 (m, 1 
H, CHCH3), 4.07 (m, 1 H, NCHCO2), 3.69 (s, 3 H, CO2CH3), 3.46 (s, 6 H, OCH3), 1.39 
(d, J = 5.6 Hz, 3 H, CHCH3); 13C-NMR (50 MHz, CDCl3) mixture of diastereomers 
169.6 (s, CO2CH3), 135.6 (s, i-Ph), 128.2 (d, 2 C, Ph), 127.9 (d, 2 C, Ph), 127.5 (d, 
Ph), 104.2 [d, CH(OCH3)2], 88.6 (d, OCHN), 67.5 (t, CH2Ph), 64.4 (d, CHCH3), 55.7 (d, 
NCHCO2), 52.3 (q, CO2CH3), 19.5 (q, CHCH3).  
 
(2S,3R)-3-(t-Butyl-dimethyl-silanyloxy)-2-(2,2-dimethoxy-ethylamino)-butyric acid 
methyl ester (82).  
 
 
 
 
 
 
Compound 81 (3.70 g, 14.9 mmol) was dissolved in MeOH (45 mL), then 60% 
aqueous solution of dimethoxyacetaldehyde (75) (2.59 g, 14.9 mmol) and 10% Pd/C 
(329 mg) were successively added, and the resulting mixture was stirred overnight at 
room temperature under a hydrogen atmosphere. Then, the suspension was filtered on 
Celite and MeOH was removed under reduced pressure. The resulting mixture was 
partitioned between water and Et2O. The combined organic layers were washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure to yield compound 
82 as a colourless oil (4.95 g, 99%). (Found: C, 53.86; H, 10.00; N, 4.22. C15H33NO5Si 
requires C, 53.70; H, 9.91; N, 4.17%); [α]25D -11.4 (c 1.1, CH2Cl2); 1H-NMR (400 MHz, 
CDCl3)  4.53 [t, J = 5.2 Hz, 1 H, CH(OCH3)2], 4.18 (qui, J = 5.3 Hz, 1 H, OCHCH3), 3.73 
(s, 3 H, CO2CH3), 3.37 (s, 6 H, OCH3), 3.37 (m, 1 H, NCHCO2), 2.94 (dd, J = 12.2, 5.8 
Hz, 1 H, CH2CH), 2.73 (dd, J = 12.2, 5.0 Hz, 1 H, CH2CH), 1.25 (d, J = 6.4 Hz, 3 H, 
CHCH3), 0.85 [s, 9 H, (CH3)3CSi], 0.44 (s, 3 H, CH3Si), 0.14 (s, 3 H, CH3Si); 13C-NMR 
(50 MHz, CDCl3) 171.9 (s, CO2CH3), 102.9 [d, CH(OCH3)2], 69.1 (d, OCHCH3), 66.8 (d, 
NCHCO2), 54.4 (q, OCH3), 53.6 (q, OCH3), 52.0 (q, CO2CH3), 48.9 (t, CH2CH), 25.7 [q, 
3 C, (CH3)3CSi], 20.8 (q, CHCH3), 17.9 [s, (CH3)3CSi], -4.2 (q, CH3Si), -5.1 (q, CH3Si); 
MS m/z 304 (M+-CH3O, 8), 291 (15),  278 (6), 246 (13), 159 (38), 73 (100).  
 
(2R,3S,6R/S)-6-Methoxy-2-methyl-morpholine-3-carboxylic acid methyl ester (83).  
 
 
 
 
 
 
SOCl2 (511 µL, 7 mmol) was added dropwise, at 0 °C, to 7 mL of MeOH. The resulting 
solution was used to dissolve compound 82 (600 mg, 1.79 mmol). The resulting 
mixture was refluxed for 4 h, and then concentrated under reduced pressure. The 
crude material was dissolved again in MeOH, neutralized with Amberlist A-21, and the 
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solvent was evaporated to dryness. The product was directly used without further 
purification for the subsequent protection step. An analytical pure sample was 
obtained after purification through flash column chromatography (EtOAc). (Found: C, 
50.86; H, 8.08; N, 7.22. C8H15NO4 requires C, 50.78; H, 7.99; N, 7.40%); 1H-NMR (400 
MHz, CDCl3) 3:2 mixture of diastereomers α and β 4.47 (s, 0.4 H, H-6 β), 4.40 (dd, J = 
8.8, 2.4 Hz, 0.6 H, H-6 α), 3.88 (qd, J = 5.0, 1.8 Hz, 0.4 H, H-2 β), 3.74 and 3.73 (s, 3 
H, CO2CH3), 3.65 (qd, J = 4.2, 1.2 Hz, 0.6 H, H-2 α), 3.50 (s, 1.8 H, OCH3 α), 3.39 (s, 
1.2 H, OCH3 β), 3.27 (d, J = 9.4 Hz, 0.4 H, H-3 β), 3.18 (d, J = 9.4 Hz, 0.6 H, H-3 α), 
3.04 (dd, J = 12.4, 2.4 Hz, 0.6 H, H-5 α), 2.92-2.90 (m, 0.8 H, H-5 β), 2.59 (dd, J = 
12.4, 8.8 Hz, 0.6 H, H-5 α), 1.75-1.95 (br, 1 H, NH), 1.25 (d, J = 6.4 Hz, 1.8 H, CHCH3 
α), 1.15 (d, J = 6.0 Hz, 1.2 H, CHCH3 β); 13C-NMR  (50 MHz, CDCl3) mixture of 
diastereomers 171.1 (s, CO2CH3), 100.6 and 95.6 (d, C-6), 73.7 and 65.4 (d, C-2), 
63.6 and 62.8 (d, C-3), 56.1 and 54.5 (q, OCH3), 52.1 (q, CO2CH3), 47.9 and 47.2 (t, 
C-5), 18.2 (q, CHCH3).   
 
(2R,3S,6R/S)-6-Methoxy-2-methyl-morpholine-3,4-dicarboxylic acid 4-benzyl 
ester 3-methyl ester (88).  
 
 
 
 
 
 
Crude cyclic acetal 83 was dissolved in H2O (5 mL) and NaHCO3 (297 mg, 3.54 mmol) 
was added. The mixture was stirred until complete dissolution of the salt, then dioxane 
(8 mL) was added. The flask was cooled at 0 °C with an ice bath and Cbz-Cl (253 mg, 
1.77 mmol) was added dropwise. After 10 minutes the ice bath was removed and the 
reaction mixture was stirred 1 day at room temperature. Afterwards, EtOAc (25 mL) 
and water (10 mL) were added. The aqueous layer was discarded and the organic 
phase was washed with 1M HCl, brine, and dried over Na2SO4. The solvent were 
removed under reduced pressure, and the crude material was used without purification 
for the elimination reaction. An analytical pure sample was obtained after purification 
through flash column chromatography (Hexanes-EtOAc 3:1). (Found: C, 59.77; H, 
6.78; N, 4.24. C16H21NO6 requires C, 59.43; H, 6.55; N, 4.33%); 1H-NMR  (400 MHz, 
CDCl3) mixture of diastereomers, mixture of rotamers 7.34-7.25 (m, 5 H, Ph), 5.23-
5.01 (m, 2 H, CH2Ph), 4.82-4.78 (m, 1 H, H-6), 4.70-4.63 (m, 1 H, H-2), 4.32-4.10 (m, 
2 H, H-3 and H-5), 3.98-3.42 (m, 3 H, CO2CH3), 3.42-3.38 (m, 3 H, OCH3), 1.43-1.35 
(m, 3 H, CHCH3); 13C-NMR (50 MHz, CDCl3) mixture of diastereomers, mixture of 
rotamers 170.2 (s, CO2CH3), 135.9 (s, i-Ph), 128.3-127.6 (d, 5 C, Ph), 97.0 (d, C-6), 
69.1 (d, C-2), 67.6 (t, CH2Ph), 59.5 (d, C-3), 55.3 (q, OCH3), 52.3 (q, CO2CH3), 44.3 (t, 
C-5), 20.0 and 18.9 (q, CHCH3).  
 
(2R,3S)-2-Methyl-2,3-dihydro-[1,4]oxazine-3,4-dicarboxylic acid 4-benzyl ester 3-
methyl ester (62d).  
 
 
 
 
 
Crude protected acetal 83 was dissolved in toluene (10 mL) containing a catalytic 
amount of p-toluenesulfonic acid monohydrate (34 mg, 0.18 mmol) and placed in a 
single-necked round-bottomed flask equipped with a reflux condenser and a dropping 
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funnel containing approximately 10 g of 4Å molecular sieves. The mixture was refluxed 
for 2 h, then cooled to room temperature and filtered through a thin layer of NaHCO3. 
Toluene was removed under reduced pressure, and the crude product was purified by 
flash column chromatography (Hexanes-EtOAc 7:2) to yield compound 62d as 
colourless oil (406 mg, 78% over 3 steps from compound 82). (Found: C, 61.80; H, 
6.01; N, 4.91. C15H17NO5 requires C, 61.85; H, 5.88; N, 4.81%); [α]26D -7.2 (c 0.2, 
CHCl3). 1H-NMR  (400 MHz, CDCl3) 3:2 mixture of rotamers α and β 7.39-7.30 (m, 5 H, 
Ph), 6.39 (d, J = 4.8 Hz, 0.4 H, H-6 β) 6.27 ( d, J = 4.8 Hz, 0.6 H, H-6 α), 5.88 (d, J = 
4.8 Hz, 0.4 H, H-5 β) 5.75 ( d, J = 4.8 Hz, 0.6 H, H-5 α), 5.25 (AB, part A, J = 12 Hz, 
0.4 H, CH2Ph β), 5.24 (s, 1.2 H, CH2Ph α), 5.16 (AB, part B, J = 12 Hz, 0.4 H, CH2Ph 
β), 4.83 (qd, J = 6.4, 1.2 Hz, 0.6 H, H-2 α), 4.72 (qd, J = 6.4, 1.2 Hz, 0.4 H, H-2 β), 
4.68 (s, 0.6 H, H-3 α), 4.55 (s, 0.4 H, H-3 β), 3.77 (s, 1.8 H, CO2CH3 α), 3.69 (s, 1.2 H, 
CO2CH3 β), 1.31 (d, J = 6.4 Hz, 1.8 H, CHCH3 α) 1.30 (d, J = 6.4 Hz, 1.2 H, CHCH3 β); 
13C-NMR (50 MHz, CDCl3) mixture of rotamers 168.4 (s, CO2CH3), 152.8 (s, NCO2), 
135.6 (s, i-Ph), 128.4-127.7 (d, 5 C, Ph), 126.8 and 125.7 (d, C-6), 104.7 and 104.3 (d, 
C-5), 69.7 and 69.1 (d, C-2), 68.0 and 67.7 (t, CH2Ph), 58.1 and 57.3 (d, C-3), 52.6 (q, 
CO2CH3), 17.2 (q, CHCH3); MS m/z 291 (M+, 4.6), 188 (15.9), 91 (100).  
 
Cyclopropanation with Cu(OTf)2 and (S,S)-2,2’-isopropylidene-bis(4-t-butyl-2-
oxazoline), general procedure A. To a solution of dihydroxazine 62c (626 mg, 2.24 
mmol) in dry CH2Cl2 (4 mL) cooled in an ice-salt bath were added Cu(OTf)2 (16 mg, 
0.045 mmol), (S,S)-2,2’-isopropylidene-bis(4-t-butyl-2-oxazoline) (16 mg, 0.056 mmol) 
and phenylhydrazine (4.4 µL, 0.045 mmol). After 30 min, a 1.2 M solution of 
diazoacetate in dry CH2Cl2 was added (quantity and time according to Table 4.1). The 
reaction was then gently warmed to room temperature and stirred for 16 h. Then, the 
mixture was concentrated under reduced pressure and the residue was purified by 
flash column chromatography (Hexanes-EtOAc 3:1) to yield the cyclopropanated 
products. 
 
Cyclopropanation with Cu(OTf)2, without chiral ligand, general experimental 
procedure B. To a solution of dihydroxazine scaffold 62c (417 mg, 1.49 mmol) in dry 
CH2Cl2 (3 mL) cooled in an ice-salt bath were added Cu(OTf)2 (11 mg, 0.030 mmol) 
and phenylhydrazine (2.9 µL, 0.030 mmol). After 30 min, a 1.2 M solution of 
diazoacetate in dry CH2Cl2 was added (quantity and time according to Table 4.1). The 
reaction was then gently warmed to room temperature and stirred for 16 h. Then, the 
mixture was concentrated under reduced pressure and the residue was purified by 
flash column chromatography (Hexanes-EtOAc 3:1) to yield the cyclopropanated 
products. 
 
Cyclopropanation with Rh2(OAc)4, general experimental procedure C. To a 
solution of dihydroxazine scaffold 62c (522 mg, 1.87 mmol) in dry CH2Cl2 (4 mL) 
cooled in an ice-salt bath Rh2(OAc)4 (2.5 mol %) and a 1.2 M solution of diazoacetate 
in dry CH2Cl2 were added (quantity and time according to Table 4.1). The reaction was 
then gently warmed to room temperature and stirred for 16 h. The mixture was 
concentrated under reduced pressure and the residue was purified by flash column 
chromatography (Hexanes-EtOAc 3:1) to yield the cyclopropanated products. 
 
 (1S,4S,6R,7R)-2-Oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 5-
benzyl ester 7-ethyl ester 4-methyl ester (-)-(69a). 626 mg 
(2.24 mmol) of compound (S)-62c were treated according to 
general procedure A using 4.5 equivalents of ethyl diazoacetate 
(6 h time of addition) to yield 81 mg (10%) of (-)-69a as the minor N
O
CO2Me
Cbz
EtO2C
H
H
(-)-69a
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stereoisomer, or in higher amounts according to general procedure B. (Found: C, 
60.02; H, 5.71; N, 3.70. C18H21NO7 requires C, 59.50; H, 5.83; N, 3.85%); [α]25D -48.1 
(c 1.2, CHCl3); 1H-NMR (400 MHz, CDCl3) 2:1 mixture of rotamers α and β 7.35-7.29 
(m, 5 H, Ph), 5.29 (AB, part A, J = 12.5 Hz, 0.66 H, CH2Ph α), 5.17 (AB, part B, J = 
12.5 Hz, 0.66 H, CH2Ph α), 5.24-5.11 (m, 0.66 H, CH2Ph β), 4.47 (t, J = 4.8 Hz, 0.66 
H, H-4 α), 4.19 (t, J = 4.8 Hz, 0.33 H, H-4 β), 4.20-4.03 (m, 3 H, CO2CH2CH3 and H-1), 
4.03 (dd, J = 11.6, 5.2 Hz, 0.66 H, H-3 α), 3.94 (dd, J = 11.6, 5.2 Hz, 0.33 H, H-3 β), 
3.84 (dd, J = 11.6, 4.8 Hz, 1 H, H-3), 3.78 (s, 2 H, CO2CH3 α), 3.67 (s, 1 H, CO2CH3 
β), 3.54-3.49 (m, 1 H, H-6), 2.00 (t, J = 3.2 Hz, 1 H, H-7), 1.98 (t, J = 7.2 Hz, 2 H, 
CO2CH2CH3);  13C-NMR (50 MHz, CDCl3) mixture of rotamers 169.4 (s, CO2), 169.2 (s, 
CO2), 155.9 (s, NCO2), 135.7 (s, i-Ph), 128.2-127.1 (d, 5 C, Ph), 67.8 and 67.7 (t, 
CH2Ph), 64.6 and 64.1 (t, C-3), 60.7 (t, CO2CH2CH3), 59.1 (d, C-1) 53.1 and 52.6 (d, 
C-4) 52.0 (q, CO2CH3), 33.9 (d, C-6), 26.4 and 26.0 (d, C-7), 14.2 (q, CO2CH2CH3); 
MS m/z 363 (M+, 0.8), 318 (0.2), 290 (2), 228 (15), 182 (18), 91 (100).  
 
 (1S,4S,6R,7R)-2-Oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 5-
benzyl ester 7-t-butyl ester 4-methyl ester (-)-69b. Compound 
(-)-69b was obtained from (S)-62c as the minor diastereomer 
according to general procedure A, or in higher amounts 
according to general procedure B. (Found: C, 61.06; H, 6.71; N, 
3.55. C20H25NO7 requires C, 61.37; H, 6.44; N, 3.58%); [α]25D -
61.3 (c 1.1, CHCl3); 1H-NMR  (400 MHz, CDCl3) 2:1 mixture of 
rotamers α and β 7.38-7.28 (m, 5 H, Ph), 5.28 (AB, part A, J = 12.4 Hz, 0.66 H, CH2Ph 
α), 5.24 (AB, part A, J = 7.9 Hz, 0.33 H, CH2Ph β), 5.14 (AB, part B, J = 12.4 Hz, 0.66 
H, CH2Ph α), 5.10 (AB, part B, J = 8.0 Hz, 0.33 H, CH2Ph β), 4.45 (t, J = 4.8 Hz, 0.66 
H, H-4 α), 4.38 (t, J = 4.8 Hz, 0.33 H, H-4 β), 4.10 (m, 0.33 H, H-1 β), 4.09 (dd, J = 7.2, 
3.2 Hz, 0.66 H, H-1 α), 3.94 (dd, J = 11.6, 3.2 Hz, 0.66 H, H-3 α), 3.90 (dd, J = 11.6, 
4.8 Hz, 0.33 H, H-3 β), 3.82 (dd, J = 11.6, 4.8 Hz, 1 H, H-3), 3.77 (s, 2 H, CO2CH3 α), 
3.65 (s, 1 H, CO2CH3 β), 3.47 (dd, J = 7.2, 3.2 Hz, 0.33 H, H-6 β), 3.42 (dd, J = 7.2, 
3.2 Hz, 0.66 H, H-6 α), 1.92 and 1.89 (t, J = 3.2 Hz, 1 H, H-7), 1.43 [s, 3 H, 
CO2C(CH3)3 β], 1.37 [s, 6 H, CO2C(CH3)3 α]; 13C-NMR (50 MHz, CDCl3) mixture of 
rotamers 169.4 (s, CO2), 168.1 (s, CO2), 156.0 (s, NCO2), 135.6 (s, i-Ph), 128.3-127.2 
(d, 5 C, Ph), 81.0 [s, C(CH3)3], 67.8 (t, CH2Ph), 64.5 and 64.1 (t, C-3), 58.8 (d, C-1), 
53.1 (d, C-4), 52.6 (d, C-6) 52.1 (q, CO2CH3), 33.5 (d, C-7), 28.0 and 27.4 [q, 3 C, 
C(CH3)3]; MS m/z 335 (M+- t-Bu, 2), 318 (0.4), 291 (3), 200 (15), 91 (100).  
 
 (1R,4S,6S,7S)-2-Oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 5-
benzyl ester 7-ethyl ester 4-methyl ester (+)-70a. 626 mg (2.24 
mmol) of compound (S)-62c were treated according to general 
procedure A using 4.5 equivalents of ethyl diazoacetate (6 h time 
of addition) to yield 512 mg (63%) of (+)-70a. (Found: C, 60.1; H, 
5.11; N, 3.62. C18H21NO7 requires C, 59.50; H, 5.83; N, 3.85%); 
[α]25D 5.5 (c 1.2, CHCl3); 1H-NMR   (400 MHz, CDCl3) 3:2 mixture 
of rotamers α and β 7.35-7.28 (m, 5 H, Ph), 5.27 (AB, part A, J = 12.5 Hz, 0.6 H, 
CH2Ph α), 5.22 (AB, part B, J = 12.5 Hz, 0.6 H, CH2Ph α), 5.21 (AB, part A, J = 13.1 
Hz, 0.4 H, CH2Ph β), 5.13 (AB, part B, J = 13.1 Hz, 0.4 H, CH2Ph β), 4.27 (d, J = 3.2 
Hz, 0.6 H, H-4 α), 4.24 (d, J = 3.2 Hz, 0.4 H, H-4 β), 4.20-4.05 (m, 4 H, CO2CH2CH3, 
H-3, and H-1), 3.84 (dd, J = 11.6, 3.6 Hz, 0.6 H, H-3 α), 3.80 (dd, J = 11.6, 3.6 Hz, 0.4 
H, H-3 β), 3.74 (s, 1.8 H, CO2CH3 α), 3.63 (s, 1.2 H, CO2CH3 β), 3.53 (dd, J = 7.2, 3.6 
Hz, 0.4 H, H-6 β), 3.49 (dd, J = 7.2, 3.6 Hz, 0.6 H, H-6 α), 2.38 (dd, J = 3.6, 2.4 Hz, 0.6 
H, H-7 α), 2.29 (dd, J = 3.6, 2.4 Hz, 0.4 H, H-7 β), 1.26 (t, J = 7.2 Hz, 1 H, CO2CH3 β), 
1.21 (t, J = 7.2 Hz, 2 H, CO2CH3 α); 13C-NMR (50 MHz, CDCl3) mixture of rotamers 
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170.5 and 170.0 (s, CO2), 169.9 and 169.8 (s, CO2), 156.1 and 155.4 (s, NCO2), 135.8 
and 135.5 (s, i-Ph), 128.2-127.2 (d, 5 C, Ph), 67.7 and 67.6 (t, CH2Ph), 65.9 and 65.5 
(t, C-3), 60.6 (t, CO2CH2CH3), 58.1 and 57.8 (d, C-1), 55.4 and 54.9 (d, C-4), 52.6 (q, 
CO2CH3), 35.3 and 35.2 (d, C-6), 27.5 and 27.3 (d, C-7), 14.2 (q, CO2CH2CH3); MS 
m/z 363 (M+, 1.2), 246 (15.2), 228 (17.4), 91 (100).  
 
 (1R,4S,6S,7S)-2-Oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 5-
benzyl ester 7-t-butyl ester 4-methyl ester (+)-70b. 625 mg 
(2.24 mmol) of compound (S)-62c were treated according to 
general procedure A using 4.5 equivalents of t-butyl 
diazoacetate (6 h time of addition) to yield 447 mg (51%) of (+)-
70b. (Found: C, 61.36; H, 6.31; N, 3.46. C20H25NO7 requires C, 
61.37; H, 6.44; N, 3.58%); [α]26D 14.1 (c 0.6, CHCl3); 1H-NMR  
(400 MHz, CDCl3) 2:1 mixture of rotamers α and β 7.37-7.27 (m, 5 H, Ph), 5.30 (AB, 
part A, J = 13.1 Hz, 0.66 H, CH2Ph α), 5.17 (AB, part B, J = 13.1 Hz, 0.66 H, CH2Ph 
α), 5.22-5.12 (m, 0.66 H, CH2Ph β), 4.25 (d, J = 2.8 Hz, 0.66 H, H-4 α), 4.23 (d, J = 2.8 
Hz, 0.33 H, H-4 β), 4.13-4.06 (m, 0.66 H, H-1 β and H-3 β), 4.02 (dd, J = 7.2, 2.4 Hz, 
0.66 H, H-1 α), 4.01 (d, J = 12.0 Hz, 0.66 H, H-3 α), 3.83 (dd, J = 12.0, 3.6 Hz, 1 H, H-
3), 3.74 (s, 2 H, CO2CH3 α), 3.64 (s, 1 H, CO2CH3 β), 3.45 (dd, J = 7.2, 3.6 Hz, 0.33 H, 
H-6 β), 3.41 (dd, J = 7.2, 3.6 Hz, 0.66 H, H-6 α), 2.27 (dd, J = 3.6, 2.4 Hz, 0.66 H, H-7 
α), 2.19 (dd, J = 3.6, 2.4 Hz, 0.33 H, H-7 β), 1.44 [s, 3 H, CO2C(CH3)3 β], 1.37 [s, 6 H, 
CO2C(CH3)3 α]; 13C-NMR (50 MHz, CDCl3) mixture of rotamers 170.1 (s, CO2), 169.1 
(s, CO2), 156.2 (s, CO2), 135.7 (s, i-Ph), 128.2-127.2 (d, 5 C, Ph), 80.9 [s, C(CH3)3], 
67.7 (t, CH2Ph), 65.9 and 65.4 (t, C-3), 57.6 (d, C-1), 54.9 (d, 2 C, C-4 and C-6) 52.5 
(q, CO2CH3), 35.0 (d, C-7), 28.4 and 28.1 [q, 3 C, C(CH3)3]; MS (m/z) 335 (M+- t-Bu, 
2), 318 (0.3), 291 (1), 200 (16), 91 (100). 
 
 (1R,4R,6S,7S)-2-Oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 5-
benzyl ester 7-t-butyl ester 4-methyl ester (+)-69b. 390 mg (1.41 mmol) of 
compound (R)-62c were treated according to general procedure 
A using 4.5 equivalents of t-butyl diazoacetate (6 h time of 
addition) to yield 336 mg (61%) of (+)-69b, with identical NMR 
data as for (-)-69b. (Found: C, 61.11; H, 6.62; N, 3.54. 
C20H25NO7 requires C, 61.37; H, 6.44; N, 3.58%); [α]25D 58.6 (c 
1.0, CHCl3).  
 
(1S,4R,6R,7R)-2-Oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 5-benzyl 
ester 7-t-butyl ester 4-methyl ester (-)-70b. Compound (-)-70b was obtained from 
(R)-62c as the minor diastereomer according to general 
procedure A, or in higher amounts according to general 
procedure B, with identical NMR data as for (+)-70b. (Found: C, 
61.31; H, 6.34; N, 3.49. C20H25NO7 requires C, 61.37; H, 6.44; N, 
3.58%); [α]25D -15.8 (c 1.0, CHCl3).  
 
 
 (1R,3R,4S,6S,7S)-3-Methyl-2-oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic 
acid 5-benzyl ester 7-t-butyl ester 4-methyl ester (71). To a 
solution of dihydroxazine 62d (450 mg, 1.54 mmol) in dry CH2Cl2 
(4 mL) cooled in an ice-salt bath were added Cu(OTf)2 (14 mg, 
0.038 mmol), (S,S)-2,2’-isopropylidene-bis(4-t-butyl-2-oxazoline) 
(11 mg, 0.038 mmol) and phenylhydrazine (3.0 µL, 0.031 mmol). 
After 30 min, a 1.2 M solution of t-butyl-diazoacetate (5 eq.) in dry 
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CH2Cl2 was added during 6 h. During the addition the volume was maintained 
constant, expelling CH2Cl2 by passing nitrogen through the flask. The reaction was 
then gently warmed to room temperature and stirred 16 h. The mixture was 
concentrated under reduced pressure and the residue was purified by flash column 
chromatography (Hexanes-EtOAc 3:1) to yield 405 mg (65%) of 71. (Found: C, 62.42; 
H, 6.93; N, 3.52. C21H27NO7 requires C, 62.21; H, 6.71; N, 3.45%); [α]24D 34.6 (c 1.9, 
CHCl3); 1H-NMR (400 MHz, CDCl3) 3:1 mixture of rotamers α and β 7.34-7.24 (m, 5 H, 
Ph), 5.29 (AB, part A, J = 12.3 Hz, 0.75 H, CH2Ph α), 5.21 (AB, part A, J = 12.2 Hz, 
0.25 H, CH2Ph β), 5.13 (AB, part B, J = 12.6 Hz, 0.75 H, CH2Ph α), 5.06 (AB, part B, J 
= 12.3 Hz, 0.25 H, CH2Ph β), 4.34 (q, J = 6.8 Hz, 0.75 H, H-2 α), 4.27 (q, J = 6.8 Hz, 
0.25 H, H-2 β), 4.08 (s, 0.75 H, H-4 α), 4.03 (s, 0.25 H, H-4 α), 3.79 (dd, J = 7.2, 3.2 
Hz, 0.25 H, H-1 β), 3.75 (dd, J = 7.2, 3.2 Hz, 0.75 H, H-1 α), 3.68 (s, 2.25 H, CO2CH3 
α), 3.58 (s, 0.75 H, CO2CH3 β), 3.54 (dd, J = 7.2, 3.2 Hz, 0.25 H, H-6 β), 3.48 (dd, J = 
7.2, 3.2 Hz, 0.75 H, H-6 α), 2.27 (t, J = 3.2 Hz, 0.75 H, H-7 α), 2.17 (t, J = 3.2 Hz, 0.25 
H, H-7 β), 1.44 (d, J= 6.4 Hz, 2.25 H, CHCH3 α), 1.44-1.41 (m, 0.75 H, CHCH3 β), 1.41 
[s, 2.25 H, CO2C(CH3)3 β], 1.35 [s, 6.75 H, CO2C(CH3)3 α]; 13C-NMR  (50 MHz, CDCl3) 
mixture of rotamers 170.5 (s, CO2), 169.4 (s, CO2), 156.8 (s, NCO2), 135.7 (s, i-Ph), 
128.3-127.2 (d, 5 C, Ph), 80.7 [s, C(CH3)3], 70.1 and 69.6 (d, C-3), 67.6 (t, CH2Ph), 
58.8 and 58.4 (d, C-1), 52.7 (q, CO2CH3), 52.3 (d, C-4), 34.9 and 34.7 (d, C-6), 27.9 
and 27.6 [q, 3 C, C(CH3)3], 27.5 (d, C-7), 17.8 (q, CHCH3); MS m/z 405 (M+, 0.1), 305 
(2), 260 (9), 214 (51), 91 (100). 
 
(1R,4S,6S,7S)-3-Methyl-2-oxa-5-aza-bicyclo[4.1.0]heptane-4,5,7-tricarboxylic acid 
5-benzyl ester 4-methyl ester (19).  
 
 
 
 
 
 
Compound (+)-70b (240 mg, 0.61 mmol) was dissolved in CH2Cl2 (2.8 mL) and TIS 
(125 µL, 0.61 mmol) and TFA (1.2 mL) were added sequentially. The mixture was 
stirred 50 minutes at room temperature and then the solvents were removed under 
reduced pressure. The crude product obtained was redissolved in 5% Na2CO3 (20 mL) 
and the solution was extracted with Et2O. The acqueous phase was acidified at pH 1-2 
with concentrated HCl and extracted with CH2Cl2 (4x10 mL). The dichloromethane 
exctracts were combined, dried over Na2SO4 and concentrated under reduced 
pressure to obtain compound 89 (174 mg, 85%). (Found: C, 57.36; H, 5.21; H, 4.19. 
C16H17NO7 requires C, 57.31; H, 5.11; N, 4.18%); [α]26D 5.8 (c 1.0, CHCl3); 1H-NMR 
(400 MHz, CDCl3) 3:2 mixture of rotamers α and β 7.36-7.28 (m, 5 H, Ph), 5.27-5.10 
(m, 2 H, CH2Ph), 4.25 (d, J = 2.8 Hz, 0.6 H, H-4 α), 4.21 (d, J = 2.8 Hz, 0.4 H, H-4 β), 
4.17-4.05 (m, 2 H, H-3), 3.85-3.78 (m, 1 H, H-1), 3.74 (s, 1.8 H, CO2CH3 α), 3.61 (s, 
1.2 H, CO2CH3 β), 3.59-3.55 (m, 1 H, H-6), 2.39 (s, 0.6 H, H-7 α), 2.29 (s, 0.4 H, H-7 
β); 13C-NMR (50 MHz, CDCl3) mixture of rotamers 175.6 and 175.0 (s, CO2), 170.5 and 
170.2 (s, CO2), 156.3 and 155.8 (s, NCO2), 135.8 and 135.4 (s, i-Ph), 128.4-127.3 (d, 
5 C, Ph), 68.0 and 67.8 (t, CH2Ph), 65.9 and 65.5 (t, C-3), 58.4 and 58.2 (d, C-4), 55.4 
and 54.9 (d, C-1), 52.6 (q, CO2CH3), 36.0 and 35.8 (d, C-6), 27.4 (d, C-7); MS m/z 335 
(M+, 0.2), 290 (0.3), 246 (6), 232 (3), 200 (11), 91 (100).  
 
(1R,4S,6S,7R)-7-Hydroxymethyl-3-methyl-2-oxa-5-aza-bicyclo[4.1.0]heptane-4,5-
dicarboxylic acid 5-benzyl ester 4-methyl ester (20). 
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N-Methylmorpholine (52 µL, 0.47 mmol) and isobutyl chloroformiate (61 µL, 0.45 
mmol) were added, at 0°C, to a solution of compound 89 (144 mg, 0.43 mmol) in dry 
THF (4 mL). After 25 minutes, the white suspension was added dropwise at -78 °C to a 
suspension of NaBH4 (32 mg, 0.86 mmol) in THF/MeOH 3:1 (4 mL). After 30 minutes 
at -78 °C a second portion of NaBH4 (32 mg, 0.86 mmol) was added and the mixture 
was stirred another 30 minutes at -78 °C and then was gently warmed to -40 °C, until 
all the mixed anidride was consumed (TLC monitoring). The reaction was quenched 
with 10% AcOH/H2O (2 mL), diluted with H2O (8 mL), and extracted with EtOAc. The 
combined organic extracts were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure to a residue which was purified by flash column 
chromatography (EtOAc-Hexanes 3:1, then EtOAc) to yield alcohol 90 (112 mg, 81%). 
(Found: C, 59.98; H, 5.71; N, 5.02. C16H19NO6 requires C, 59.81; H, 5.96; N, 4.36%); 
[α]25D 74.6 (c 1.1, CHCl3); 1H-NMR (400 MHz, CDCl3) 1:1 mixture of rotamers α and β 
7.40-7.29 (m, 5 H, Ph), 5.29-5.10 (m, 2 H, CH2Ph), 4.16 (dd, J = 12.0, 3.2 Hz, 1 H, H-
3), 4.03 (d, J = 12.0 Hz, 1 H, H-3), 3.83-3.72 (m, 2 H, CH2OH), 3.74 (s, 1.5 H, CO2CH3 
α), 3.64-3.59 (m, 1 H, H-4), 3.58 (s, 1.5 H, CO2CH3 β), 3.26-3.19 (m, 1 H, H-1), 2.76-
2.70 (m, 1 H, H-6), 1.82-1.80 (m, 1 H, H-7);  13C-NMR  (50 MHz, CDCl3) mixture of 
rotamers 170.8 and 170.5 (s, CO2), 156.6 (s, NCO2), 135.8 and 135.6 (s, i-Ph), 128.4-
127.8 (d, 5 C, Ph), 67.8 (t, CH2OH), 66.1 and 65.8 (t, CH2Ph), 61.1 and 60.8 (t, C-3), 
56.2 and 55.7 (d, C-1), 55.4 and 54.9 (d, C-4), 52.5 (q, CO2CH3), 30.3 and 30.0 (d, C-
6), 28.6 and 28.2 (d, C-7); MS m/z 303 (M+- OH, 1), 290 (4), 218 (2), 200 (2), 91 (100).  
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Introduction to part II: β-hydroxy-α-amino  
acids 
 
 
 
5.1 Asymmetric synthesis of β-hydroxy-α-amino acids 
 
In this section an overview of the most common and recent asymmetric synthesis of β-
hydroxy-α-amino acids is presented. This section is not comprehensive of all the literature 
reported so far, but it just collects some highlights of the different approaches that 
appeared relevant to the author. The various synthetic strategies are presented on the 
basis of the key reaction used. 
 
5.1.1 Asymmetric aldol reaction 
 
A common approach towards the synthesis of β-hydroxy-α-amino acids is the aldol 
reaction of glycine equivalents with aldehydes. The different strategies will be described 
according to the different kind of glycine equivalent used. 
 
Glycinate Schiff bases 
 
One of the first notable and original approaches to β-hydroxy-α-amino acids using Schiff 
bases goes back to the beginning of the 80’s and describes the use of glycine Schiff 
bases which are activated after complexation to a chiral Ni(II) or Cu(II) complex.96 In this 
case the chiral complex is then reacted with aldehydes in the presence of NaOMe, 
yielding the correspronding β-hydorxy-amino acids after hydrolysis with respectable 
diastereo and enantioselectivities.  
 
Scheme 5.1 Aldol reaction of chiral Ni(II) complexes of glycine Schiif bases. 
 
 
 
 
 
 
 
Many efforts have been made to use glycinate Schiff bases in the presence of a suitable 
chiral catalyst. Among the first attempts of asymmetric catalytic synthesis (1999) 
                                               
96 Belokon, Y.N.; Bulychev, A.G.; Vitt, S.V.; Struchkov, Y.T.; Batsanov, A.S.; Tatiana Timofeeva, T.V.; 
Tsyryapkin, V.A.; Ryzhov, M.C.; Lysova, L.A.; Bakhmutov, V.I.; Belikov, V.M.; J. Am. Chem. Soc. 1984, 107, 
4252-4259. And References therein. 
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of β-hydroxy-α-amino acids using glycinate Schiff bases there is the work by the group of 
Corey97 describing the addition of trimethylsilyl enol ether derivative of tert-
butylglycinatebenzophenone Schiff base (95) to aldehydes using the chiral ammonium 
cinchonidine-derived bifluoride salt 97 as catalyst, under Mukayama-aldol conditions. 
Various branched aliphatic aldehydes were subjected to these reaction conditions, 
providing enantiomeric excesses in the range 72-95% for the syn diasteromer.  
 
Scheme 5.2 Mukayama-aldol approach catalysed by a chiral bifluoride salt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 2002 the group of Shibasaki reported the addition of glycinate Schiff bases to 
aldehydes without preformation of enol silyl ethers using a heterobimetallic lanthanide 
catalyst.98 In this case the major diasteromer obtained was mainly the anti even if 
diastereoselectivity and enantioslectivity were modest. In 2004 the cinchona alkaloid 
derived chiral ammonium salt developed by Park and Jew99 was used by the Castle 
group100 as a catalyst for the aldol reaction of unprotected glycinate Shiff bases to 
aldehydes under homogeneous conditions, in the presence of stoichiometric amounts of  
the organic base phosphazene base tert-butyliminotri(pyrrolidino)phosphorane (BTTP). 
The syn diastereomers were obtained as major compounds with ee in the range 52-83%. 
A big improvement in enantio- and diastereoselectivities with the direct aldol of glycinate 
Schiff bases was achieved by the group of Maruoka,101 that reached very good 
enantioselectivities (up to 99% ee) and diastereoselectivities (up to >96:4 in favour of the 
anti diastereoisomer) using the axially chiral ammonium salt 104 under phase transfer 
catalysis conditions. Reaction conditions were particularly effective for the addition to 
aliphatic, greasy aldehydes. 
                                               
97 Horikawa, M.; Busch-Petersen, J.; Corey, E.J. Tetrahedron Letters, 1999, 3843-3846.  
98Yoshikawa, N.; Shibasaki, M. Tetrahedron, 2002, 52, 8289-8298. 
99 Jew, S.-s.;Yoo, M.-S.; Jeong, B.-S.; Park, I.-Y.; Park, H.-g. Org. Lett. 2002, 4, 4245. 
100 Mettath, S.; Skrikanth, G.S.C.; Dangerfield, B.S.; Castle, S.L. J. Org. Chem., 2004, 69, 6489-6492. 
101 Ooi, T.; Kameda, T.; Maruoka, K. J. Am. Chem. Soc.; 2004, 126, 9685-9694. 
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Scheme 5.3 Phase transfer catalysed aldol reaction using the axially chiral ammonium 
salt 104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzymatic activation of glycine 
 
Many approaches have been reported where enzymes are used to activate simple glycine 
towards aldehydes. In 1992 the enzyme serine hydroxymethyltransferase102 (SHMT) has 
been used by Young103 for the reaction of glycine with a variety of aldehyde substrates to 
form β-hydroxyaminoacids in reasonable yields. Anyway, although L-stereospecificity was 
observed at the α-centre, stereospecificity was not high at the β-centre. In the beginning of 
the 90’s, many enzymatic approaches to β-hydroxy-α-amino acids based on the use of 
different threonine aldolases were presented.104 In 1997 the group of Wong cloned and 
overexpressed in E. coli the genes coding for the Escherichia coli L-threonine aldolase 
(LTA; EC 2.1.2.1) and Xanthomonus oryzae D-threonine aldolase (DTA).105 These 
enzymes accepted a wide range of aldehydes as acceptors, providing mixtures of 
diastereomeric products. LTA gave mainly erythro-β-hydroxy-α-L-amino acids from 
aliphatic aldehydes and the threo isomers from aromatic aldehydes, while DTA gave 
threo-β-hydroxy-α-D-amino acids as main kinetically controlled products. 
Diastereoselectivities ranged from modest to good but a careful control of experimental 
conditions and addition of pyridoxal phospate as cofactor were needed. 
 
 
 
 
 
 
 
 
                                               
102 For a review about SHMT see: Matthews, R.; Drummond, J.T. Chem. Rev., 1990, 90, 1275-1290. 
103 Saeed, A.; Young, W.D.; Tetrahedron, 1992, 48, 2507-2514. 
104 (a) Ikemi, M.; Morikawa, T.; Miyoshi, T.; Shimizu, S.; Kataoka, M.; Yamada, H. Biochem. Eng. 2001, Proc. 
Asia-Pac. Biochem. Eng. Conf. 1992, 96. (b) Vassilev, V. P.; Uchiyama, T.; Kajimoto, T.; Wong, C.-H. 
Tetrahedron Lett. 1995, 36, 4081. (b) Herbert, R. B.; Wilkinson, B.; Ellames, G. J.; Kunec, E. K. J. Chem. 
Soc., Chem. Commun. 1993, 205. 
105 Kimura, T; Vassilve, V.P.; Shen, G.J.; Wong, C.H.; J. Am. Chem. Soc., 1997, 119, 11734-11742. 
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Scheme 5.4 Threonine Aldolase catalyzed addition of glycine to aldehydes 
 
 
 
 
 
 
 
In 2000, the Ely Lilly R&D reported an efficient synthesis of oral carbacephalosporin 
antibiotic loracarbef 110 using SHMT catalysed aldol of glycine and 4-pentenaldehyde 
107 to prepare the required intermediate L-erythro-2-amino-3-hydroxy-6-heptenoic acid 
109 on a multigram scale.106 
 
Scheme 5.5 Application of SHMT catalysed aldol reaction for the synthesis of Lorecarbef 
110. 
 
 
 
 
 
 
 
In 2007 a protocol for the production of L-allo-threonine with a continuos process using 
the serine hydroxymethyltransferase GlyA form Escherichia coli was developed.107 The 
authors obtained  L-allo-threonine in an enzyme membrane reactor (EMR) with 
diastereoselectivity higher then 96% with a space time yield of 227 g L−1 d−1 without 
significant loss of enzyme activity over 120 h of operation. 
In general, enzymatic methods present tha advantage of being environmentally friendly 
and use the simplest possible starting materials (glycine and aldehyde) but require strong 
efforts to obtain high levels of diastereoselectivities for every aldehyde which is used. 
Moreover the use of a cofactor or additives is needed. All this factors make enzyme-based 
startegies not the first choice in the common organic-laboratory practice, where a quick 
and simple procedure is needed. Anyway, enzymatic processes can be the method of 
choice for an industrial process where a single product is needed in batch quantities and a 
long optimization doesn’t represent a substantial drawback. 
 
Isocyanoacetates 
 
Addition of isocyanoacetates to aldehydes is a common reaction for the synthesis of  
oxazolines, which are direct precursors of β-hydroxy-α-amino acids after hydrolysis. The 
reaction is catalysed by many inorganic bases such as sodium cyanide in ethanol108 and 
                                               
106 Jackson, B.G.; Pedersen, S.W.; Fisher, J.W.; Misner, J.; Gardner, J.P.; Staszak, M.A.; Doecke, C.; Rizzo, 
J.; Aikins, J.; Farkas, E.;  Trinkle, K.L.; Vicenzi, J.; Reinhard, M.; Kroeff, E.P.; Higginbotham, C.A.; Gazak, 
R.J.; Zhang, T.Y. Tetrahedron, 2000, 56, 5667-5677.  
107 Makart, S.; Bechtold, M.; Panke, S. J. of Biotechnol. 2007, 130, 402-410. 
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by a combination of a tertiary amine and a transition metal salt, the most common of which 
are Au(I), Pd(II)109, Cu(I).110 Among the asymmetric versions of this reactions the most 
notable approach is that reported by the group of Ito111 and successively studied by 
Togni112 and co-workers in series of papers appeared from the second half of the 80’s.  
 
Scheme 5.6 Asymmetric aldol reaction of isocyanoacetates catalysed by a chiral 
ferrocenylphosphine-gold(I) complex 113. 
 
 
 
 
 
 
 
 
 
 
 
Ito designed one of the first bifunctional metal-organic catalyst,16 based on a chiral 
ferrocenylphosphine-gold(I) complex prepared in situ by mixing a gold(I) salt and the 
ligand 113, bearing a tertiary amine on a side chain. The mechanism of action of catalyst 
113 has been deeply studied113 and it has been reported that the chiral complex 113 acts 
as a bifunctional metal-organic catalyst, in which the gold cation serves as a Lewis acid 
and is binded by the isocyanide, enhancing the acidity of the α-protons of the 
isocyaoacetate which are deprotonated by the tertiary amine present on the side chain. 
Less successful approaches are based on the use of chiral Pincer complexes of Pd(II) and 
Pt(II).114 Different palladium complexes have been tested but enantioselectivities and 
diastereoselectivies are still modest.  
 
Isothiocyanato-acetates 
 
In 1986 Evans reported the highly syn diastereoselective aldol reaction of the chiral 
glycine synthon 116, as its derived stannous enolate.115 Yields ranging from 71 to 92% 
and diastereoselectivities up to 99:1 were obtained. Final cleavage of the chiral auxiliary 
allowed the isolation of the corresponding β-hydroxy-α-amino acids. 
 
 
                                               
109 Guillena, G.; Rodriguez, G.; Van Koten, G. Tetrahedron Letters, 2002, 43, 3895-3898. 
110 (a) Ito, Y.; Matsuura, T.; Saegusa, T., . Tetrahedron Letters, 1985, 26, 5781-5784. (b) Benito-Garagorri, D.; 
Bocokic, V.; Kirchner, K. Tetrahedron Letters, 2006, 47, 8641-8644 and references therein.  
111 Ito, Y.; Sawamura, M.; Hayashi, T. J. Am. Chem. Soc., 1986, 108, 6405-6406.  
112 (a) Pastor, S.D.; Togni, A. J. Am. Chem. Soc., 1989, 111, 2333-2334. (b) Pastor, S.D.; Togni, A. J. Org. 
Chem., 1990, 55, 1649-1664. 
113 See Ref 16 
114 (a) Gosiewska,S.; Martinez Herreras, S.; Lutz, M.; Anthony L., Spek, A. L.; Havenith, R.W.A.; van Klink, 
G.P.M.; van Koten, G.; Klein Gebbink, R.J.M., Organometallics, 2008, 27, 2549-2559. (b) Yoon, M.S.;  
Ramesh, R.; Kim, J.; Ryu, D.; Ahn, K.H., J. Organomet. Chem., 2006, 691, 5927-5934.  
115 (a) Evans, D. A.; Weber, A. E. J. Am. Chem. Soc. 1986, 108, 6757–6761. (b) Evans, D. A.; Weber, A. E. J. 
Am. Chem. Soc. 1987, 109, 7151–7157. 
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Scheme 5.7 Evans chiral oxazolidinone 
 
 
 
 
 
 
 
 
The mothod proved quite robust and general and has been applied to the synthesis of 
numerous β-hydroxy-α-amino acids.116 
In 2008 an organocatalytic approach using α-isothiocyanato imides has been reported by 
the group of Seidel.117 The isothiocyanato imide 120 was reacted in the presence of 
various aldehydes in the presence of the bifunctional thiourea catalyst 121. Various 
aldehydes gave the resultant syn β-hydroxy-α-amino acids in high enantioselectivities (up 
to 96%) and good diastereoselectivities (in the range 82:18 to 97:3). Aromatic aldehydes 
proved to be the best substrates in terms of yield and enantioselectivity. 
 
Scheme 5.8 Organocatalysed aldol reaction of isothiocyanato imides and aldehydes. 
 
 
 
 
 
 
 
 
 
α-Azido enolates 
 
The previously described strategy based on the use of Isothiocyanato-acetate has a major 
drawback in the hydrolysis step of the resulting oxazolidin-2-thione. This process, which is 
needed to recover the desired free amino alcol, is not a trivial step as prior transformation 
of the oxazolidin-2-thione into the more easily hydrolysed oxazolidin-2-one is needed.118 In 
order to overcome this problem, the use of α-azido-enolates has been developed. The use 
of azide group as a masked amine would introduction the amine group with a simple and 
clean reduction step. Nevertheless it is well known that  enolates of α-azido ketones or 
esters are not stable and that they spontaneously decompose into α-imino ketones or 
esters.119 Recently (2008), the group of Franck an co-workers reported that α-azido 
                                               
116 (a) Evans, D. A.; Weber, A. E. J. Am. Chem. Soc. 1987, 109, 7151–7157. (b) Lago, M. A.; Samanen, J.; 
Elliott, J. D. J. Org. Chem. 1992, 57, 3493–3496. (c) Boger, D. L.; Colletti, S. L.; Honda, T.; Menezes, R. F. J. 
Am.Chem. Soc. 1994, 116, 5607–5618. (d) Boger, D. L.; Patane, M. A.; Zhou, J. J. Am. Chem. Soc. 1994, 
116, 8544–8556. (e) Herbert, B.; Kim, I. H.; Kirk, K. L. J. Org. Chem. 2001, 66, 4892–4897. 
117 Li, L.; Klauber, E.G.; Seidel, D.; J. Am. Chem. Soc. 2008, 130, 12248–12249. 
118 (a) M. A. Lago, J. Samanen, J. D. Elliot, J. Org. Chem. 1992, 57, 3493-3496; (b) B. Herbert, I. H. Kim, K. L. 
Kirk, J. Org. Chem. 2001, 66, 4892-4897.  
119 (a) P. Martin, Helv. Chim. Acta 1989, 72, 1554-1582; (b) T. Patonay, R. V. Hoffman, J. Org. Chem. 1995, 
60, 2368-377; (c) Y. Murakami, T. Watanabe, H. Suzuki, N. Kotabe, T. Takahashi, K. Toyanari, M. Ohno, K. 
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enolates of N-acyl-thiazolidin-2-thione substrates are stabilized by the presence of Ti(IV) 
species and react with aldehydes to give syn-β-hydroxy-α-azido esters in good yield. 
Moreover the thiazolidin-2-thiones can act as a chiral auxiliary. The authors proved that 
syn-β-hydroxy-α-azido esters can be obtained in high diastereoselectivities when the 
phenyl-glycine derived thiazolidin-2-thiones where used. 
 
Scheme 5.9 Isothiocyanate vs azide as a masked amino group for the synthesis of -β-
hydroxy-α-amino esters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alkoxyoxazoles 
 
Suga and Ibata described an aldol addition/acyl transfer process wherein 5-
methoxyoxazole 123 functions as a glycine enolate synthon.120 
 
Scheme 5.10 
 
 
 
 
 
 
The reaction is catalysed by lewis acids, In particular aluminium-based lewis acids are 
efficient and have been applied in enantioselective versions by Suga and Ibata120 and 
later by the Evans group in 2001.121 It should be noted that the major diastereomer 
obtained is always the cis oxazoline, which can be epimerized to the more stable trans 
isomer by treatment with a catalytic amount of DBU. Evans reached enantiselectivities 
and diastereoselectivities up to >99:1 in the presence of aromatic aldehydes and the 
                                                                                                                                              
Takase, T. Suzuki, K. Kondo, Chem. Pharm. Bull. 1997, 45, 1739-1744; (d) A. Padwa, M. M. SN, M. D. 
Weingarten, Tetrahedron 1997, 53, 2371-2386; (e) G. Geen, C. J. Shaw, J. B. Sweeney, Synlett 1999, 1444- 
1446; (f) T. Patonay, E. JuhNsz-TOth, A. BMnyei, Eur. J. Org. Chem. 2002, 285-295. 
120 H. Suga, K. Ikai, T. Ibata, J. Org. Chem. 1999, 64, 7040-7047, and references therein. 
121 Evans, D.A.; Janey, J.M.; Magomedov, N.; Tedrow, J.S.;  Angew. Chem. Int. Ed. 2001, 40, 1884-18888. 
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catalyst 127, prepared from a diaminobinaphthyl-derived ligand 126 and 
dimethylaluminum chloride (Scheme 5.11). 
 
Scheme 5.11 Syntheis of the aluminium catalyst (R)-127 employed by Evans. 
 
 
 
 
 
 
 
 
 
 
 
5.1.2 Hydrogenation via dynamic kinetic resolution 
 
A very elegant strategy is based on the hydrogenation via dynamic kinetic resolution of 
protected α-amino-β-keto esters (128), using chiral transition metal catalysts. The chiral 
lability of 2-substituted 3-oxo carboxylic esters of type 128, coupled with the high chiral 
recognition ability of chiral hydrogenation complexes offers the possibility of 
stereoselective hydrogenation utilizing dynamic stereomutation as outlined in Scheme 
5.12. If the racemization of the enantiomers (R)-128 and (S)-128 can be rapid enough with 
respect to the hydrogenation then, when rates of the reaction of the two enantiomers (R)-
128 and (S)-128 are substantially different, the hydrogenation forms one isomer 
selectively among the four possible stereoisomeric products. 
 
Scheme. 5.12 Concept for the Dynamic Kinetic Resolution approach to β-hydroxy-α-
amino acids (the concept is exemplified in case the syn product is prevalent). 
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This concept has been successfully applied in 1989 by Noyori, who synthesised the 
hydroxyl amino ester 131, useful intermediate for the preparation of L-DOPS, an anti-
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Parkinsonian agent.122 The catalyst used was the simple RuBr2[R-BINAP] and the syn 
diastereomer was the major as exemplified in scheme 5.13. 
 
Scheme 5.13 Noyori synthesis of intermediate 131. 
 
  
 
 
 
 
 
The reaction developed by Noyori has been applied to the synthesis of various hydroxy- 
amino acids and different type of catalysts based on Ru(II) have been reported.123 
Recently, in 2004, Hamada reported a new approach, in which instead of the syn 
diastereomer, the major product is the anti β-hydroxy-α-amino acid.124 This difference in 
stereoselectivity is obtained using unprotected α-amino-β-keto esters hydrochloride salts, 
in the presence of Ru-BINAP catalysts. The anti-selectivity is attributed by the authors to a 
chelating effect of the amino group, which originates a 5 membered transition state in the 
presence of the chiral ruthenium catalyst. This five member transition state would then 
originate the anti diastereomer. In the case of the use of a benzoylated amino-group, the 
transition state is a 6 member ring and the successive hydrogenation gives rise to the syn 
diastereomer. 
Scheme 5.14 
 
 
 
 
 
 
 
 
 
 
 
This methodology has been successfully applied by the authors cited in Ref. 29 to 13 
different substrates, providing discrete to excellent enantioselectivities and excellent anti 
                                               
122 Suzuki, T.; Sakoda, S.; Ueji, M.; Kishimoto, S.; Hayashi, A.; Kondo, T.; Narabayashi, H. Neurology 1984, 
34, 1446. 
123 (a) K. Mashima, Y. Matsumura, K. Kusano, H. Kumobayashi, N. Sayo, Y. Hori, T. Ishizaki, S. Akutagawa, 
H. Takaya, J. Chem. Soc. Chem. Commun. 1991, 609. (b) J.-P. Genet, C. Pinel, S. Mallart, S. Juge, S. 
Thorimbert, J. A. Laffitte, Tetrahedron: Asymmetry 1991, 2, 555-567; (c) M. Kitamura, M. Tokunaga, R. 
Noyori, J. Am. Chem. Soc. 1993, 115, 144-152; (d) K. Mashima, K. Kusano, N. Sato, Y. Matsumura, K. 
Nozaki, H. Kumobayashi, N. Sayo, Y. Hori, T. Ishizaki, S. Akutagawa, H. Takaya, J. Org. Chem. 
1994, 59, 3064-3076; (e) J.-P. Genet, M. C. C. de Andrade, V. Ratovelomanana-Vidal, Tetrahedron Lett. 
1995, 36, 2063-2066; (f) E. Coulon, M. C. C. de Andrade, V. Ratovelomanana-Vidal, J.-P. Genet, Tetrahedron 
Lett. 1998, 39, 6467-6470; i) K. Makino, N. Okamoto, O. Hara, Y. Hamada, Tetrahedron: Asymmetry 2001, 
12, 1757-1762. 
124 Makino, K.; Goto, T.; Hiroki, Y.; Hamada, Y. Angew. Chem. Int. Ed. 2004, 43, 882-882. 
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diastereoselectivities. Best substrates proved to be aliphatic ketones, while aromatic 
ketones gave good diastereoselectivities but low enantiomeric excesses. 
 
Scheme 5.15 Anti-selective hydrogentation of α-amino-β-keto esters hydrochloride salts. 
 
 
 
 
 
 
 
 
In 2004 also a different approach to anti-selective hydrogenation was reported using 
ruthenium catalysts. In this case the anti selectivity was obtained using α-phtalimido-β-
keto esters as substrates for the hydrogenation and C3-TunePhos as chiral ligands. The 
process was successfully applied to the high-yielding preparation of allo-threonine in 99% 
ee and >97:3 anti:syn ratio.125 Other papers have then appeared, in which anti-selectivity 
is obtained in the presence of Ru-based catalysts.126 
More recently, Hamada and co-workers have developed highly anti-selective and 
enantioselective catalysts for the hydrogenation of α-amino-β-keto esters based on 
iridium(I) complexes.127 This new catalysts are effective with aromatic substituted keto 
esters, so they are complementary to the Ru(II) catalysts described by Hamade. 
 
5.1.3 Sharpless asymmetric dihydroxylation, amino-hydroxylation and 
epoxidation  
 
Asymmetric aminohydroxylation of α,β-unsaturated esters would provide an ideal strategy 
for the synthesis of syn β-hydroxy-α-amino esters, providing the desired products in one 
single step from easily available olefinic precursors. Unfortunately standard asymmetric 
aminohydroxylation of unsaturated esters with PHAL ligands system usually affords the 
corresponding β-amino esters. In 1998 Sharpless reported a modification in which the 
regiochemical outcome of the reaction could be reversed using AQN ligands in the 
presence of cinnamate esters.128 
 
 
 
 
 
 
 
                                               
125 Lei, A.; Wu, S.; He, M.;. Zhang, X. J. Am. Chem. Soc. 2004, 126, 1626-1627. 
126 (a) Mordant, C.; Dunkelmann, P.; Ratovelomanana-Vidal, V.; Genet, J. P. Chem. Commun. 2004, 1296-
1297. (b) Mordant, C.; Dunkelmann, P.; Ratovelomanana-Vidal, V.; Genet, J.-P. Eur. J. Org. Chem. 2004, 
3017-3026. 
127 (a) Makino, K.; Hiroki, Y.; Hamada, Y. J. Am. Chem. Soc. 2005, 127, 5784-5785. (b) Makino, K.; Iwasaki, 
M.; Hamada, Y.; Org. Lett. 2006, 4573-4576. 
128 Tao, B.; Schlingloff, G.; Sharpless, K.B. Tetrahedron Letters 1998, 39, 2507-2510. 
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Scheme 5.16 Asymmetric aminohydroxylation approach to β-hydroxy-α-amino esters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
These finding opened the field to various application of asymmetric aminohydroxylation for 
the synthesis of β-hydroxy-α-amino esters.129  
In 1996 Goodman and Shao reported a highly enantioselective synthesis of allo-thronine 
and β-hydroxy-valine using asymmetric Sharpless dihydroxylation.130 The preparation of 
allo-threonine was based on the asymmetric dihydroxylation of benzyl crotonate; the diol 
was the converted to its 2,3-cyclic sulfite with SOCl2 and oxidized to cyclic sulfate X in a 
one-pot synthesis. Nucleophilic displacement by NaN3 at the α-C of cyclic sulfate X occurs 
with clean inversion of chirality, and acidic hydrolysis provides the desired α-azido ester 
that is then reduced and deprotected in a single hydrogenation step. 
 
Scheme 5.17 Sharpless Asymmetric dihydroxylation strategy for the synthesis of allo-
thronine. 
 
 
 
 
 
 
 
 
 
During the enantioselective synthesis of (+)-Lacatcystin and its analogues by Omura and 
Amos B Smith III, it was required a scalable and flexible process to access to four possible 
stereoisomer of hydroxy-leucine.131 The reported approach was based on a catalytic 
Sharpless epoxidation of olefin 147 and a benzyl isocyanate-induced opening of epoxide 
148. A final base-catalysed epimerization of the oxazolidinone ester 152 is used in case 
the syn diastereomer is needed.  The process provides an access to all four possible 
diastereomer of hydoxy-leucine in high yield and high enantiomeric excess (>97%). 
 
                                               
129 (a) Park, H.; Cao, B.; Joullie, M. M. J. Org. Chem. 2001, 66, 7223. (b) Miller, M. J. J. Org. Chem. 2002, 67, 
4759. 
130 Shao, H.; Goodman, M.; J. Org. Chem. 1996, 61, 2582-2583. 
131 Nagamitsu, T.; Sunazuka, T.; Tanaka, H.;Omura, S.; Sprengeler, P.A.; Smith III, A.B. J. Am. Chem. Soc. 
1996, 118, 3584-3590. 
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Scheme 5.18 Synthesis of hydroxyleucines based on asymmetric sharpless epoxidation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 Bifucnctional metal-organic catlysis 
 
A concept that has recently emerged in the wide field of catlysis is the part concerning the 
bifunctional metal-organic catalysis. “….There is a growing emphasis on multifunctional 
systems, in which multiple parts of a catalyst or multiple catalysts work together to 
promote a specific reaction. These efforts, in part, are resultdriven, and they are also part 
of a movement toward emulating the efficiency and selectivity of nature’s catalysts, 
enzymes….” (Ethan Alden-Danforth and Thomas Lectka, Account Chemical Research, 
2007, 41, 655-663). Two of the main approaches towards catalysis in organic chemistry 
are represented by metal activation of a substrate and by organic activation 
(organocatlysis). Very often the two strategies are complementary and, in some cases, 
they could even be used together, working in tandem in a single reaction.132 These 
bifunctional systems can help to overcome some of the most recent challenges in current 
organic chemistry, providing a solution for the activation of system where both, 
orgnocatalysis and metal catalysis, have previously failed. Two mechanisms can be 
described for the activation provided by metal-organic bifunctional catalysis. In a first case 
the metal activates one of the reagents while the organic catalyst activates the second 
substrate. In a second case, both the metal catalyst and the organic catalyst cooperate to 
activate one of the substrates. The two systems are illustrated in scheme 5.19, where the 
metal catalyst is represented by a Lewis acid and the organic catalyst is represented by a 
Lewis base (for example a tertiary amine).   
 
 
 
                                               
132 For a review see: Alden-Danforth, E.; Lectka, T.; Acc. Chem. Research, 2007, 41, 655-663. 
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Scheme 5.19 
 
 
 
 
 
 
A first problem that arises in the design of a practical bifunctional metal-organic system is 
the compatibility between the two catalysts that should act in synergy. In most cases the 
metal catalyst is a Lewis acid and the organic catalyst is a Lewis base. In this situation the 
two systems must be chosen carefully so that they don’t react with each other. The large 
potential for the “self quenching” of the catalytic system can be avoided by a fine tuning of 
the two catalytic systems based on the “hard-soft” characters of the Lewis acid and the 
Lewis base. When an asymmetric catalyst is needed, a second point that should be 
considered is that often the LA and the LB are both linked together through a chiral 
scaffold, which must be properly chosen. A seminal example that can be used to illustrate 
how the concept is realised in practice is the Lewis base-BINOL-phosphine oxide catalyst 
for the asymmetric Strecker133 and Reissert134 reaction reported by Shibasaky and co-
workers. 
  
Scheme 5.20 Dual activation of Shibasaky’s Strecker (left) and Reissert reaction (right) 
 
 
 
 
 
 
 
 
 
Using BINOL as a scaffold, they envisioned a catalyst-organized transition-state complex, 
where Al(III) activates the electrophile, while the tethered phosphine oxide interacts with 
TMS-CN. 
 
5.3 Aims & Concept 
 
In the first part, a new strategy for the synthesis of morpholines has been presented, using 
serine and threonine as cheap, enantiopure starting materials. This strategy requires the 
use of enantiopure β-hydroxy-α-amino acids building blocks and so is limited by the 
availability of suitable starting materials from the chiral pool. In order to extend the 
synthetic utility a reliable source of enantiopure β-hydroxy-α-amino acids was required. 
Although many different strategies for the asymmetric preparation of this starting materials 
have been reported so far, we found attractive and challenging the possibility of 
developing our own method. When we faced the problem we thought about the possibility 
                                               
133 Hamashima, Y.; Sawada, D.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 1999, 121, 2641-2642. 
134 Shibasaki, M.; Kanai, M.; Funabashi, K. Chem. Commun. 2002, 1989-1999, and references therein. 
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of exploiting a catalytic method and we decided to carry on this new project in 
collaboration with the group of Professor Darren Dixon from the University of Manchester, 
which is specialised in the field of asymmetric catalysis. Together with Professor Darren 
Dixon we chose to focus our attention on the reaction of addition of α-isocyanoacetates to 
aldehydes. The reaction is catalysed by the cooperative action of transition metals and 
organic bases such as tertiary amines. The most common metals are palladium(II), 
copper(I), silver(I), gold(I). The products are oxazolines, which are a protected form of β-
hydroxy-α-amino esters and can be readily converted to this latter after hydrolysis. Few 
attempts to obtain enantioselectivity in this reaction have been reported using Au(I) or 
Pd(II) complexes and are discussed in the previous section (5.1.1). The only remarkable 
catalyst has been reported by Ito and is based on the use of gold complexes. In this 
scenery we thought that the discovery of a new catalytic system based on a less 
expensive metal then gold could be a valuable contribute to the scientific community.  
In this second part, we describe the design, synthesis and screen of a small library of 
bifunctional metal-organic catalysts for the enantio- and diastereoselective addition of 
isocyanoacetates to aldehydes. Optimization of this silver-catalysed reaction lead to the 
synthesis of syn β-hydroxy-α-amino esters with up to 96% enantiomeric excess. Moreover 
this new methodology allows the synthesis of β-hydroxy-α-amino acids bearing a fully 
substituted (quaternary) α-carbon with enantioselectivities up to 97%. 
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ABSTRACT 
 
 
 
 
 
 
 
 
 
 
 
 
A small library of amino-phosphine ligands has been designed and synthesized using 
cinchona alkaloid-derived scaffolds as source of chirality. This new ligands have been 
screened, together with various transition metals, as catalyst for the asymmetric addition 
of α-isocyanoacetates to aldehydes. Some of the ligands proved to be particularly 
effective in the presence of different silver salts. After a careful optimization, high 
diastereoselectivities (up to 98%) and enantioselectivities (up to 97%) were obtained. The 
new catalytic system was also efficient in the presence of α-substituted isocyanides, thus 
allowing the simultaneous creation of a quaternary and a tertiary stereogenic center next 
to each other. Finally, an efficient hydrolysis procedure for the conversion of oxazolines to 
the corresponding β-hydroxy-α-amino acids is disclosed. 
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6.1 Introduction 
 
Optically active β-hydroxy-α-amino acids represent extremely important targets in organic 
chemistry. These structures are intermediates in the synthesis of many compounds such 
as β-lactams,135 morpholines,136 aziridines137 and many bioactive natural products, 
especially glycopeptide antibiotics such as vancomycin and many others.138 Moreover, in 
our case, β-hydroxy-α-amino acids are the precursors of the morpholine-based amino 
acids described in the first part of this thesis work and a reliable source of these starting 
materials was of primary importance in order to increase the diversity generated through 
the strategy described in the first part. Many approaches have been developed for their 
asymmetric preparation and the most of them have been introduced in Chapter 5. One of 
the most valuable strategies is the addition of α-isocyanoacetates to aldehydes. The 
reaction, first discovered by Schöllkopf139 yields oxazolines, which are readily converted to 
β-hydroxy-α-amino esters/acids after mild hydrolysis.140 Some asymmetric versions have 
been developed and are based on the use of pincer Pd(II) complexes and on the use 
ferrocenylphosphine gold(I) complexes. Attempts based on the use of palladium 
complexes only yielded modest enantioselectivities while the gold(I) complexes disclosed 
by Ito are more efficient and in the best cases can reach ee/de>90%. Unfortunately this 
approach requires the use of expensive gold complexes and a multistep synthesis is 
required for the preparation of pherrocenylphosphine ligands. We decided to develop our 
own catalytic system and we thought about using a bifunctional metal-organic system 
based on a combination of a chiral amine and a transition metal. This idea was suggested 
by literature papers that reported a cohoperative effect between the amine and the 
transition metal. The former would infact act as a base, able to create an enolate from the 
isocyanoacetate and the latter would act as a Lewis acid, being cohordinated by the 
isocyanide and thus enhancing the acidity of the -protons of the isocyanoacetate, which 
are then more easily deprotonated.      
 
6.2 New catalyst design  
 
In order to develop a new metal-organic bifunctional catalytic system for the 
enantioselective addition of α-isocyanoacetate esters to aldehydes, we identified the 
cinchona alkaloid skeleton (Figure 6.1) as a versatile, powerful and readily accessible 
structure and we decided to plan our catalyst design using cinchona alkaloid derived 
scaffolds as source of chirality. We knew from previous work141 that the addition of α-
                                               
135 (a) Nagamitsu, T.; Sunazuka, T.; Tanaka, H.; Omura, S.; Sprengeler, P.A.; Smith, A. B., III. J. Am. Chem.  
Soc. 1996, 118, 3584. (b) Evans, D.A.; Weber, A. E. J. Am. Chem. Soc. 1986, 108, 6757. 
136 Sladojevich, F.; Trabocchi, A.; Guarna, A. J. Org. Chem. 2007, 72, 4254-4257. 
137 Tanner, D. Angew. Chem., Int. Ed. Engl. 1994, 33, 599 
138 For a review on Vancomicyn and related glycopeptide antibiotics see: Nicolaou, K.C.; Boddy, C.N.C.; 
Bräse, S.; Winssinger, N. Angew. Chem. Int. Ed. 1999, 38, 2096-2152. 
139 Hoppe, D.; Schollkopf, U. Justus Liebigs Ann. Chem. 1972, 763, I. 
140 Ito, Y.; Sawamura, M.; Hayashi, T.; J. Am. Chem. Soc. 1986, 108, 6406-6407. 
141 (a) Guillena, G.; Rodriguez, G.; Van Koten, G. Tetrahedron Letters, 2002, 43, 3895-3898. (b) Ito, Y.; 
Matsuura, T.; Saegusa, T., . Tetrahedron Letters, 1985, 26, 5781-5784. (c) Benito-Garagorri, D.; Bocokic, V.; 
Kirchner, K. Tetrahedron Letters, 2006, 47, 8641-8644 and references therein. (d) Ito, Y.; Sawamura, M.; 
Hayashi, T. J. Am. Chem. Soc., 1986, 108, 6405-6406.  
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isocyanoacetate esters to aldehydes is catalyzed by a variety of late transition metals, in 
the presence of organic bases such as tertiary amines.  
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Catlyst design 
 
Cinchona alkaloids combine a basic bridgehead nitrogen with a secondary alcohol, which 
can be used to add a further functionality, such as a strong-coordinating ligand, able to 
give strong binding with a late transition metal. Moreover the alcohol of cinchona alkaloids 
can be easily converted into a primary amine using a well established protocol consisting 
of “one pot” Mitsunobu-Staudinger142, allowing further and simple catalyst differentiation. 
We identified phosphines and ureas/thioureas as ligands to be used to bind the transition 
metal required for our reaction. In this chapter the synthesis of this new catalyst will be 
described, together with the screening of optimal reaction conditions. Finally the scope of 
the reaction will be discussed.   
 
 
6.3 Ligand synthesis  
 
6.3.1 Preparation of Chiral Scaffolds 
 
The starting point in the synthesis of the new catalyst family was the preparation of chiral 
scaffolds. As chiral scaffolds we used commercially available cinchona alkaloids and the 
corresponding 9-amino(9-deoxy) epi-amines 159 and 161.  
The trihydrochloride salts of this chiral amines were synthesised on a multigram scale via 
a one-pot Mitsunobu/Staudinger reaction following a literature procedure (Scheme 6.1).8 
This reaction utilised naturally occurring alkaloid cinchonine and cinchonidine,  
diphenylphosphoryl azide (DPPA) as a source of azide instead of the more potentially 
hazardous hydrogen azide (HN3). The 1H-NMR indicated only one diastereomer signifying 
no retention of stereochemistry via neighbouring group participation. 
 
 
 
 
 
                                               
142 (a) Brunner, H.; Bügler, J.; Nuber, B. Tetrahedron: Asymm., 1995, 6, 1699. 98) Brunner, H.; Bügler, J. Bull. 
Soc. Chim. Belg., 1997, 106, 77. 99) Brunner, H.; Schmidt, P.; Prommesberger, M. Tetrahedron: Asymm., 
2000, 11, 1501. 100) Brunner, H.; Schmidt, P. Eur. J. Org. Chem., 2000, 2119. 101) Brunner, H.; Baur, M. A. 
Eur. J. Org. Chem., 2003, 2854. 
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Scheme 6.1 Preparation of 9-amino(9-deoxy) epi-amines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the synthesis of catalysts, also the scaffolds deriving from the reduction of the double 
bonds were used. These were prepared from the corresponding amines trihydrochloride 
salts by catalytic hydrogenation using Pd/C in hydrogen atmosphere and a mixture MeOH-
HCl 1M as solvent (Scheme 6.2). The crude products obtained proved to be NMR-pure 
and were directly used as substrates for the next coupling reactions without any 
purification.  
Scheme 6.2 Hydrogenation of 9-amino(9-deoxy) epi-amines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.2 Functionalization of Cinchona Scaffolds 
 
Ligands containing an urea or thiourea moiety were obtained by coupling of 9-
amino(9-deoxy) epi-amines with iso(thio)cyanate R-CNX (X = S, O) and according to 
literature reported procedures.143 
                                               
143 Ye, J.; Dixon, D. J.; Hynes, P. S. Chem. Commun., 2005, 4481-4483. 
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Ligands incorporating phosphines were synthesised after coupling of Cinchona scaffolds 
with 2-(diphenylphosphino)benzoic acid or 1-(diphenylphosphino)-2-naphthoic acid.144 
When natural alkaloids were used, the coupling was performed between the acid and the 
alcohol of the scaffold. When 9-amino(9-deoxy) epi-amines were used, the coupling was 
performed between the acid and the primary amine at C-9. In both cases the coupling 
reaction was performed using carbodiimides as activating system. Products were then 
isolated after flash chromatography purification. 
 
Scheme 6.3 Synthesis of Ligands deriving from 9-amino(9-deoxy) epi-cinchonine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 6.4 Ligands deriving from 9-amino(9-deoxy) epi-cinchonidine and quinidine 
 
 
 
 
 
 
 
                                               
144 Trost, B. M..; Van Vranken, D. L.; Bingel, C. J. Am. Chem. Soc. 1992, 114, 9327-9343. 
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6.4 Preliminary screen 
 
Having some of the designed ligands in hands, the next step was the screen of the 
experimental conditions, in order to obtain reactivity and stereocontrol. The screening was 
performed mixing an equimolar amount of ligand and metal salt/complex in a given 
solvent, stirring for approximately 5 minutes in order to obtain the formation of the active 
catalyst in situ, and then adding the isocyanide and the aldehyde. Benzaldehyde and t-
butyl-isocyanoacetate were selected as reagents for the screen. 
 
Scheme 6.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1 Preliminary Screen 
 
 
Ligand Solvent Metal Salt T(oC) Time (h) 
Conv.a 
(%) 
d.r.a 
Trans:cis 
Eeb of 
trans 
(%) 
167 DCM AgOAc 25 2 100 5:1 29 
165 DCM AgOAc 25 4 25 - 25 
174 DCM AgOAc 25 24 100 2:1 -3 
172 AcOEt Ag2O -20 36 100 13:1 76 
170 MTBE Ag2O -20 24 100 11:1 76 
171 MTBE Ag2O -20 24 100 19:1 90 
171 DCM AgOAc 25 16 100 5:1 62 
171 DCM Ag2O 25 2.5 100 6:1 71 
171 DCM Ag2CO3 25 3.5 100 5:1 64 
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171 DCM (PPh3)3AuCl 25 48 100 2:1 44 
171 DCM AgF 25 48 100 4.5:1 67 
171 DCM CuCl 25 48 30 4:1 0 
 
a Determined by 1H-NMR. b Determined by HPLC analysis with a chiral column after conversion to derivative 
182 
 
Many attempts were made and the first variable we decided to screen was the kind of 
metal. We focused on soft transition metals, which are known catalysts for the reaction. 
We found that: 
1) Good yields of product could be achieved with many different cations. In detail Cu(I), 
Ag(I), Au(I) were found to be the most active species. 
2) For a given metal ion, strong change in reactivity was observed according to the metal 
source that was used. For example for the series CuX (where X is a halogen), once a 
ligand was fixed, it was observed: CuCl>CuBr>CuI. The trend was not easy to rationalise 
and it was found to be dependent on many factors. In the case of silver salts a clear 
indication was that reactivity was improved by the increased basicity of the silver salt. It 
was observed: Ag2O>Ag2CO3>AgOAc>AgOTf>AgSBF6. 
3) Urea and thiourea based ligands were less promising in terms of stereocontrol and in 
all cases gave enantioselectivities in the range 25-35% for the major diasteroisomer. 
Thiourea ligand 167, gave rise to a very slow reaction, probably due the poisoning of the 
silver cation caused by the thiourea moiety. 
4) Most interesting results were obtained using phosphine-based ligands in the presence 
of silver salts. Silver oxide was found to be the most reactive and the best in inducing 
enantioselectivity. 
Selected examples are summarized in Table 6.1. 
 
 
6.5 Further optimization  
 
Having identified the system ligand 171-Ag2O as a promising catalytic system, we started 
a deep screen of reaction conditions with the aim of further optimize enantioselectivity and 
diastereoselectivity. 
 
Temperature 
Enantioselectivity and diastereoselecty in favour of the trans oxazoline improved with 
lowering the temperature. We identified a temperature of -20°C as an optimal compromise 
between reactivity-stereoselectivity. At this temperature the reaction reached 
completeness in 24 h, with 5 mol% of ligand 171 and 2.5 mol% of Ag2O. 
Lower reaction temperatures, such as -40°C gave rise to very long reaction times, even at 
higher catalyst loading and didn’t provide a remarkably increase in enantioselectivity. 
 
Solvent 
The most common organic solvents were tested. MeOH and other protic solvents were 
known from preliminary studies with similar catalyst to give slow reactivity and poor 
enantioselectivities and were omitted from the screen. Usually reaction were first run at 
room temperature with different solvents, so that a quick data could be obtained (typical 
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reaction time at 25 °C was 2 hours). The interesting results were then repeated at -20 °C 
(the optimal temperature identified previously).  
 
Scheme 6.6 Solvent screen 
 
 
 
 
 
 
 
Table 6.2 
 
Solvent Temp (oC) 
Time 
(h) 
Conversiona 
(%) 
d.r.a 
trans:cis 
Eeb of 
trans (%) 
DCM 25  2.5 100  6:1 71 
Toluene  25  1.5 100 9:1 74 
THF 25  1.5  100 13:1 80 
DME 25  1.5  100  10:1 80 
THF -20  24  100  23:1 86 
MTBE -20 24 100 19:1 90 
Et2O -20 24 100 18:1 86 
Cyclohexane 25 24 100 17:1 60 
AcOEt -20  24  100  14:1  94 
 
a Determined by 1H-NMR. b Determined by HPLC analysis with a chiral column after conversion to derivative 
182 
 
Ethereal solvents and AcOEt proved all very effective in inducing stereoselection. AcOEt 
and MTBE were selected as the best solvents.  
 
Additives and Concentration effects 
The addition of 4Å powdered MS sieves was beneficial and caused a further improvement 
in enantioselectivity. The reaction was found to be also sensitive to concentration of 
substrates. At concentrations higher then 1 M of isocyanide, a decrease in 
enantioselectivity was registered.  A plausible explanation for this effect can be found in 
the change of coordination of the isocyanide around the silver ion. It has been reported 
that isocyanide coordination.145 Optimal concentration range was found 0.3 M in 
isocyanide. 
When trying to expand reaction scope, it was also found that the optimal concentration of 
aldehyde was substrate-dependent and two different values of aldehyde concentration 
were found effective (0.36 M and 0.51 M, corresponding to 1.2 and 1.7 equivalents of 
aldehyde with respect to the isocyanide when 500 µL of solvent are used).  
When the pseudo-enantiomeric ligand 175 was employed the same experimental 
conditions, enantioselectivity resulted slightly lower (-91%).  
 
 
                                               
145  
CN CO2t-Bu
CHO
N
CO2t-Bu
O
1.2 eq.
Ag2O 2.5 mol %
Ligand 171 5 mol%
Solvent, Temperature
176 177
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Table 6.3 
 
Ligand Solvent Time (h) 
Conva  
(%) 
d.r.a 
trans:cis 
Eeb of 
trans (%) 
171 AcOEt (0.7 M)  24 100 13:1  94 
171 AcOEt (0.3 M) 24 100 20:1  95 
171 AcOEt (0.3 M) + MS 4A) 24 100 21:1  96 
175 AcOEt (0.3 M + MS 4A) 24  100  12:1 -91 
 
a Determined by 1H-NMR. b Determined by HPLC analysis with a chiral column after conversion to derivative 
182 
 
 
6.6 Reaction scope 
 
Once identified the best reaction conditions we started to investigate the scope. The first 
isocyanide which was considered was t-butyl-isocyanoacetate. Many different aldehydes 
were used and both aromatic and aliphatic aldehydes proved to be reactive, even if 
branched aliphatic aldehydes required longer reaction time. Selected examples are 
reported in table 6.4.  
 
Scheme 6.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.4 
 
 
aDetermined by 1H-NMR. bDetermined by HPLC analysis with a chiral column. cIsolated yield after conversion 
to derivative 182. dDetermined after conversion to derivative 182. eIsolated yield after hydrolysis to the 
corresponding formamide. fDetermined after hydrolysis to the corresponding formamide. 
 
 
Product L R2 Solv. Eq. of  Ald. t (h) 
Conv 
 (%) d.r.
a 
Yield 
major 
(%) 
Eeb of 
major 
(%) 
177a 171 Ph AcOEt 1.2 24 100 21:1 72c 96d 
177a 175 Ph AcOEt 1.2 24 100 12:1 76c -91d 
177b 171 4-F-Ph AcOEt 1.7 24 100 15:1 77 92 
177c 171 3-Br-Ph AcOEt 1.7 24 100 10:1 67 92 
177d 171 t-Bu AcOEt 1.2 24 100 99:1 81e 91f 
177e 171 4-Ome AcOEt 1.7 24 100 13:1 60 89 
N
HN
N
O
PPh2
Ligand 171
N
HN
N
O
PPh2
Ligand 175
CN CO2t-Bu R2
O
H N
O
t-BuO2C
R2171, 175 (5 mol %)Ag2O (2.5 mol %)
Solvent
MS 4A
-20 °C176 180 a-e 177
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Diastereoselectivity was mainly governed by steric factors when aliphatic aldehydes were 
reacted. When pivalaldehyde was used, the only diastereomer observed was the trans 
product. The enantioselectivity observed with aliphatic aldehydes was less pronounced 
compared to the reaction model and in many cases the ee of the trans diastreoisomer was 
in the range 50-70%. When aromatic aldehydes different from benzaldehyde were 
employed, reactivity proved to be increased by EWG groups on the aromatic ring. 
Diastereoselectivity was not only governed by steric factors (many orto-susbstituted 
benzaldehydes gave lower diastereoselectivity compared to the correspondent meta-and 
para-substituted). Enantioselectivities for aromatic aldehydes were variable, in the range 
70-90+% but it was not possible to identify a general trend between enantioselectivity and 
electronic/steric properties of the aldehydes.  
From our and previous work in the field of cinchona based catalysis, it appeared clear that 
enantioselectivity was enhanced by the presence of an aromatic moiety in the substrates. 
In order to realize these conditions, we decided to screen some isocyanide containing 
aromatic rings. We found an interesting substrate in the isocyanide 179, deriving from 
phenylglicine methyl ester.146  
Scheme 6.8 
 
 
 
 
 
 
Table 6.5 
 
 
 
 
 
 
 
 
 
               aDetermined by 1H-NMR. bDetermined by HPLC analysis with a chiral column. 
 
The use of 179 as substrate was attractive also because it allows the simultaneous 
creation of a quaternary stereocennter next to a tertiary stereocenter, starting from two 
achiral substrates. When the isocyanide 179 was subjected to the optimized reaction 
conditions it proved to be reactive, especially when the aldehyde was aromatic and 
substituted with EWG groups. In many cases the use of MTBE gave the best results in 
terms of diastereoselectivity. Interestingly, the diastereomeric ratio outcome was hard to 
rationalize on the basis of simple steric effects and probably electronic reasons are very 
important in governing the diastereoselectivity. Unfortunately more experimental data 
need to be collected to reach a deep understanding of the reasons governing the 
diastereomeric ratio. 
                                               
146 Damien Bonne, Mouloud Dekhane, and Jieping Zhu, J. Am. Chem. Soc., 2005, 127, 6926-6927. 
Product R2 Solv. Eq. of  Ald. 
T 
(h) 
Conva 
 (%) D.r.
a 
Yield 
major 
(%) 
Eeb of 
major 
(%) 
181b 4-F-Ph MTBE 1.7 16 100 11:1 78 94 
181c 3-Br-Ph AcOEt 1.7 22 100 3.5:1 59 96 
181f 3-OMe-Ph MTBE 1.7 56 100 12:1 50 93 
181g 3-F-Ph MTBE 1.7 16 100 15:1 67 97 
181h 4-Cl-Ph MTBE 1.7 16 100 11:1 56 96 
181i 4-CO2Me-Ph MTBE 1.7 16 100 8:1 57 93 
181j 4-Br-Ph AcOEt 1.7 22 100 5:1 55 90 
CN CO2Me
R2
O
H
171 (5 mol %)
Ag2O (2.5 mol %)
Solvent
MS 4A
-20 °C179 180b-c, f-j
181
N
O
MeO2C
R2
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As it was previously hypothesized, the enantiocontrol was particularly good and 
enantiomeric excesses up to 97 % for the major diastereoisomer were obtained. Some 
selected examples are reported in table 6.5. 
 
 
6.7 Conversion of oxazolines to amino acids derivatives 
 
The oxazolines synthesised represent direct precursors of β-hidroxy α-amino acids and 
many protocols have been reported for the conversion of this heterocycles to the 
corresponding amino acids or amino esters. Usually these procedures use oxazoline 
incorporating a methyl- or ethyl-ester moiety and are based on acid hydrolysis or 
alcoholisis step. Many of the oxazolines presented in this chapter contain a t-butyl ester 
which was not compatible with literature reported references. Moreover, treatment of 
oxazolines with strong acidic conditions caused a partial epimerization of the trans 
oxazolines. It was found that the best experimental conditions for the conversion of 
oxazolines to amino esters were based on a treatment with acidic methanol for 1 hour and 
45 minutes at 0°C.  
Scheme 6.9 
 
 
 
 
 
 
 
 
 
These conditions lead to the formation of the intermediate formamide and the subsequent 
methanolysis of the formamide resulted faster then the t-butyl ester cleavage. In an 
optimised procedure the oxazoline cleavage was performed on the crude oxazoline 177a 
and the resultant amino ester hydrochloride was neutralized, benzoylated and purified by 
flash column chromatography to obtain compound 182 with 55% yield as a single 
diastereomer with 96% ee. This proved that the conversion of oxazoloines to the 
corresponding amino-ester under the conditions described herein is racemization-free.  
 
 
6.8 Stereochemistry assignament 
 
Diasatereomeric oxazolines derived from t-butylisocyanoacetate were assigned as cis or 
trans on the basis of the difference of the coupling constants between α- and β-protons. It 
is known that protons having a trans relationship have a smaller coupling constant then 
protons in a cis relationship. Absolute configuration of oxazoline deriving from 
benzaldehyde and t-butylisocyanoacetate was then assigned as (4S, 5R) converting the 
CN CO2t-Bu
CHO
N
CO2t-Bu
O
1.2 eq.
Ag2O 2.5 mol %
Ligand 171 5 mol%
AcOEt, MS 4A
-20 °C
176
177a
21:1 d.r.
1) MeOH-SOCl2
    0°C 1 h 45'
2) BzCl-CH2Cl2
    NaHCO3 sat
3) Chromatography
NHBz
CO2t-Bu
HO
182
Single diastereomer
55% Isolated yield 
(3 steps)
96 % ee
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oxazoline to the corresponding β-hidroxy α-amino acid and comparing the sign of the 
optical rotatory power with literature reported values.147  
 
Scheme 6.10 
 
 
 
 
 
 
Absolute configuration of oxazolines deriving from different aromatic aldehydes was then 
assigned by analogy. Absolute configuration of the oxazoline deriving from pivalaldehyde 
and t-butylisocyanoacetate (171d) remains unknown. 
Relative configuration of oxazolines derived from isocyano-phenyl-acetic acid methyl 
ester, 179, was assigned according to the crystal structure of the major diastereomer 
obtained in the reaction with 3-fluoro-benzaldehyde.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Crystal structure of compound 181g 
 
The absolute configuration of oxazolines 181b-c, f-j, deriving from isocyano-phenyl-acetic 
acid methyl ester, remains unknown. 
 
 
6.9 Mechanicistic hypothesis  
 
Although a complete study has not carried out, a first mechanicistic hypothesis can be the 
one represented in scheme 6.11. The idea is that the isocyanide acts as a ligand and 
cohordinates the silver ion. This cohordination enhances acidity of the -hydrogens of the 
isocyanide and brings the pro-nucleophile in a favorable position for the deprtotonation 
that can be carried on by the bridgehead nitrogen of the cinchona scaffold. 
 
 
 
 
 
                                               
147 Ito, Y.; Sawamura, M.; Hayashi, T.; Journal of the American Chemical Society; 1986; 6405 – 6406. 
N
CO2t-Bu
O
177a
1) MeOH-SOCl2
    0°C 1 h 45'
2) NaHCO3 aq.
NH2
CO2t-Bu
HO
182
HCl 6M 
2 h 15'
NH3
CO2H
HO
119
91% ee
Cl
[]D27 (c 1.1 HCl 6M) -43.6
N
CO2Me
O
F
Ph
181g
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Scheme 6.11 Activation of the isocyano-acetate by the catalyst developed in this chapter. 
 
 
 
 
 
 
 
 
 
A simple experiment has been made, in order to prove the cohoperaitve mechanism 
between the silver salt and the ligand. The best reaction conditions were set using tert-
butyl-isocyanoacetate and benzaldehyde. In a first vessel the reaction was run without 
ligand and only silver oxide. In a second vessel the reaction was run with the presence of 
the ligand but without silver oxide. The reaction run with only silver oxide took 5 days to 
reach complete conversion. The reaction run with only the ligand presented just traces of 
product after 5 days. Standard reaction conditions, obtained combining ligand and silver 
oxide, required 24 hours to reach full conversion. This simple test is a clear hint of the 
bifunctional nature of the catalytic system, prooving that both, tha amine and the silver 
salt, are required for the reaction to occur.   
Further studies are needed to provide a model that can explain the origin of enantio- and 
diastereo-selectivity.  
 
 
6.10 Conclusions 
 
In this chapter the first silver-based catalytic system for the addition of α-isocyanoacetates 
to aldehydes has been developed. New amino-phosphine ligands based on cinchona-
alkaloid derived chiral scaffolds have been designed and synthesised. These ligands have 
been successfully applied to the addition of t-butylisocyanoacetate and isocyano-phenyl-
acetic acid methyl ester to aldehydes, obtaining enantioselectivities up to 97% and 
diastereoselectivities up to 98%. When the isocyanide derived from phenyl glycine is 
used, compounds with a quaternary next to a tertiary stereocenter are obtained in a single 
step, starting from two achiral substrates. 
A method for the conversion of oxazoline to the corresponding amino ester without 
racemization and epimerization has been described. Finally a mechanicistic hypothesis, 
describing the catalytic system as a bifunctional metal-organic catalyst has been 
presented. Further experimental research is needed to give a complete explanation of the 
origin of enantio- and diastereoselectivity. 
 
 
6.11 Experimental for chapter 6 
 
General Experimental 
All reagents bought from commercial sources were used as sold. Organic solvents were 
concentrated under reduced pressure using a Büchi rotary evaporator. Syringes, needles 
N
HN
N
O
Ph
PNCRO2C
Ph
M
H
N
H HN
N
O
Ph
P
Ph
M
N
O
RO
R = t-butyl
M = AgLn
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and cannulae were oven dried at 140 °C. Anhydrous dichloromethane, toluene, DIPA 
were purified by distillation over calcium hydride. Ethyl acetate used for the 
enantioselective preparation of oxazolines was dried and stored over 4Å MS. TLC 
analyses were performed using Merck aluminium-backed or glass-backed plates pre-
coated with silica (0.25 mm, 60 F254) and visualized under UV light (254 nm) and/or by 
the use of p-anisaldehyde using the solvent system indicated. Systems using ‘petroleum 
ether’ refer to light petroleum 40-60 °C. Column chromatography was performed on silica 
Kieselgel 60 (40-60 µm). Infrared spectra were recorded on an ATI Matison: Genesis 
Series FTIR spectrometer from a thin film, with absorption maxima (νmax) recorded in 
wavenumbers (cm-1). NMR spectra were recorded using a Bruker Avance 400 MHz or 500 
MHz spectrometer, chemical shifts (δ) are quoted in parts per million referenced to the 
residual solvent peak. The multiplicity of each signal is designated using the following 
abbreviations; s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet, bs, broad singlet. 
Coupling constants (J) are reported in Hertz (Hz). High resolution mass spectra (accurate 
mass) were recorded on a Thermo Finnigan Mat 95XP mass spectrometer. Melting points 
were obtained using a Griffin melting point apparatus and remain uncorrected. 
Known compounds are indicated by a reference to a previous literature report in their title 
line. 
Isocyano-phenyl-acetic acid methyl ester (179)  was synthesized by dehydration of the 
corresponding formamide according to the procedure reported by Zhu et al. for the 
preparation of methyl 2-isocyano-2-(4-methoxyphenyl)acetate. 
 
Practical Experimental 
 
Synthesis and characterization of Catalyst 170 
 
 
 
 
 
 
 
 
Epi-Amino-Cinchonine 161 (120 mg, 0.41 mmol) was dissolved in dry CH2Cl2 (2 mL). 2-
(diphenylphosphino)benzoic acid (120 mg, 0.39 mmol), 4-dimethylaminopyridine (2.4 mg, 
0.020 mmol) and N,N'-Dicyclohexylcarbodiimide (88 mg, 0.43 mmol) were sequentially 
added. The resultant mixture was stirred at room temperature for 24 hours, concentrated 
under reduced pressure and purified by flash column chromatography AcOEt/MeOH 
gradient 100:0 to 100:4 to yield 207 mg (83 %) of product. [α]D28 = +86.0 (c 0.5, CH2Cl2); 1H-
NMR (CDCl3, 500 MHz) δ 8.66 (d, J = 4.5 Hz, 1H), 8.28 (d, J =  8.5 Hz, 1H), 8.02 (d, J =  
8.5 Hz, 1H), 7.62-7.56 (m, 2H), 7.49 (t, J = 7.5 Hz, 1H), 7.27-7.16 (m, 12H), 7.13-7.10 (m, 
2H), 6.83 (dd, J = 7.40, 4.0 Hz, 1H), 5.79 (m, 1 H), 5.32 (br, 1H), 5.08 (d, J = 10.5 Hz, 1H), 
5.03 (d, J = 17.5 Hz, 1H), 2.83 (br, 1H), 2.75-2.66 (m, 4H), 2.16 (dd, J = 15.0, 8.0 Hz, 1H), 
1.52 (s, 1H), 1.42-1.40 (m, 1H), 1.36-1.30 (m, 1H), 1.21-1.16 (m, 1H), 0.81-0.76 (m, 1H); 
13C-NMR (CDCl3, 100 MHz) (C-P coupling constants not removed) δ 168.0, 149.0, 147.4, 
145.8, 145.7, 140.3, 140.0, 139.0, 136.5, 136.4, 136.0, 135.9, 134.67, 134.45, 133.24, 
132.88, 132.70, 132.50, 129.19, 127.92, 127.72, 127.60, 127.57, 127.52, 127.45, 126.32, 
N
HN
N
O
N
H2N
N
PPh2
CO2H
DCC, DMAP
CH2Cl2
PPh2
168
161
170
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125.43, 124.92, 122.51, 114.05, 59.17, 50.79, 50.56, 47.92, 45.72, 38.02, 26.22, 25.36, 
24.05; 31P-NMR (162 MHz, CDCl3) δ -10.5; IR νmax/cm-1 2934, 1648, 1508, 1478, 744, 696; 
MPT 99-101 °C; HRMS (ES+): calcd. for C38H37N3O1P1 [M+H]+ 582.2669, found 582.2658. 
 
Synthesis and characterization of catalyst 171 
 
 
 
 
 
 
 
 
 
Epi-Amino-Cinchonine*3HCl salt [161*3HCl] (2.024 g, 5.03 mmol) was dissolved in 30 mL 
of a mixture of 2:1 MeOH/HCl 1M and 10% Pd/C (303 mg) was added. The reaction 
mixture was stirred under a hydrogen atmosphere for 7 h at room temperature and then 
filtered through Celite washing with water and MeOH. The filtrate was concentrated under 
reduced pressure and neutralized with sat. NaHCO3. The resultant solution was extracted 
several times with CH2Cl2. The combined CH2Cl2 extracts were dried over Na2SO4 and 
concentrated under reduced pressure to yield a colourless oil which was dissolved in 20 
mL of dry CH2Cl2. 2-(diphenylphosphino)benzoic acid (1.47 g, 4.80 mmol), 4-
dimethylaminopyridine (59 mg, 0.48 mmol) were added. The mixture was cooled at 0 oC, 
N-(3-Dimethylaminoprpyl)-N’-ethylcarbodiimide hydrochloride (920 mg, 4.80 mmol) was 
added and then the ice bath was removed and the resultant solution was stirred at room 
temperature for 24 h. CH2Cl2 was then removed under reduced pressure and the crude 
was dissolved in Et2O and washed with water, NaHCO3 10 %, brine and dried over 
Na2SO4. The organic phase was concentrated under reduced pressure and purified by 
flash column chromatography (CH2Cl2/MeOH 16:1). Impure fractions were further purified 
by flash column chromatography (AcOEt/CH2Cl2/MeOH 5:2:1) to yield 1.70 g (58 %) of 
product. [α]D25 = +67.2 (c 0.5, CH2Cl2); 1H-NMR (CDCl3, 400 MHz) δ 8.76 (d, J = 4.8 Hz, 
1H), 8.39 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.73-7.58 (m, 4H), 7.40-7.19 (m, 
13H), 6.92 (dd, J = 7.2, 4.0 Hz, 1H), 5.36 (br, 1H), 3.00-2.52 (m, 4H), 2.49-2.44 (m, 1H), 
1.51 (s, 1H), 1.49-1.30 (m, 5H), 1.29-1.16 (m, 1H), 0.90 (t, J = 7.0 Hz, 3H); 13C-NMR 
(CDCl3, 100 MHz) (C-P coupling constants not removed) δ 169.1, 150.1, 148.4, 146.9, 
141.4, 141.0, 137.7, 137.6, 137.2, 137.1, 135.9, 135.6, 134.3, 133.9, 133.8, 133.6, 133.5, 
130.2, 127.4, 126.5, 123.5, 119.6, 60.3, 51.51, 49.0, 37.2, 27.1, 25.9, 25.7, 25.0, 12.1; 
31P-NMR (162 MHz, CDCl3) δ -10.36;  
 
Synthesis and characterization of Catalyst 172 
 
 
 
 
 
 
 
N
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O
N
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Epi-amino-cinchonine 161 (270 mg, 0.92 mmol), 1-(diphenylphosphino)-2-naphthoic 
acid148 (258 mg, 0.72 mmol) and 4-dimethylaminopyridine (8.8 mg, 0.072 mmol) were 
dissolved in dry CH2Cl2 (4 mL). The reaction mixture was cooled with an ice/salt bath and 
solid N-(3-Dimethylaminoprpyl)-N’-ethylcarodiimide hydrochloride (138 mg, 0.72 mmol) 
was added. The flask was gently warmed to room temperature and stirred for 16 h. The 
reaction mixture was diluted with AcOEt, washed with water, brine and dried over Na2SO4. 
The organic phase was concentrated under reduced pressure and purified by flash 
column chromatography (CH2Cl2/MeOH 13:1) to yield 248 mg (54 %) of product. [α]D25 = 
+61.7 (c 1.75, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 8.80 (d, J = 4.4 Hz, 1H), 8.38 (d, J = 
8.4 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 
7.62 (t, J = 7.2 Hz, 1H), 7.50 (d, J = 4.4 Hz, 2H), 7.34 (q, J = 6.8 Hz, 5H), 7.25 (t, J = 7.6 
Hz, 1H), 7.18-7.10 (m, 7H), 7.01 (t, J = 8.4 Hz, 1H), 5.85-5.76 (m, 1H), 5.48 (br, 1H), 5.09 
(d, J = 10.4, 1H), 5.03 (d, J = 17.6 Hz, 1H), 3.20-2.20 (m, 4H), 2.07 (s, 1H), 1.51 (s, 1H), 
1.40-1.10 (m, 4H), 0.83 (s, 1H); 13C-NMR (100 MHz, CDCl3) δ 169.1, 150.1, 148.4, 146.9, 
141.4, 141.0, 137.7, 137.6, 137.2, 137.1, 135.9, 135.6, 134.3, 133.9, 133.8, 133.6, 133.5, 
130.2, 127.4, 126.5, 123.5, 119.6, 60.29, 51.51, 49.0, 37.2, 25.9, 25.7, 25.0; 31P-NMR 
(162 MHz, CDCl3) δ -12.6; IR νmax/cm-1 1654, 1508, 1482, 744, 696, 570; MPT 108-110 
°C; HRMS (ES+): calcd. for C42H39O1N3P1 [M+H]+ 632.2825, found 632.2822.  
 
Synthesis and characterization of Catalyst 174 
 
 
 
 
 
 
 
 
(+)-Quinidine 173 (550 mg, 1.70 mmol) was dissolved in dry CH2Cl2 (4 mL). 2-
(diphenylphosphino)benzoic acid (528 mg, 1.72 mmol), 4-dimethylaminopyridine (10.0 mg, 
0.085 mmol) and N,N'-Diisopropylcarbodiimide (300 µL, 1.85 mmol) were sequentially 
added. The resultant mixture was stirred at room temperature for 18 hours and then 
concentrated under reduced pressure. THF was added to precipitate the urea which was 
filtered off. The resultant clear solution was concentrated under reduced pressure and 
purified by flash column chromatography (CH2Cl2/MeOH) to yield 510 mg (55 %) of 
product. [α]D28 = -5.1 (c 1.9, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 8.66 (d, J = 4.5 Hz, 1H), 
8.17-8.14 (m, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.45-7.15 (m, 15H), 6.94-6.90 (m, 1H), 6.70 
(d, J = 8.0, 1H), 5.99-5.90 (m, 1H), 5.08-5.03 (m, 2H), 3.94 (s, 3H), 3.36 (q, J =  8.7 Hz,), 
2.90-2.66 (m, 4H), 2.25 (q, J = 8.7, 1H), 1.89-1.76 (m, 2H), 1.58-1.51 (m, 3H); 13C-NMR 
(100 MHz, CDCl3) (C-P coupling constants not removed) δ 165.6, 157.7, 147.2, 144.4, 
143.3, 141.2, 141.0, 140.0, 137.6, 137.5, 137.3, 137.2, 134.2, 133.8, 133.6, 133.3, 133.1, 
132.2, 131.4, 130.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.1, 121.8, 118.9, 114.8, 
101.4, 73.2, 59.1, 55.5, 49.3, 48.7, 39.5, 27.5, 26.1, 23.9; 31P-NMR (162 MHz, CDCl3) δ -
                                               
148 Barry M. Trost, Richard C. Bunt, Rémy C. Lemoine, and Trevor L. Calkins, J. Am. Chem. Soc., 2000, 122, 
5968-5976. 
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4.31; IR νmax/cm-1 1716, 1434, 1248, 1228, 1102, 1054, 744, 732, 698; MPT 83-85 °C. 
HRMS (ES+): calcd. for C39H37N2O3P1 [M+H]+ 613.2615, found 613.2604. 
 
 
Synthesis and characterization of Catalyst 175 
 
 
 
 
 
 
 
 
 
 
Epi-Amino-Cinchonidine*3HCl [159*3HCl] salt (1.26 g, 3.13 mmol) was dissolved in 18 mL 
of a mixture of 2:1 MeOH/HCl 1M and 10% Pd/C (188 mg) was added. The reaction 
mixture was stirred under a hydrogen atmosphere for 6 h at room temperature and then 
filtered through Celite washing with water and MeOH. The filtrate was concentrated under 
reduced pressure and neutralized with sat. NaHCO3. The resultant solution was extracted 
several times with CH2Cl2. The combined CH2Cl2 extracts were dried over Na2SO4 and 
concentrated under reduced pressure to yield a colourless oil which was dissolved in 20 
mL of dry CH2Cl2. 2-(diphenylphosphino)benzoic acid (961 mg, 3.14 mmol), 4-
dimethylaminopyridine (38 mg, 0.31 mmol) were added. The mixture was cooled at 0 oC, 
N-(3-Dimethylaminoprpyl)-N’-ethylcarbodiimide hydrochloride (602 mg, 3.14 mmol) was 
added and then the ice bath was removed and the resultant solution was stirred at room 
temperature for 16 h. CH2Cl2 was then removed under reduced pressure and the crude 
was dissolved in Et2O and washed with water, NaHCO3 10 %, brine and dried over 
Na2SO4. The organic phase was concentrated under reduced pressure and purified by 
flash column chromatography (AcOEt to AcOEt/CH2Cl2/MeOH 5:2:1) to yield 1.20 g (66%, 
2 steps) of product. [α]D28 = - 4.4 (c 1, CH2Cl2); 1H-NMR (CDCl3, 400 MHz) δ 8.78 (d, J = 
4.4 Hz, 1H), 8.40 (d, J = 8.4 Hz, 1H), 8.10 (dd, J = 8.4, 0.8 Hz, 1H), 7.70 (t, J = 6.8 Hz, 
1H), 7.63 (dd, J = 6.8, 3.6 Hz, 1H), 7.58 (t, J = 7.2, 1H), 7.42-7.21 (m, 12H), 7.18 (td, J = 
7.2, 1.6 Hz, 1H), 6.91 (s, 1H), 5.36 (br, 1H), 3.03 (dd, J = 13.6, 10 Hz, 2H), 2.85 (br, 1H), 
2.49-2.61 (m, 1H), 2.11-2.25 (m, 1H), 1.80-1.60 (m, 4H), 1.25-1.08 (m, 3H), 0.91-0.84 (m, 
1H), 0.76 (t, J = 7.6 Hz, 3H); 13C-NMR (CDCl3, 100 MHz) (C-P coupling constants not 
removed) δ 169.1, 150.1, 148.5, 141.4, 141.2, 137.7, 137.5, 137.2, 137.1, 135.8, 135.6, 
134.4, 133.8, 133.6, 130.2, 129.0, 128.8, 128.7, 128.6, 128.5, 127.4, 126.6, 123.7, 119.5, 
60.2, 57.3, 51.5, 40.9, 37.0, 28.2, 27.3, 25.5, 25.1, 12.0; 31P-NMR (162 MHz, CDCl3) δ -
10.87; IR νmax/cm-1 2360, 1648, 1508, 1458, 744, 696; MPT 107-109 °C. 
 
General procedure for the enantioselective synthesis of Oxazolines  
Ligand 171 (6.7 mg, 0.011 mmol) was dissolved in 0.7 mL of solvent (according to Table 
6.4 & 6.5), Ag2O (1.2 mg, 0.0051 mmol) was added. The heterogeneous mixture was 
stirred for approximately 2 minutes and the isocyanide (0.21 mmol, 1 eq.) and powdered 
4Å MS were sequentially added. The flask was cooled in a dry ice/acetone bath and the 
aldehyde (equvailents according to Table 6.4 & 6.5) was added. The flask was then 
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quickly transferred in a -20 °C fridge and the reaction mixture was stirred for the amount of 
time specified in Table 6.4 & 6.5, until all the isocyanide was consumed (TLC, p-
Anisaldehyde). The reaction mixture was then quickly filtered through a short pad of silica 
(in a glass pipette) and eluted with AcOEt. The filtrate was concentrated under reduced 
pressure and treated in the way described for each entry. 
 
Synthesis and characterization of Compound 177a  
Obtained according to the general procedure, using tert-
butylisocyanoacetate (0.21 mmol, 30 mg) and benzaldehyde (0.25 mmol, 
26 µL) as starting materials and AcOEt as solvent. Crude was purified by 
flash column chromatography (E.P./AcOEt 3:1) to yield 31 mg (59 %) of 
product as a colourless oil. [α]D25 = +99.6 (c 0.64, CH2Cl2); 1H-NMR (500 
MHz, CDCl3) δ 7.40-7.20 (m, 5 H, aromatic protons), 7.08 (d, J = 2.0 Hz, N=CH), 5.60 (d, 
J = 8.0, 1H), 4.51 (dd, J = 8.0, 2.0 Hz, 1H), 1.52 (s, 9H, tBu); 13C-NMR (125 MHz, CDCl3) 
δ 169.5 (s, 1C, C=O), 156.0 (d, 1C, C=N), 139.2 (s, 1C, Ph), 128.9 (d, 2C, Ph), 125.6 (d, 
2C, Ph), 82.5 (s, 1C, tBu), 82.3 (d, 1C), 76.2 (d, 1C), 28.00 (q, 3C, tBu); IR νmax/cm-1 2978, 
1732, 1688, 1626, 1370, 1156, 1106; HRMS (ES+): calcd. for C14H17N1O3Na1 [M+Na]+ 
270.1101, found 270.1095. The ee (96%) was calculated after conversion to the N-
benzoylated amino ester using the same procedure described in “direct conversion to N-
benzoylated amino ester”  
 
Synthesis and characterization of Compound 177b  
btained according to the general procedure, using tert-
butylisocyanoacetate (0.21 mmol, 30 mg) and 4-fluoro- benzaldehyde 
(0.36 mmol, 38 µL) as starting materials and AcOEt as solvent. Crude 
was purified by flash column chromatography (E.P./AcOEt) 3.5:1 to 
yield 43 mg (77 %) of product as a colourless oil. The ee was 
determined by HPLC using a Ciralpak OD [hexane/iso-propanol 90:10, λ 220 nm, 1.0 
mL/min] t (major) = 5.75 min., t (minor) = 7.37 min. (92%). [α]D25 = +248.4 (c 1.5, CH2Cl2); 
1H-NMR (400 MHz, CDCl3) δ 7.49-7.45 (m, 2 H, aromatic protons), 7.28-7.24 (m, 3 H, 
aromatic protons and N=CH), 5.76 (d, J = 8.0, 1H), 4.65 (dd, J = 8.0, 2.0 Hz, 1H), 1.70 (s, 
9H, tBu); 13C-NMR (125 MHz, CDCl3) δ 169.3 (s, 1C, C=O), 162.8 (d, JC-F = 247.7 Hz, 1C, 
C-F), 155.9 (d, 1C, C=N), 135.00 (d, JC-F = 3.01 Hz, 1C, Ph), 127.45 (d, JC-F = 8.2 Hz, 2C, 
Ph), 115.86 (d, JC-F = 21.74 Hz, 2C, Ph), 82.7 (s, 1C, tBu), 81.6 (d, 1C), 76.2 (d, 1C), 27.9 
(q, 3C, tBu); IR νmax/cm-1 1732, 1626, 1512, 1156, 1104. 
 
Synthesis and characterization of Compound 177c  
Obtained according to the general procedure, using tert-
butylisocyanoacetate (0.21 mmol, 30 mg) and 3-bromo-
benzaldehyde (0.36 mmol, 42 µL) as starting materials and AcOEt as 
solvent. Crude was purified by flash column chromatography 
(E.P./AcOEt 3:1) to yield 47 mg (69 %) of product as a colourless oil. 
The ee was determined by HPLC using a Ciralpak OD [hexane/iso-propanol 90:10, λ 230 
nm, 1.0 mL/min] t (major) = 6.23 min., t (minor) = 8.20 min. (92%). [α]D25 = +168.2 (c 1, 
CH2Cl2); 1H-NMR (500 MHz, CDCl3) δ 7.41-7.10 (m, 4 H, aromatic protons), 7.08 (d, J = 
2.0 Hz, N=CH), 5.60 (d, J = 8.0, 1H), 4.51 (dd, J = 8.0, 2.0 Hz, 1H), 1.52 (s, 9H, tBu); 13C-
NMR (125 MHz, CDCl3) δ 169.2 (s, 1C, C=O), 155.9 (d, 1C, C=N), 141.5 (s, 1C, Ph), 
N
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131.7 (d, 1C, Ph), 130.5 (d, 1C, Ph), 286.6 (d, 1C, Ph), 124.1 (d, 1C, Ph), 123.0 (s, 1C, 
Ph), 82.9 (s, 1C, tBu), 81.3 (d, 1C), 76.2 (d, 1C), 28.00 (q, 3C, tBu); IR νmax/cm-1 2978, 
1732, 1626, 1368, 1154, 1102. 
Synthesis and characterization of hydrolysed form of compound 177d  
Obtained according to the general procedure, using tert-
butylisocyanoacetate (0.21 mmol, 30 mg) and pivalaldehyde (0.25 mmol, 
27 µL) as starting materials and AcOEt as solvent. Crude reaction mixture 
was dissolved in 2.5 mL of AcOEt saturated with 5% solution of Citric acid 
and stirred until complete conversion of the starting material (TLC), about 
6-8 hours. The organic phase was washed with 5% NaHCO3 sol., dried over Na2SO4 and 
concentrated under reduced pressure. The crude was purified by flash column 
chromatography (E.P./AcOEt 1:1) to yield 42 mg (81 %) of product. The ee was 
determined by HPLC using a Ciralpak OD [hexane/iso-propanol 80:20, λ 210 nm, 1.0 
mL/min] t (minor) = 4.62 min., t (major) = 6.66 min. (91%); [α]D27 = -20.1 (c 0.25, CH2Cl2); 
1H-NMR (400 MHz, CDCl3) δ 8.21 (s, 1H, H-C=O), 6.59 (d, J = 8.4 Hz, N-H), 4.74 (d, 9.2 
Hz, 1H, Cα-H), 3.72 (s, 1H, Cβ-H), 2.42 (br, 1H, O-H), 1.46 (s, 9 H, tBu-H), 0.96 (s, 9H, tBu-
H); 13C-NMR (100 MHz, CDCl3) 171.1 (s, 1C, ROC=O), 160.9 (d, 1C, HC(O)NH), 82.4 (s, 
1C, Me3C-O), 78.1 (d, 1C, Cβ), 51.5 (d, 1C, Cα), 35.4 (s, 1C, Me3C-C), 27.9 (q, 3C, tBu), 
26.0 (q, 3C, tBu); IR νmax/cm-1 3384, 2978, 1714, 1656, 1368. 
 
Synthesis and characterization of Compound 177e  
Obtained according to the general procedure, using tert-
butylisocyanoacetate (0.21 mmol, 30 mg) and p-anisaldehyde (0.36 
mmol, 43 µL) as starting materials and AcOEt as solvent. Crude was 
purified by flash column chromatography (E.P./AcOEt 2:1) to yield 35 
mg (60 %) of product as a colourless oil. The ee was determined by 
HPLC using a Ciralpak OD [hexane/iso-propanol 90:10, λ 230 nm, 1.0 
mL/min] t (major) = 7.74 min., t (minor) = 8.95 min. (89%). [α]D27 = +118.4 (c 0.25, CH2Cl2); 
1H-NMR (400 MHz, CDCl3) δ 7.19-7.16 (m, 2 H, aromatic protons), 6.98 (d, J = 2.0 Hz, 
1H, N=CH), 6.85-6.83 (m, 2H, aromatic protons), 5.48 (d, J = 8.0, 1H), 4.41 (dd, J = 8.0, 
2.0 Hz, 1H), 1.44 (s, 9H, tBu); 13C-NMR (125 MHz, CDCl3) δ 169.6 (s, 1C, C=O), 159.9 (d, 
1C, C=N), 156.0 (s, 1C, Ph), 131.1 (s, 1C, Ph), 127.2 (d, 2C, Ph), 114.2 (d, 2C, Ph), 82.4 
(s, 1C, tBu), 82.3 (d, 1C), 76.0 (d, 1C), 27.9 (q, 3C, tBu); IR νmax/cm-1 1732, 1624, 1516, 
1252, 1156, 1106. 
 
Synthesis and characterization of Compound 181b 
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 4-fluoro-benzaldehyde 
(0.36 mmol, 38 µL) as starting materials and TBME as solvent. Crude 
was quickly purified by flash column chromatography (E.P./AcOEt 3:1) to 
yield 49 mg (78 %) of product. The ee was determined by HPLC using a 
Ciralpak OD [hexane/iso-propanol 90:10, λ 230 nm, 1.0 mL/min] t 
(major) = 10.37 min., t (minor) = 11.61 min. (94%); [α]D27 = +158.0 (c 2.6, CH2Cl2); 1H-
NMR (400 MHz, CDCl3) δ 7.69-7.66 (m, 2H, aromatic protons), 7.44-7.33 (m, 5H, aromatic 
protons), 7.31 (s, 1H, N=CH), 5.75 (s, 1H, Cβ-H), 3.25 (s, 3H, OCH3); 13C-NMR (100 MHz, 
CDCl3) δ 169.6 (s, 1C, C=O), 162.9 (d, JC-F = 248.50 Hz, 1C), 155.4 (d, C=N), 141.3 (s, 
1C), 132.2 (d, JC-F = 3.38 Hz, 1C), 128.5 (d, 3C), 128.3 (d, JC-F = 17.40 Hz 2C), 126.6 (d, 
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2C), 115.5 (d,  JC-F = 21.76 Hz, 2C), 89.1 (d, 1C, Cβ), 84.2 (s, 1C, Cα), 52.3 (q, 1C, OCH3); 
IR νmax/cm-1 2362, 1740, 1638, 1512, 1228, 1104, 698; HRMS (ES+): calcd. for 
C17H15O3N1F1 [M+H]+ 300.1035, found 300.1032.  
Synthesis and characterization of Compound 181c  
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 3-bromo-
benzaldehyde (0.36 mmol, 42 µL) as starting materials and AcOEt as 
solvent. Crude was purified by flash column chromatography 
(E.P./AcOEt 3.5:1) to yield 45 mg (59 %) of product as colourless oil. 
The ee was determined by HPLC using a Ciralpak OD [hexane/iso-propanol 90:10, λ 230 
nm, 1.0 mL/min] t (major) = 10.06 min., t (minor) = 12.53 min. (97%); [α]D25 = +138.6 (c 
1.12, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 7.31-7.59 (m, 2H, aromatic protons), 7.45-
7.42 (m, 2H, aromatic protons), 7.37-7.19 (m, 6H, aromatic protons+N=CH), 5.62 (s, 1H, 
Cβ-H), 3.21 (s, 3H, OCH3); 13C-NMR (100 MHz, CDCl3) δ 169.4 (s, 1C, C=O), 155.4 (d, 
1C, C=N), 141.1 (s, 1C), 138.6 (s, 1C), 132.1 (d, 1C), 130.0 (d, 1C), 129.6 (d, 1C), 128.5 
(d, 1C), 128.3 (d, 1C), 126.6 (d, 1C), 125.3 (d, 1C), 122.5 (s, 1C), 88.8 (d, 1C, Cβ), 84.4 (s, 
1C, Cα), 52.4 (q, 1C, OCH3); IR νmax/cm-1 1738, 1638, 1238, 1104, 694; HRMS (ES+): 
calcd. for C17H15O3N1Br1 [M+H]+ 360.0230, found 360.0231.  
 
Synthesis and characterization of Compound 181f  
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 3-methoxy-
benzaldehyde (0.36 mmol, 43 µL) as starting materials and TBME as 
solvent.  Crude was purified by flash column chromatography 
(E.P./AcOEt 3:1) to yield 33 mg (50 %) of product as a colourless oil. 
The ee was determined by HPLC using a Ciralpak OD [hexane/iso-propanol 90:10, λ 230 
nm, 1.0 mL/min] t (major) = 12.46 min., t (minor) = 14.15 min. (93%); [α]D28 = +154.0 (c 1, 
CH2Cl2); 1H-NMR (400 MHz, CD2Cl2) δ 7.60-7.58 (m, 2H, aromatic protons), 7.35-7.20 (m, 
5H, aromatic protons+N=CH), 6.88-6.80 (m, 2H), 5.64 (s, 1H, Cβ-H), 3.74 (s, 3H, OCH3), 
3.11 (s, 3H, OCH3); 13C-NMR (100 MHz, CD2Cl2) δ 170.1 (s, 1C, C=O), 160.1 (s, 1C), 
155.7 (d, 1C, N=CH), 142.1 (s, 1C), 138.4 (s, 1C), 129.8 (d, 1C), 128.7 (d, 2C), 128.4 (d, 
1C), 127.2 (d, 2C), 119.3 (d, 1C), 114.6 (d, 1C), 112.7 (d, 1C), 89.6 (d, 1C, Cβ), 84.8 (s, 
1C, Cα), 55.72 (q, 1C, OCH3); IR νmax/cm-1 1740, 1638, 1238, 1108, 742, 698; HRMS 
(ES+): calcd. for C18H17O4N1Na1 [M+Na]+ 334.1050, found 334.1050. 
 
Synthesis and characterization of Compound 181g  
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 3-fluoro-benzaldehyde 
(0.36 mmol, 38 µL) as starting materials and TBME as solvent. Crude 
was purified by flash column chromatography (E.P./AcOEt 3.5:1).to 
yield 42 mg (67 %) of product. The ee was determined by HPLC using 
a Ciralpak OD [hexane/iso-propanol 90:10, λ 230 nm, 1.0 mL/min] t (major) = 9.07 min., t 
(minor) = 10.61 min. (97%); [α]D30 = +157.8 (c 1.9, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 
7.70-7.68 (m, 2H, aromatic protons), 7.44-7.34 (m, 4H, aromatic protons), 7.32 (s, 1H, 
N=CH), 7.16 (d, J = 8.0 Hz, 1H, aromatic proton), 7.11-7.04 (m, 2H, aromatic protons), 
5.73 (s, 1H, Cβ-H), 3.26 (s, 3H, OCH3); 13C-NMR (100 MHz, CDCl3) δ 169.4 (s, 1C, C=O), 
162.6 (d, JC-F = 247.23 Hz, 1C, C-F), 155.3 (d, 1C, C=N), 141.1 (s, 1C), 138.8 (d, JC-F = 
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7.12 Hz, 1C), 130.05 (d, JC-F = 8.15 Hz, 1C), 128.5 (d, 2C), 128.3 (s, 1C), 126.6 (d, 2C), 
122.3 (d, JC-F = 2.93 Hz, 1C), 115.9 (d, JC-F = 21.08 Hz, 1C), 113.7 (d, JC-F = 22.75 Hz, 
1C), 88.90 (d, 1C, Cβ), 84.4 (s, 1C, Cα), 52.3 (q, 1C, OCH3); HRMS (ES+): calcd. for 
C17H15O3N1F1 [M+H]+ 300.1035, found 300.1030.  
 
Synthesis and characterization of Compound 181h  
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 4-chloro-benzaldehyde 
(0.36 mmol, 50 mg) as starting materials and TBME as solvent. Crude 
was purified by quick flash column chromatography (E.P./AcOEt 3.5:1) to 
yield 37mg (56 %) of product. The ee was determined by HPLC using a 
Ciralpak OD [hexane/iso-propanol 95:5, λ 230 nm, 1.0 mL/min] t (major) = 13.99 min., t 
(minor) = 15.87 min. (96%); [α]D30 = +222.6 (c 1.50, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 
7.68-7.66 (m, 2H, aromatic protons), 7.43-7.30 (m, 8H, aromatic protons+N=CH), 5.73 (s, 
1H, Cβ-H), 3.25 (s, 3H, OCH3); 13C-NMR (100 MHz, CDCl3) δ 169.5 (s, 1C, C=O) 155.4 (d, 
C=N), 141.1 (s, 1C), 134.9 (s, 1C), 134.8 (s, 1C), 128.6 (d, 2C), 128.5 (d, 2C), 128.3 (s, 
1C), 128.0 (d, 2C), 126.6 (d, 2C), 89.0 (d, 1C, Cβ), 84.3 (s, 1C, Cα), 52.4 (q, 1C, OCH3); IR 
νmax/cm-1 1738, 1637, 1493, 1241, 1108, 1091; HRMS (ES+): calcd. for C17H14O3N1Cl1Na1 
[M+Na]+ 338.0554, found 338.0559. 
 
Synthesis and characterization of Compound 181i 
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 4-Formyl-benzoic 
acid methyl ester (0.36 mmol, 58 mg) as starting materials and 
TBME as solvent. Crude was redissolved in Et2O, washed with 
NaHSO3 1M (3x), NaHCO3 sat. (1x), dried over K2CO3 and quickly 
purified by flash column chromatography (Et2O/E.P. 4:1) to yield 41 mg (57 %) of product. 
The ee was determined by HPLC using a Ciralpak OD [hexane/iso-propanol 90:10, λ 230 
nm, 1.0 mL/min] t (major) = 15.39 min., t (minor) = 20.37 min. (93%); [α]D24 = +173.3 (c 
1.50, CH2Cl2); 1H-NMR (400 MHz, CDCl3) δ 8.07 (d, J = 8.4, 2H, aromatic protons), 7.70-
7.68 (m, 2H, aromatic protons), 7.46-7.36 (m, 5H, aromatic protons), 7.34 (s, 1H, N=CH), 
3.93 (s, 3H, OCH3), 3.19 (s, 3H, OCH3); 13C-NMR (100 MHz, CDCl3) δ 169.4 (s, 1C, C=O) 
166.5 (s, 1C, C=O), 155.4 (d, 1C, C=N), 141.2 (s, 1C) 141.1 (s, 1C), 130.7 (s, 1C), 129.7 
(d, 2C), 128.6 (d, 2C), 128.3 (d, 2C), 126.6 (d, 2C), 89.1 (d, 1C, Cβ), 84.6 (s, 1C, Cα), 52.4 
(q, 1C, OCH3), 52.3 (q, 1C, OCH3); IR νmax/cm-1 1724, 1638, 1436, 1280, 1106, 700; 
HRMS (ES+): calcd. for C19H17O5N1Na1 [M+Na]+ 362.0999, found 360.0991. 
 
Synthesis and characterization of Compound 181j  
Obtained according to the general procedure, using isocyano-phenyl-
acetic acid methyl ester (0.21 mmol, 37 mg) and 4-bromo-benzaldehyde 
(0.36 mmol, 66 mg) as starting materials and AcOEt as solvent Crude 
was purified by flash column chromatography (E.P./AcOEt 3.5:1) to yield 
42 mg (55 %) of product. The ee was determined by HPLC using a 
Ciralpak OD [hexane/iso-propanol 90:10, λ 230 nm, 1.0 mL/min] t 
(major) = 10.28 min., t (minor) = 11.53 min. (90%); [α]D25 = +197.8 (c 1.60, CH2Cl2); 1H-
NMR (400 MHz, CDCl3) δ 7.61-7.59 (m, 2H, aromatic protons), 7.47-7.45 (m, 2H, aromatic 
protons), 7.36-7.17 (m, 6H, aromatic protons+N=CH), 5.64 (s, 1H, Cβ-H), 3.18 (s, 3H, 
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OCH3); 13C-NMR (100 MHz, CDCl3) δ 169.5 (s, 1C, C=O) 155.4 (d, C=N), 141.1 (s, 1C), 
135.3 (s, 1C), 131.6 (d, 2C), 128.5 (d, 2C), 128.3 (d, 2C), 126.6 (d, 2C), 123.1 (s, 1C), 
89.0 (d, 1C, Cβ), 84.2 (s, 1C, Cα), 52.4 (q, 1C, OCH3); IR νmax/cm-1 1736, 1638, 1240, 
1106, 1072, 700; HRMS (ES+): calcd. for C17H15O3N1Br1 [M+H]+ 360.0230, found 
360.0233. 
 
Direct conversion of Oxazoline 177a to N-benzoylated amino ester 182 
 
 
 
 
 
 
 
Crude oxazoline 177a prepared according to general procedure was dried in vacuo and 
dissolved in 1.5 mL MeOH dry. The reaction mixture was cooled at 0 oC and 1.5 mL of 1M 
solution of SOCl2 in MeOH (2M HCl) are added drop wise. The solution was stirred 1 h 45’ 
at 0 oC and then the solvent was removed under reduced pressure. The resultant oil was 
dissolved in CH2Cl2 (2 mL) and few drops of sat. NaHCO3 solution were added under 
vigorous stirring until pH 8 (pH paper). The flask was cooled at 0 oC and 1 equivalent 
(0.21 mmol) of benzoyl chloride was added. After 20’ the ice bath was removed and the 
reaction mixture was stirred further 40’. The suspension was partitioned between CH2Cl2 
and water. The organic extracts were dried over Na2SO4 and purified by flash column 
chromatography (E.P./AcOEt 3.5:1) to yield 39 mg (55 % for 3 steps) of 182 as a single 
diastereomer. The ee was determined by HPLC using a Ciralpak AD [hexane/iso-propanol 
80:20, λ 230 nm, 1.0 mL/min] t (minor) = 7.98 min., t (major) = 23.05 min. (96%); [α]D25 = 
+60.4 (c 0.5, CHCl3); 1H-NMR (500 MHz, CDCl3) δ 7.70 (d, J = 7.0 Hz, 2H, aromatic 
protons), 7.48 (t, J = 7.5 Hz, 1H, aromatic proton), 7.41-7.38 (m, 4H, aromatic protons), 
7.32 (t, J = 7.0 Hz, 2H), 7.29-7.25 (m, 1H, aromatic proton), 6.92 (d, J = 8.0 Hz, N-H), 5.26 
(d, 4.0 Hz, 1H), 4.96 (dd, J = 8.5, 4.0 Hz, 1H), 3.32 (br, 1H, O-H), 1.42 (s, 9H, tBu); HRMS 
(ES+): calcd. for C20H23O4N1Na1 [M+Na]+ 364.1519, found 364.1510. 
Spectroscopic data were consistent with previously reported data for this compound.149 
 
Preparation of Racemic Compounds 
 
Racemic Oxazolines deriving from tert-butylisocyanoacetate 
Racemic oxazoilnes derived from tert-butylisocyanoacetate were obtained by dissolving 1 
equivalent of isocyanide and 1.2 equivalents of the corresponding aldehyede in dry 
CH2Cl2 (approximately 5 mL/mmol) at 0°C and adding 10 mol % of DBU as catalyst. The 
reaction mixture was then stirred at 0°C until TLC indicated complete consumption of the 
isocyanide (2-16 hours). The resultant solution was then diluted with CH2Cl2, washed with 
water, dried over Na2SO4 and concentrated under reduce pressure. The crude obtained 
was purified using the same method described for the enantioenriched examples. 
 
Racemic Oxazolines deriving from Isocyano-phenyl-acetic acid methyl ester 
                                               
149 Hasegawa K., Arai S., Nishida A., Tetrahedron, 2006, 62, 1390-1401. 
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Racemic oxazolynes derived from Isocyano-phenyl-acetic acid methyl ester were obtained 
by dissolving 1 equivalent of isocyanide and 1.2 equivalents of the corresponding 
aldehyde in dry CH2Cl2 (approximately 5 mL/mmol) at 0°C and adding 10 mol% of DBU 
and 5 mol% of Ag2O. The reaction mixture was then gently warmed at room temperature 
until TLC indicated complete consumption of the isocyanide (2-16 hours). The resultant 
solution was then concentrated under reduced pressure and purified using the same 
method described for the enantioenriched examples. 
 
X-Ray Crystal structure of Compound 181g 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Table 1.  Crystal data and structure refinement for s3049twa.  
   
   
      Identification code               z:\s3049\work\s3049twa  
   
      Empirical formula                 C17 H14.67 F N O3.33  
   
      Formula weight                    305.30  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Rhombohedral,  R3  
   
      Unit cell dimensions              a = 25.205(8) A   alpha = 90 deg.  
                                        b = 25.205(8) A    beta = 90 deg.  
                                        c = 5.987(3) A   gamma = 120 deg.  
   
      Volume                            3294(2) A^3  
   
      Z, Calculated density             9,  1.385 Mg/m^3  
   
      Absorption coefficient            0.105 mm^-1  
N
CO2Me
O
F
Ph
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      F(000)                            1434  
   
      Crystal size                      0.80 x 0.08 x 0.08 mm  
   
      Theta range for data collection   2.80 to 25.02 deg.  
   
      Limiting indices                  -29<=h<=27, -30<=k<=30, 0<=l<=7  
   
      Reflections collected / unique    1288 / 1288 [R(int) = 0.0000]  
   
      Completeness to theta = 25.02     99.9 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9917 and 0.9207  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    1288 / 1 / 184  
   
      Goodness-of-fit on F^2            1.072  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0498, wR2 = 0.0937  
   
      R indices (all data)              R1 = 0.0625, wR2 = 0.0986  
   
      Largest diff. peak and hole       0.246 and -0.264 e.A^-3  
   
         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for s3049twa.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          F(1)         -460(2)        907(1)      -4715(5)       45(1)  
          O(1)         1022(2)       1928(2)       3513(6)       38(1)  
          O(2)         1150(2)       1853(2)       -150(6)       35(1)  
          O(3)          521(2)       3173(2)        740(6)       26(1)  
          N(1)         1058(2)       2987(2)       3370(7)       24(1)  
          C(1)          115(1)       2147(1)       -723(5)       23(1)  
          C(2)           65(1)       1817(1)      -2648(4)       26(1)  
          C(3)         -422(2)       1222(1)      -2893(5)       31(1)  
          C(4)         -858(1)        959(1)      -1213(6)       32(1)  
          C(5)         -808(1)       1289(1)        712(5)       30(1)  
          C(6)         -322(1)       1883(1)        957(4)       28(1)  
          C(7)          690(2)       2770(2)       -401(9)       22(1)  
          C(8)         1179(2)       2768(2)       1238(8)       22(1)  
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          C(9)         1844(1)       3209(1)        462(4)       23(1)  
          C(10)        2036(1)       3140(1)      -1641(4)       28(1)  
          C(11)        2644(1)       3507(2)      -2274(4)       29(1)  
          C(12)        3061(1)       3943(1)       -804(6)       31(1)  
          C(13)        2870(1)       4012(1)       1299(5)       27(1)  
          C(14)        2262(1)       3645(1)       1932(4)       25(1)  
          C(15)        1112(2)       2125(2)       1401(9)       26(1)  
          C(16)         951(3)       1322(3)       3814(12)      58(2)  
          C(17)         725(2)       3207(2)       2875(9)       26(1)  
          O(1S)           0             0          8560(40)      69(5)  
          O(1T)         259(12)       389(11)     10360(40)      69(5)  
         ________________________________________________________________  
   
           Table 3.  Bond lengths [A] and angles [deg] for s3049twa.  
           _____________________________________________________________  
   
            F(1)-C(3)                     1.325(4)  
            O(1)-C(15)                    1.335(6)  
            O(1)-C(16)                    1.457(7)  
            O(2)-C(15)                    1.186(6)  
            O(3)-C(17)                    1.364(6)  
            O(3)-C(7)                     1.452(6)  
            N(1)-C(17)                    1.250(6)  
            N(1)-C(8)                     1.482(6)  
            C(1)-C(2)                     1.3900  
            C(1)-C(6)                     1.3900  
            C(1)-C(7)                     1.526(5)  
            C(2)-C(3)                     1.3900  
            C(2)-H(2)                     0.9500  
            C(3)-C(4)                     1.3900  
            C(4)-C(5)                     1.3900  
            C(4)-H(4)                     0.9500  
            C(5)-C(6)                     1.3900  
            C(5)-H(5)                     0.9500  
            C(6)-H(6)                     0.9500  
            C(7)-C(8)                     1.577(7)  
            C(7)-H(7)                     1.0000  
            C(8)-C(15)                    1.548(7)  
            C(8)-C(9)                     1.549(5)  
            C(9)-C(10)                    1.3900  
            C(9)-C(14)                    1.3900  
            C(10)-C(11)                   1.3900  
            C(10)-H(10)                   0.9500  
            C(11)-C(12)                   1.3900  
            C(11)-H(11)                   0.9500  
            C(12)-C(13)                   1.3900  
            C(12)-H(12)                   0.9500  
            C(13)-C(14)                   1.3900  
            C(13)-H(13)                   0.9500  
            C(14)-H(14)                   0.9500  
            C(16)-H(16A)                  0.9800  
            C(16)-H(16B)                  0.9800  
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            C(16)-H(16C)                  0.9800  
            C(17)-H(17)                   0.9500  
            O(1T)-O(1T)#1                 1.50(4)  
            O(1T)-O(1T)#2                 1.50(4)  
   
            C(15)-O(1)-C(16)            114.5(5)  
            C(17)-O(3)-C(7)             104.6(4)  
            C(17)-N(1)-C(8)             105.7(4)  
            C(2)-C(1)-C(6)              120.0  
            C(2)-C(1)-C(7)              118.5(3)  
            C(6)-C(1)-C(7)              121.2(3)  
            C(1)-C(2)-C(3)              120.0  
            C(1)-C(2)-H(2)              120.0  
            C(3)-C(2)-H(2)              120.0  
            F(1)-C(3)-C(2)              119.6(2)  
            F(1)-C(3)-C(4)              120.4(2)  
            C(2)-C(3)-C(4)              120.0  
            C(5)-C(4)-C(3)              120.0  
            C(5)-C(4)-H(4)              120.0  
            C(3)-C(4)-H(4)              120.0  
            C(6)-C(5)-C(4)              120.0  
            C(6)-C(5)-H(5)              120.0  
            C(4)-C(5)-H(5)              120.0  
            C(5)-C(6)-C(1)              120.0  
            C(5)-C(6)-H(6)              120.0  
            C(1)-C(6)-H(6)              120.0  
            O(3)-C(7)-C(1)              108.6(3)  
            O(3)-C(7)-C(8)              102.3(4)  
            C(1)-C(7)-C(8)              114.6(4)  
            O(3)-C(7)-H(7)              110.3  
            C(1)-C(7)-H(7)              110.3  
            C(8)-C(7)-H(7)              110.3  
            N(1)-C(8)-C(15)             113.7(4)  
            N(1)-C(8)-C(9)              110.0(4)  
            C(15)-C(8)-C(9)             106.4(3)  
            N(1)-C(8)-C(7)              103.1(4)  
            C(15)-C(8)-C(7)             111.5(4)  
            C(9)-C(8)-C(7)              112.3(4)  
            C(10)-C(9)-C(14)            120.0  
            C(10)-C(9)-C(8)             120.0(3)  
            C(14)-C(9)-C(8)             119.8(3)  
            C(11)-C(10)-C(9)            120.0  
            C(11)-C(10)-H(10)           120.0  
            C(9)-C(10)-H(10)            120.0  
            C(10)-C(11)-C(12)           120.0  
            C(10)-C(11)-H(11)           120.0  
            C(12)-C(11)-H(11)           120.0  
            C(13)-C(12)-C(11)           120.0  
            C(13)-C(12)-H(12)           120.0  
            C(11)-C(12)-H(12)           120.0  
            C(14)-C(13)-C(12)           120.0  
            C(14)-C(13)-H(13)           120.0  
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            C(12)-C(13)-H(13)           120.0  
            C(13)-C(14)-C(9)            120.0  
            C(13)-C(14)-H(14)           120.0  
            C(9)-C(14)-H(14)            120.0  
            O(2)-C(15)-O(1)             125.1(4)  
            O(2)-C(15)-C(8)             123.9(5)  
            O(1)-C(15)-C(8)             111.0(4)  
            O(1)-C(16)-H(16A)           109.5  
            O(1)-C(16)-H(16B)           109.5  
            H(16A)-C(16)-H(16B)         109.5  
            O(1)-C(16)-H(16C)           109.5  
            H(16A)-C(16)-H(16C)         109.5  
            H(16B)-C(16)-H(16C)         109.5  
            N(1)-C(17)-O(3)             120.6(5)  
            N(1)-C(17)-H(17)            119.7  
            O(3)-C(17)-H(17)            119.7  
            O(1T)#1-O(1T)-O(1T)#2        60.001(11)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
           #1 -x+y,-x,z    #2 -y,x-y,z      
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Conclusions & Further Work 
 
 
 
 
 
7.1 Conclusions 
 
During a first part of this thesis work a new strategy for the synthesis of morpholines has 
been discovered and applied to the synthesis of relevant cyclic -amino acids. In 
particular, the methodology has been applied to an efficient and high yielding synthesis of 
Fmoc-morpholine-3-carboxylic acid (Chapter 2) and for the preparation of costrained and 
geometrically diversified scaffolds to be used for peptidomimetics and new library 
templates (Chapter 4). Moreover, Fmoc-morpholine-3-caroxylic acid has been proved to 
be compatible with solid phase peptide synthesis by inserting it in small peptide 
sequences. Two of this tetrapeptides containing morpholine-3-carboxylic acid have been 
studied by means of NMR, IR and molecular modeling thecniques, in order to study the 
conformational folding induced by the presence of morpholine-3-carboxylic acid (Chapter 
3). This new strategy is based on the use of enantiopure -hydroxy--amino acids, which 
(apart from serine and threonine) are not easily available compounds and so we decided 
to  focus our attention on the development of a new synthetic methodology for the 
asymmetric synthesis of -hydroxy--amino acids. In the second part, the development of 
a new methodolgy to access this class of compounds is described. An highly enantio- and 
diastereo-selective addition of isocyanoacetates to aldehydes is described, in order to 
obtain enantioenriched oxazolines, which are then readily hydrolysed to -hydroxy--
amino esters. The catalytic system is based on a "de novo" designed and synthesised 
amino-phosphine ligand which works in the presence of silver salts. Although the 
mechanism has not been fully investigated a bifunctional metal-organic catalysis is 
hypothsised.  
This thesis work has been published in 3 artcles in peer reviewed journals and is part of 
an European Patent Application. A further manuscript about the second part is in 
preparation. 
 
 
7.2 Further work 
 
To furhter expand this thesis work we believe that a conclusive study of the mechanism of 
action of the catalytic system discovered in the second part would be of great interest. We 
also believe that that the new ligand designed could be applied to different reaction where 
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a bifunctional metal-organic mechanism of action is postulated. Among the many 
examples there is the possibility of keep using the same nuchlophiles, isocyanoacetates, 
in the presence of different electrophiles such as imines. Finally, the new strategy for the 
preparation of -hydroxy--amino esters could be exploited to prepare the starting 
materials required for the synthesis of new morpholine-3-carboxylic acids (using the 
methodology developed in the first part), in order to expand the number of new cyclic-
amino acids available to the scientific community.  
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